Crystallization and structure of staphylococcus aureus peptide deformylase

ABSTRACT

Staphylococcus aureus  peptide deformylase has been crystallized, and the three-dimensional x-ray crystal structure has been solved to 1.9 Å resolution. The x-ray crystal structure is useful for solving the structure of other molecules or molecular complexes, and designing modifiers of peptide deformylase activity.

This application claims the benefit of the U.S. Provisional Application Ser. No. 60/215,550, filed Jun. 30, 2000, which is incorporated herein by reference in its entirety.

FIELD OF THE INVENTION

The present invention is related to the crystallization and structure determination of Staphylococcus aureus peptide deformylase (S. aureus pdf).

BACKGROUND OF THE INVENTION

In all bacteria as well as mitochondria and chloroplasts the initiation of protein synthesis normally requires an N-formylated methionine residue. The special initiation tRNA, tRNA_(f) ^(Met), is charged with methionine by the Methionyl-tRNA synthetase (EC 6.1.10) which adds a methionine to either of the methionine tRNAs with the consumption of ATP. The formyl group is added to the charged tRNA_(f) ^(Met) from 10-formyltetrahydrofolate which is catalyzed by methionine-tRNA_(f) ^(Met) formyl-transferase (EC 2.1.2.9). The formylated tRNA is transferred to the ribosome where protein synthesis is initiated (FIG. 1). All nascent polypeptides are synthesized with N-formyl methionine at the n-terminus.

Mature proteins do not by and large retain n-formyl methionine at the n-terminus. In fact, a rather heterogenous population of amino acids are normally found at the n-terminus of mature proteins—alanine, glycine, serine, threonine, or methionine. Larger amino acids are rarely found, which suggests that multiple catabolic processing might occur after or in concert with protein synthesis. All known amino-terminal peptidases cannot use formylated peptides as substrates. After translation, the formyl group is removed by Peptide Deformylase (pdf) as illustrated in FIG. 2. This metalloenzyme (EC 3.5.1.27) removes the formyl group from the peptide amino-terminus and releases the protein for possible further processing by methionine aminopeptidase (MAP; EC 3.4.11.18). The formylation/deformylation cycle is unique to eubacteria and does not occur in eucaryotic protein synthesis. The essential deformylation activity of pdf makes it an attractive target for crystallization and structural studies. Such studies may lead to the design of new antibiotics.

SUMMARY OF THE INVENTION

In one aspect, the present invention provides crystalline S. aureus peptide deformylase. Optionally, one or more methionine may be replaced with selenomethionine. The crystal may optionally include a coordinated metal ion selected from the group of metals consisting of Fe, Zn, Ni and combinations thereof.

In one embodiment, the crystal has the orthorhombic space group symmetry C222₁. Preferably, the unit cell has dimensions a, b, and c; wherein a is about 90 Å to about 100 Å, b is about 116 Å to about 128 Å, and c is about 45 Å to about 50 Å; and wherein α=β=γ=90°. More preferably, a is about 92 Å to about 95 Å, b is about 121 Å to about 124 Å, and c is about 47 Å to about 49 Å.

In another embodiment, the present invention provides a crystal of S. aureus peptide deformylase having the monoclinic space group symmetry C2. Preferably, the unit cell has dimensions a, b, and c; wherein a is about 85 Å to about 100 Å, b is about 35 Å to about 50 Å, and c is about 90 Å to about 110 Å; and wherein α=γ=90° and β is about 90° to about 95°. More preferably, a is about 91 Å to about 95 Å, b is about 41 Å to about 44 Å, and c is about 102 Å to about 105 Å.

In still another embodiment, the present invention provides a crystal of S. aureus peptide deformylase having the tetragonal space group symmetry P4₁ or P4₂2₁2. Preferably, the unit cell has dimensions a, b, and c; wherein a and b are about 130 Å to about 190 Å, and c is about 30 Å to about 70 Å; and wherein α=β=γ=90°. More preferably, a and b are about 160 Å to about 164 Å, and c is about 45 Å to about 49 Å.

In another aspect, the present invention provides a method for crystallizing an S. aureus peptide deformylase molecule or molecular complex. In one embodiment the method includes preparing a stock solution of purified S. aureus peptide deformylase at a concentration of about 1 mg/ml to about 50 mg/ml; contacting the stock solution with a precipitating solution containing about 1% by weight to about 35% by weight PEG having a number average molecular weight between about 300 and about 20,000; about 0 M to about 0.2 M MgCl₂; and about 0% by weight to about 25% by weight DMSO; the precipitating solution being buffered to a pH of about 5 to about 9; and allowing S. aureus peptide deformylase to crystallize from the resulting solution. Preferably, the precipitating solution contains about 15% by weight to about 25% by weight PEG having a number average molecular weight between about 3000 and about 5,000 ; about 0.05 M to about 0.15 M MgCl₂ and is buffered to a pH of about 8 to about 9.

In another embodiment the method for crystallizing an S. aureus peptide deformylase molecule or molecular complex includes preparing a stock solution of purified S. aureus peptide deformylase at a concentration of about 1 mg/ml to about 50 mg/ml; contacting the stock solution with a precipitating solution containing about 1% by weight to about 40% by weight PEG having a number average molecular weight between about 300 and about 20,000; about 0.005 M to about 0.5 M citric acid; about 0% by weight to about 25% by weight DMSO; and sufficient base to adjust the pH of the precipitating solution to about 5.0 to about 6.5; and allowing S. aureus peptide deformylase to crystallize from the resulting solution. Preferably, the precipitating solution contains about 1% by weight to about 40% by weight PEG having a number average molecular weight between about 2000 and about 4,000; about 0.05 M to about 0.2 M citric acid, and sufficient base to adjust the pH of the precipitating solution to about 5.0 to about 5.5.

In still another embodiment the method for crystallizing an S. aureus peptide deformylase molecule or molecular complex includes preparing a stock solution of purified S. aureus peptide deformylase at a concentration of about 1 mg/ml to about 50 mg/ml; contacting the stock solution with a precipitating solution containing about 0.2 M to about 1.5 M sodium citrate; about 0.005 M to about 0.5 M Hepes; about 0% by weight to about 25% by weight DMSO; and sufficient base to adjust the pH of the precipitating solution to about 7.0 to about 8.5; and allowing S. aureus peptide deformylase to crystallize from the resulting solution. Preferably, the precipitating solution contains about 25% by weight to about 35% by weight PEG having a number average molecular weight between about 2000 and about 4,000; about 0.05 M to about 0.2 M citric acid, and sufficient base to adjust the pH of the precipitating solution to about 5.0 to about 5.5.

In still another embodiment the method for crystallizing an S. aureus peptide deformylase molecule or molecular complex includes preparing a stock solution of purified S. aureus peptide deformylase at a concentration of about 1 mg/ml to about 50 mg/ml; contacting the stock solution with a precipitating solution containing about 1% by weight to about 40% by weight PEG having a number average molecular weight between about 300 and about 20,000; about 0 M to about 0.4 M MgCl₂; and about 0% by weight to about 25% by weight DMSO; the precipitating solution being buffered to a pH of about 7 to about 9; and allowing S. aureus peptide deformylase to crystallize from the resulting solution. Preferably, the precipitating solution contains about 15% by weight to about 35% by weight PEG having a number average molecular weight between about 3,000 and about 5,000; about 0.05 M to about 0.3 M MgCl₂; and the precipitating solution being buffered to a pH of about 8 to about 9.

In another aspect, the present invention provides a molecule or molecular complex including at least a portion of an S. aureus peptide deformylase or an S. aureus peptide deformylase-like active site including amino acids Gly58, Gly60, Leu61, Gln65, Glu109, Gly110, Cys111, Leu112, Ile150, His154, Glu155, and His158, the active site being defined by a set of points having a root mean square deviation of less than about 0.35 Å from points representing the backbone atoms of said amino acids as represented by structure coordinates listed in Table 1. Optionally, the molecule or molecular complex further includes a coordinated metal ion selected from the group of metals consisting of Fe, Zn, Ni and combinations thereof. Preferably, the metal ion is coordinated by the amino acids Cys111, His154, and His158.

In another aspect, the present invention provides a scalable three-dimensional configuration of points, at least a portion of said points, and preferably all of said points, derived from structure coordinates of at least a portion of an S. aureus peptide deformylase molecule or molecular complex listed in Table 1 and having a root mean square deviation of less than about 1.4 Å from said structure coordinates. Preferably, at least a portion of the points are derived from the S. aureus peptide deformylase structure coordinates are derived from structure coordinates representing the locations of at least the backbone atoms of a plurality of the amino acids defining at least one S. aureus peptide deformylase or S. aureus peptide deformylase-like active site, the active site including amino acids Gly58, Gly60, Leu61, Gln65, Glu109, Gly110, Cys111, Leu112, Ile150, His154, Glu155, and His158.

In another aspect, the present invention provides a machine-readable data storage medium including a data storage material encoded with machine readable data which, when using a machine programmed with instructions for using said data, displays a graphical three-dimensional representation of at least one molecule or molecular complex selected from the group consisting of (i) a molecule or molecular complex including at least a portion of an S. aureus peptide deformylase or an S. aureus peptide deformylase-like active site including amino acids Gly58, Gly60, Leu61, Gln65, Glu109, Gly110, Cys111, Leu112, Ile150, His154, Glu155, and His158, the active site being defined by a set of points having a root mean square deviation of less than about 0.35 Å from points representing the backbone atoms of said amino acids as represented by structure coordinates listed in Table 1.

In another aspect, the present invention provides a computer-assisted method for obtaining structural information about a molecule or a molecular complex of unknown structure including: crystallizing the molecule or molecular complex; generating an x-ray diffraction pattern from the crystallized molecule or molecular complex; applying at least a portion of the structure coordinates set forth in Table 1 to the x-ray diffraction pattern to generate a three-dimensional electron density map of at least a portion of the molecule or molecular complex whose structure is unknown.

In another aspect, the present invention provides a computer-assisted method for homology modeling an S. aureus peptide deformylase homolog including: aligning the amino acid sequence of an S. aureus peptide deformylase homolog with the amino acid sequence of S. aureus peptide deformylase SEQ ID NO:1 and incorporating the sequence of the S. aureus peptide deformylase homolog into a model of S. aureus peptide deformylase derived from structure coordinates set forth in Table 1 to yield a preliminary model of the S. aureus peptide deformylase homolog; subjecting the preliminary model to energy minimization to yield an energy minimized model; remodeling regions of the energy minimized model where stereochemistry restraints are violated to yield a final model of the S. aureus peptide deformylase homolog.

In another aspect, the present invention provides a computer-assisted method for identifying a potential modifier of S. aureus peptide deformylase activity including: supplying a computer modeling application with a set of structure coordinates of a molecule or molecular complex, the molecule or molecular complex including at least a portion of at least one S. aureus peptide deformylase or S. aureus peptide deformylase-like active site, the active site including amino acids Gly58, Gly60, Leu61, Gln65, Glu109, Gly110, Cys111, Leu112, Ile150, His154, Glu155, and His158; supplying the computer modeling application with a set of structure coordinates of a chemical entity; and determining whether the chemical entity is expected to bind to the molecule or molecular complex, wherein binding to the molecule or molecular complex is indicative of potential modification of S. aureus peptide deformylase activity.

In another aspect, the present invention provides a computer-assisted method for designing a potential modifier of S. aureus peptide deformylase activity including: supplying a computer modeling application with a set of structure coordinates of a molecule or molecular complex, the molecule or molecular complex including at least a portion of at least one S. aureus peptide deformylase or S. aureus peptide deformylase-like active site, the active site including amino acids Gly58, Gly60, Leu61, Gln65, Glu109, Gly110, Cys111, Leu112, Ile150, His154, Glu155, and His158; supplying the computer modeling application with a set of structure coordinates for a chemical entity; evaluating the potential binding interactions between the chemical entity and active site of the molecule or molecular complex; structurally modifying the chemical entity to yield a set of structure coordinates for a modified chemical entity; and determining whether the modified chemical entity is expected to bind to the molecule or molecular complex, wherein binding to the molecule or molecular complex is indicative of potential modification of S. aureus peptide deformylase activity.

In another aspect, the present invention provides a computer-assisted method for designing a potential modifier of S. aureus peptide deformylase activity de novo including: supplying a computer modeling application with a set of structure coordinates of a molecule or molecular complex, the molecule or molecular complex including at least a portion of at least one S. aureus peptide deformylase or S. aureus peptide deformylase-like active site, wherein the active site includes amino acids Gly58, Gly60, Leu61, Gln65, Glu109, Gly110, Cys111, Leu112, Ile150, His154, Glu155, and His158; forming a chemical entity represented by set of structure coordinates; and determining whether the chemical entity is expected to bind to the molecule or molecular complex, wherein binding to the molecule or molecular complex is indicative of potential modification of S. aureus peptide deformylase activity.

In another aspect, the present invention provides a method for making a potential modifier of S. aureus peptide deformylase activity, the method including chemically or enzymatically synthesizing a chemical entity to yield a potential modifier of S. aureus peptide deformylase activity, the chemical entity having been identified during a computer-assisted process including supplying a computer modeling application with a set of structure coordinates of a molecule or molecular complex, the molecule or molecular complex including at least a portion of a S. aureus peptide deformylase or S. aureus peptide deformylase-like active site; supplying the computer modeling application with a set of structure coordinates of a chemical entity; and determining whether the chemical entity is expected to bind to the molecule or molecular complex at the active site, wherein binding to the molecule or molecular complex is indicative of potential modification of S. aureus peptide deformylase activity.

In another aspect, the present invention provides a method for making a potential modifier of S. aureus peptide deformylase activity, the method including chemically or enzymatically synthesizing a chemical entity to yield a potential modifier of S. aureus peptide deformylase activity, the chemical entity having been designed during a computer-assisted process including supplying a computer modeling application with a set of structure coordinates of a molecule or molecular complex, the molecule or molecular complex including at least a portion of a S. aureus peptide deformylase or S. aureus peptide deformylase-like active site; supplying the computer modeling application with a set of structure coordinates for a chemical entity; evaluating the potential binding interactions between the chemical entity and the active site of the molecule or molecular complex; structurally modifying the chemical entity to yield a set of structure coordinates for a modified chemical entity; and determining whether the chemical entity is expected to bind to the molecule or molecular complex at the active site, wherein binding to the molecule or molecular complex is indicative of potential modification of S. aureus peptide deformylase activity.

In another aspect, the present invention provides a method for making a potential modifier of S. aureus peptide deformylase activity, the method including chemically or enzymatically synthesizing a chemical entity to yield a potential modifier of S. aureus peptide deformylase activity, the chemical entity having been designed during a computer-assisted process including supplying a computer modeling application with a set of structure coordinates of a molecule or molecular complex, the molecule or molecular complex including at least a portion of a S. aureus peptide deformylase or S. aureus peptide deformylase-like active site; forming a chemical entity represented by set of structure coordinates; and determining whether the chemical entity is expected to bind to the molecule or molecular complex at the active site, wherein binding to the molecule or molecular complex is indicative of potential modification of S. aureus peptide deformylase activity.

Table 1 lists the atomic structure coordinates for molecule Staphylococcus aureus peptide deformylase (S. aureus pdf) as derived by x-ray diffraction from a crystal of the protein. The following abbreviations are used in Table 1:

“Atom type” refers to the element whose coordinates are measured. The first letter in the column defines the element.

“X, Y, Z” crystallographically define the atomic position of the element measured.

“B” is a thermal factor that measures movement of the atom around its atomic center.

“Occ” is an occupancy factor that refers to the fraction of the molecules in which each atom occupies the position specified by the coordinates. A value of “1” indicates that each atom has the same conformation, i.e., the same position, in all molecules of the crystal.

ABBREVIATIONS

The following abbreviations are used throughout this disclosure:

-   Staphylococcus aureus (S. aureus) -   Escherichia coli (E. coli) -   Haemophilis influenzae (Haemop. influenzae) -   Bacillus subtilis (B. subtilis) -   Mycoplasma pneumoniae (Mycopl. pneumoniae) -   Peptide deformylase (pdf) -   Isopropylthio-β-D-galactoside (IPTG) -   (S)-2-O-(H-phosphonoxy)-L-caproyl-L-leucyl-p-nitroanilide (PCLNA) -   Dimethyl sulfoxide (DMSO) -   Polyethylene glycol (PEG) -   Beta-mercaptoethanol (BME) -   Optical density (OD) -   Multiple anomalous dispersion (MAD) -   Root mean square (r.m.s.) -   Root mean square deviation (r.m.s.d.)     PNU-172550 is a compound having the following structure:

The following abbreviations are used for amino acids throughout this disclosure: A = Ala = Alanine T = Thr = Threonine V = Val = Valine C = Cys = Cysteine L = Leu = Leucine Y = Tyr = Tyrosine I = Ile = Isoleucine N = Asn = Asparagine P = Pro = Proline Q = Gln = Glutamine F = Phe = Phenylalanine D = Asp = Aspartic Acid W = Trp = Tryptophan E = Glu = Glutamic Acid M = Met = Methionine K = Lys = Lysine G = Gly = Glycine R = Arg = Arginine S = Ser = Serine H = His = Histidine

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 is a schematic representation of the methionine cycle in bacteria.

FIG. 2 is a schematic representation of the reaction catalyzed by peptide deformylase.

FIG. 3 lists the amino acid sequences of peptide deformylases from various species of bacteria including Staphylococcus aureus peptide deformylase (pdf) with C-terminal 6×His tag (SEQ ID NO: 1); Escherichia coli pdf (SEQ ID NO:2); Haemophilis influenzae pdf (SEQ ID NO:3); Bacillus subtilis (SEQ ID NO:4); and Mycoplasma pneumoniae (SEQ ID NO:5); and Staphylococcus aureus def1 gene (a related but inactive form of the protein, also called Pseudo pdf) (SEQ ID NO:6). Alignments were generated from GCG SeqLab (Wisconsin Package Version 10.1, Genetics Computer Group, Madision, Wis.). The underlined residues show regions of importance to the activity of peptide deformylases. The highlighted amino acids show mutations for S. aureus pdf (SEQ ID NO:1).

FIG. 4 is a photograph illustrating 4-20% SDS PAGE gel of pseudo pdf, pdf1, and further purified pdf2.

FIG. 5 is a schematic secondary structure diagram of S. aureus pdf.

FIG. 6 is a depiction of the secondary structure of S. aureus peptide deformylase. The α-helices are starred and the β-sheets are not starred. Random coil connections are light gray. The single Zn/Fe atom is labeled **.

FIG. 7 is a stereo pair view of S. aureus peptide deformylase backbone from the same view as in FIG. 6.

FIG. 8 is a model showing the electro-static surface potential for pdf. The positively charged region is indicated by the arrow (+100 kcal) while the negatively charged regions are gray (−100 kcal). The surface potential was created in MOSAIC2 (Computer Aided Drug Discovery) using point charge parameters derived from the AMBER force field (Weiner et al., J. Comput. Chem., 7:230-52 (1986)) and a formal charge of plus 2 for the metal ion.

FIG. 9 is a schematic model showing the active site metal ion (gray sphere). The metal ion may be Zn, Ni, or Fe. The ion is coordinated by protein sidechains H154, H158 and C111.

FIG. 10 is a sequence alignment based on x-ray structure comparisons for E. coli pdf and S. aureus pdf proteins.

FIG. 11 is a depiction of the secondary structure of pdf for a) S. aureus pdf and b) E. coli pdf. The n-terminus ends are starred.

FIG. 12 is a stereo pair view of the superimposed alpha carbons from S. aureus pdf (dark) and E. coli pdf (light). The metal ion is indicated by the sphere.

FIG. 13 is a stereo pair view of the superposition of the active site cavity of the E. coli pdf structure. Some selected residues from S. aureus pdf are labeled.

FIG. 14 a) is a schematic illustration of PCLNA inhibitor (Hao et al., Biochemistry, 38: 4712-19 (1999)) placing subsituents into three pdf subsites. The S. aureus residue number is given first with the equivalent E. coli amino acid subsequent. The metal ion is the labeled sphere. FIG. 14 b) is a view of a surface rendering for the PCLNA complex with the E. coli enzyme with the location of the subsites indicated. The light gray surface represents hydrophobic surface associated with carbon atoms, dark gray for nitrogen atoms and medium gray for oxygen atoms.

FIG. 15 is a view of a model of the active site cleft of S. aureus pdf with PCLNA (from Hao et al., Biochemistry, 38: 4712-19 (1999)). The surface is colored according to atom type with all carbons in light gray, oxygens in medium gray, and nitrogens in dark gray. The six active site residues which are conserved between E. coli and S. aureus pdf are indicated in white. These residues line the bottom of the active site.

FIG. 16 is a view of a model of the surface rendering for PCLNA complex with E. coli enzyme (left) and of PCLNA with S. aureus enzyme (right). The light gray colors indicate the hydrophobic surface associated with carbon atoms, dark gray is for nitrogen atoms, and medium gray for oxygen atoms. Amino acid labeling indicates the surface corresponding to various residues.

FIG. 17 is a stereo view of the S1 subsite of pdf with PCLNA inhibitor. The amino acid sidechains which surround the P1, caproyl group, are indicated. Labels indicate the S.aureus amino acid first and the equivalent E.coli residue second. However, R97/N is indicated with the opposite nomenclature.

FIG. 18 is a stereo view of the S2 subsite of pdf with PCLNA inhibitor. The amino acid sidechains which surround the P2, leucyl group, are indicated. Labels indicate the S.aureus amino acid first and the equivalent E.coli residue second. However, R97/N is indicated with the opposite nomenclature.

FIG. 19 is a stereo view of the S3 subsite of pdf with PCLNA inhibitor. The amino acid sidechains which surround the P3, p-nitroanilide group, are indicated. Labels indicate the S.aureus amino acid first and the equivalent E.coli residue second.

DETAILED DESCRIPTION OF THE INVENTION

C222₁ Space Group Crystals

In one embodiment, crystals of S.aureus pdf have been obtained and belong to the C222₁ orthorhombic space group. Crystals were grown in four conditions, but crystals used for the structure solution were grown from 20% PEG 4000, 0.1M Tris pH=8.5 and 0.1M MgCl₂. Se-methionine pdf crystals were also grown and data was used to solve the pdf structure. Variation in buffer and buffer pH as well as other additives such as PEG is apparent to those skilled in the art and may result in similar crystals.

The S. aureus pdf protein was over-expressed and purified from E.coli. Crystallization attempts using pdf purified only by affinity Ni-NTA chromatography did not yield crystals, but the addition of an anion exchange purification step improved results. This further purified material resulted in many promising crystallization leads including four unique hits. Each of these hits were followed up using finely focused grid screens. All four conditions were pursued and characterized according to crystal behavior and quality. All small crystals were optimized though micro-seeding. Large, single crystals suitable for data collection were soaked in stabilization solution containing 25% glycerol prior to freezing for low temperature data collection. The useful crystals grown from the four diverse starting conditions all belong to the space group C222₁ with one molecule in the asymmetric unit. The unit cell parameters were a=94.1 b=121.87 c=47.58 Å.

Identical crystals of pdf were grown with Se-methionine pdf protein. One crystal was grown from 20% PEG 4000, 0.1M Tris pH=8.5 and 0.1 m MgCl₂ and measured 0.22×0.22×0.6 micrometer. Data from this crystal was collected at the IMCA synchrotron facility and was found to belong to the space group C222₁ as well. The pdf structure was solved using this MAD data. However, the resulting structure could not be completely refined with the MAD data; so refinement was abandoned in favor of a new data set (see below).

A second crystal was grown in the presence of 2 mM of a potential inhibitor, 10% DMSO, 20% PEG 4000, 0.1M Tris pH=8.5 and 0.1M MgCl₂. This crystal measured 0.28×0.28×0.98 micrometer. No evidence for this compound was observed in the electron density map. After freezing the crystal, data was collected on a Siemens dual Hi-star. The crystal diffracted to 1.9 Å and molecular replacement was successfully performed using the MAD-derived model. This structure was refined to a final R-factor of 18.62%.

The orthorhombic crystal form could be prepared with or without compounds. The crystals belonging to the C222₁ space group generally have unit cell parameters with a=91.6 to 95.1 Å; b=121.3 to 123.5 Å; and c=47.6 to 48.4 Å. Crystals may be grown at 20° C., for example, by mixing a buffered protein sample with 19% PEG4000, 0.1M Tris pH 8.5 and 0.2M MgCl₂. Crystals may be stabilized in 25% PEG4000; 10% glycerol; 0.1M Tris pH 8.5 and 0.2M MgCl₂ for data collection.

C2 Space Group Crystals

The Monoclinic crystal form of S. aureus pdf, C2, with unit cell parameters ranging from a=90.8 to 95.1 Å; b=42.4 to 42.7 Å; and c=104.1 to 104.4 Å. Crystals were grown at 20° C. by mixing a buffered protein sample that included 5 mM PNU-172550 with an equal volume of 30% PEG 3000; 0.1M Na Citrate pH 5.2. Other compounds could be crystallized using the same procedure with variation in PEG concentration or pH. Crystals were stabilized in a solution containing PEG; Citrate, PNU-172550 and 10% glycerol for diffraction studies.

P4₂2₁2 Space Group Crystals

Another crystal form could also be prepared with PNU-172550. This tetragonal crystal form P4₂2₁2 has unit cell parameters ranging from a=b=160.4 to 163.5 Å and c=45.2 to 48.3 Å. Crystals are grown at 20° C. by mixing a buffered protein sample that included 5 mM PNU-172550 with an equal volume of 1.375 M Na Citrate and 0.1 M Na Hepes pH 7.5. Other compounds could be crystallized using the same procedure with variation in salts and buffers. Most often no stabilization solution was employed.

Comparision of S. aureus pdf and E. coli pdf Crystals

A number of structure determination reports have reported the crystallization of the pdf from E.coli as shown in Table 2. The present disclosure is believed to be the first crystallization of S.aureus pdf, and the reported crystal forms are also unique. TABLE 2 The Space group and unit cell parameters for a variety of E. coli pdf crystals. PDB No. Space Group A edge B edge C edge Beta angle A.U. 1bs4 C2₁ 140.70 63.30 86.8 120.6 3 1bs5 C2₁ 143.4 64.10 84.6 123.2 3 1bs6 C2₁ 143.8 64.10 85.10 123.3 3 1bs7 C2₁ 143.4 64.0 84.50 123.0 3 1bs8 C2₁ 143.1 64.2 84.7 123.3 3 1bsz C2₁ 141.0 63.4 86.8 120.6 3 1dff P6₁22 55.35 55.35 230.92 120 1 1icj C2₁ 140.7 63.4 86.9 120.6 3 1bsj P6₅22 98.38 98.38 109.37 120 1 1bsk P6₅22 100.11 100.11 111.34 120 1 X-Ray Crystallographic Analysis

Each of the constituent amino acids of S. aureus pdf is defined by a set of structure coordinates as set forth in Table 1. The term “structure coordinates” refers to Cartesian coordinates derived from mathematical equations related to the patterns obtained on diffraction of a monochromatic beam of x-rays by the atoms (scattering centers) of an S. aureus pdf complex in crystal form. The diffraction data are used to calculate an electron density map of the repeating unit of the crystal. The electron density maps are then used to establish the positions of the individual atoms of the S. aureus pdf protein or protein/ligand complex.

Slight variations in structure coordinates can be generated by mathematically manipulating the S. aureus pdf or S. aureus pdf/ligand structure coordinates. For example, the structure coordinates set forth in Table 1 could be manipulated by crystallographic permutations of the structure coordinates, fractionalization of the structure coordinates, integer additions or subtractions to sets of the structure coordinates, inversion of the structure coordinates or any combination of the above. Alternatively, modifications in the crystal structure due to mutations, additions, substitutions, and/or deletions of amino acids, or other changes in any of the components that make up the crystal, could also yield variations in structure coordinates. Such slight variations in the individual coordinates will have little effect on overall shape. If such variations are within an acceptable standard error as compared to the original coordinates, the resulting three-dimensional shape is considered to be structurally equivalent. Structural equivalence is described in more detail below.

It should be noted that slight variations in individual structure coordinates of the S. aureus pdf or S. aureus pdf/ligand complex, as defined above, would not be expected to significantly alter the nature of ligands that could associate with the active sites. Thus, for example, a ligand that bound to the active site of S. aureus pdf would also be expected to bind to or interfere with another active site whose structure coordinates define a shape that falls within the acceptable error.

Binding Pockets/Active Sites/Other Structural Features

The present invention has provided, for the first time, information about the shape and structure of the active site of S. aureus pdf.

Active sites are of significant utility in fields such as drug discovery. The association of natural ligands or substrates with the active sites of their corresponding receptors or enzymes is the basis of many biological mechanisms of action. Similarly, many drugs exert their biological effects through association with the active sites of receptors and enzymes. Such associations may occur with all or any parts of the active site. An understanding of such associations helps lead to the design of drugs having more favorable associations with their target, and thus improved biological effects. Therefore, this information is valuable in designing potential modifiers of S. aureus pdf-like activity, as discussed in more detail below.

The term “active site (or binding pocket),” as used herein, refers to a region of a molecule or molecular complex, that, as a result of its shape, favorably associates with another chemical entity or compound. Thus, an active site may include or consist of features such as interfaces between domains. Chemical entities or compounds that may associate with an active site include, but are not limited to, cofactors, substrates, inhibitors, agonists, antagonists, etc.

The active site of S. aureus peptide deformylase may be represented by the amino acids in the following table, which are believed would fall within 5 Å of an incorporated modifier. Using structure coordinates of E. coli pdf with bound PCLNA and the present S. aureus pdf, the structures were superimposed using the Pharmacia program SUPERPDB.

In Model A, the 12 residues that are identical between E. coli pdf and S. aureus pdf were superimposed and chosen as the set to be minimized. The resulting distances between the α-Cs for the 12 residues, and the RMS for all the atoms in each of the corresponding residues were calculated and are reported in Table 3.

In Model B, the three residues which coordinate the metal atom (Cys111, His154, and His158 for S. aureus pdf) were chosen as the set to be minimized, and other residues within 2 Å were brought into the refinement. The resulting distances between the α-Cs for 18 active site amino acids and the RMS for all the atoms in each of the corresponding residues were calculated and are reported in Table 3.

In Model C, the 12 residues that are identical between E. coli pdf and S. aureus pdf were chosen as the set to be minimized, and other residues within 2 Å were brought into the refinement. The distances between the α-Cs for 18 active site amino acids and the RMS for all the atoms in each of the corresponding residues were calculated and are reported in Table 3. TABLE 3 Active Site Residues Model A Model B Model C α-C RMS (all α-C RMS (all α-C RMS (all S. aureus E. coli Dist., Å atoms) Dist., Å atoms) Dist., Å atoms) Arg56 Glu41 — — Too Long Too Long Ser57 Glu42 — — 1.8337 2.1387 1.8194 2.1266 Gly58 Gly43 0.4093 0.4619 0.7992 0.8537 0.7834 0.8379 Val59 Ile44 — — 0.4870 1.4130 0.4875 1.4151 Gly60 Gly45 0.5142 0.5109 0.4953 0.4869 0.4944 0.4876 Leu61 Leu46 0.4495 0.4802 0.4177 0.4842 0.4293 0.4902 Gln65 Gln50 0.1933 0.2696 0.4340 0.4239 0.4216 0.4156 Leu105 Ile86 — — 0.9699 1.5517 0.9858 1.5510 Pro106 none — — — — — — Thr107 none — — — — — — Gly108 Glu87 — — 1.7757 1.7415 1.7446 1.7150 Glu109 Glu88 0.2880 0.3478 0.6969 0.5832 0.6699 0.5618 Gly110 Gly89 0.2008 0.1993 0.6020 0.4590 0.5843 0.4439 Cys111 Cys90 0.3367 0.4177 0.3111 0.4429 0.3104 0.4398 Leu112 Leu91 0.6834 0.9241 0.6170 0.8266 0.6151 0.8243 Asn117 Arg97 — — Too Long Too Long Tyr147 Leu125 — — 1.1351 1.1966 1.1011 1.1681 Ile150 Ile128 0.1519 0.3571 0.4175 0.5381 0.3877 0.5129 Val151 Cys129 — — 0.5516 0.5981 0.5282 0.5765 His154 His132 0.2017 0.3312 0.2066 0.2882 0.2093 0.2909 Glu155 Glu133 0.2294 0.3944 0.3929 0.4743 0.3869 0.4745 His158 His136 0.2387 0.3944 0.2444 0.3116 0.2330 0.3050 Composite RMS 0.36  0.46  0.83  0.98  0.81  0.97 

The active site of S. aureus pdf preferably includes at least a portion of the amino acids Gly58, Gly60, Leu61, Gln65, Glu109, Gly110, Cys111, Leu112, Ile150, His154, Glu155, and His158; and more preferably at least a portion of the amino acids Arg56, Ser57, Gly58, Val59, Gly60, Leu61, Gln65, Leu105, Pro106, Thr107, Gly108, Glu109, Gly110, Cys111, Leu112, Asn117, Tyr147, Ile150, Val151, His154, Glu155, and His158, as shown in Table 1. As used herein, “at least a portion of the amino acids” means at least about 50% of the amino acids, preferably at least about 70% of the amino acids, more preferably at least about 90% of the amino acids, and most preferably all the amino aicds. It will be readily apparent to those of skill in the art that the numbering of amino acids in other isoforms of S. aureus pdf may be different.

The amino acid constituents of an S. aureus pdf active site as defined herein, as well as selected constituent atoms thereof, are positioned in three dimensions in accordance with the structure coordinates listed in Table 1. In one aspect, the structure coordinates defining the active site of S. aureus pdf include structure coordinates of all atoms in the constituent amino acids; in another aspect, the structure coordinates of the active site include structure coordinates of just the backbone atoms of the constituent atoms.

The term “S. aureus pdf-like active site” refers to a portion of a molecule or molecular complex whose shape is sufficiently similar to at least a portion of the active site of S. aureus pdf as to be expected to bind related structural analogues. A structurally equivalent active site is defined by a root mean square deviation from the structure coordinates of the backbone atoms of the amino acids that make up the active sites in S. aureus pdf (as set forth in Table 1) of at most about 0.8 Å, and preferably less than about 0.35 Å. How this calculation is obtained is described below.

The term “associating with” refers to a condition of proximity between a chemical entity or compound, or portions thereof, and an S. aureus pdf molecule or portions thereof. The association may be non-covalent, wherein the juxtaposition is energetically favored by hydrogen bonding, van der Waals forces, or electrostatic interactions, or it may be covalent.

Accordingly, the invention thus provides molecules or molecular complexes including an S. aureus pdf active site or S. aureus pdf-like active site, as defined by the sets of structure coordinates described above.

The crystal structure of the Staphylococcus aureus peptide deformylase enzyme (the def2 gene product) has been determined by MAD phased X-ray crystallography to 2.0 Å resolution. The protein structure reveals a fold similar to but not identical to the well characterized E.coli enzyme. Differences also extend into the active site region and will play a role in the elaboration of peptide deformylase (pdf) specific inhibitors.

Description of the Structure of pdf

The pdf structure is composed mostly of β-sheet with two lengthy helical regions near the n and c-terminus (FIG. 5). The last helical region (147-161) forms the core of the structure and is also involved in catalysis. The β-sheet regions surround the centrally located, c-terminal helix and help to create the shallow cavity into which the substrates, formylated peptides, fit. The conserved motif HEXXH (H154 through H158) is found on this c-terminal helix and is involved in the coordination of the active site metal ion. Glutamic acid 155 is also likely essential for the catalytic process. Residues nearer the beginning of the helix are likely involved in specificity and are found near the opening of the cavity.

The n-terminal helical segments form a knot-like cluster on the “top” of the protein while the β-sheet regions are found on the lower half of the protein. A “thumb” region of coil extends from the lower sheet and covers the top of the metal ion (Center left FIG. 6). The β-sheet rich section is composed of three β-sheet elements, an n-terminal anti-paralell three stranded β-sheet, a central anti-paralell three stranded β-sheet and a c-terminal mixed β-sheet. The β-sheet elements pack around the active site helix and form the walls of the active site cavity. The c-terminus of the protein forms a last short strand of mixed β-sheet and is poised at the mouth of the active site (FIG. 7).

The structure has a large number of well ordered waters which have been placed into the electron density maps based upon 3 sigma difference density during the refinement as well as the potential for good hydrogen bonding. Many waters fill the active site cavity.

The electrostatic surface potential of pdf indicates an intense positively charged surface at the back of the active site cavity—due to the presence of the metal ion. The upper surface of the protein is richly decorated with negatively charged residues, while the lower surface is generally more neutral in potential (FIG. 8).

The Active Site Metal Ion.

A large body of experimental data including X-ray and NMR structures suggests that pdf contains a metal ion in the active site (Meinnel et al., J Bacteriol., 175:993-1000 (1993); Meinnel et al., J. Bacteriol., 177:1883-87 (1995); Chan et al., Biochemistry, 36:13904-09 (1997)). In addition, activity data (Rajagopalan et al., Biochemistry, 36:13910-18 (1997); Rajagopalan et al., J. Am. Chem. Soc., 119:12418-19 (1997)) point to iron as the most active metal ion. Data is consistent with this view; however, we have no experimental evidence based upon the present X-ray data to distinguish among ions like nickel, iron or zinc. From the initial MAD map it was clear that that a tetrahedrally coordinated metal ion is found in the three-dimensional structure of S.aureus pdf with water and the protein sidechains H154, H158, and C111 coordinating the metal ion. The sequence motif HEXXH (Mazel et al., EMBO J., 13:914-23 (1994)) in the c-terminal helix is a signature motif which is found in many metalloproteases including thermolysin (Blundell, Nat. Struct. Biol., 1:73-75 (1994); Jongeneel et al., FEBS Lett., 242: 211-14 (1989); Makarova et al., J. Mol. Biology, 292:11-17 (1999)). The glutamic acid residue of this motif probably plays a dual role in metal coordination and catalysis. The water molecule, which is a metal ligand, is tightly held in place by this glutamate residue in the present crystal structure. This residue likely plays a role in the protonation and deprotonation of reaction intermediates during the catalytic cycle in a manner similar to the role of the conserved glutamate in thermolysin (Matthews, Acc. Chem. Res., 21: 333-40 (1988); Chan et al., Biochemistry, 36:13904-09 (1997)).

Comparison of S.aureus pdf to E.coli Structure

With the availability of numerous E.coli pdf X-ray and NMR structures (Table 1), it is possible to carry out a detailed comparison between these related enzymes. It should first be noted that the sequence identity between the E.coli and S.aureus enzymes is 45/134 or 33.5%. The rmsd for 134 α-carbons is 1.101 Å (1.457 Å for 861 common atoms; 1.189 Å for 536 main chain atoms). The vast majority of the identities (shown in FIG. 10) are limited to the conserved motifs (metal binding regions). A structure-based alignment of the protein sequence is given in FIG. 10. The poor sequence identity is not reflected in overall structural similarity. Both enzymes possess similar features in tertiary structure (FIG. 11).

S.aureus pdf has seven insertions with respect to the E.coli sequence (FIG. 10). The first insertion T3-M4 adds some additional hydrophobic surface area which forms a small surface for interaction with the third insertion (the extended n-terminal helix) N43-G54. The insertion after P25 adds one additional residue to the turn, which leads into the first long helix of pdf. This n-terminal helix is extended by an additional helix (insertion three N43-G54) which is not present in the E.coli structure. In the E.coli structure this helix is followed by a beta turn which drops down into the very conserved GXGLAA sequence which forms the third (and edge) strand of the n-terminal β-sheet. This strand also forms part of the wall of the active site crevice and provides loci for hydrogen bonding of peptide substrates (Hao et al., Biochemistry, 38: 4712-19 (1999)). The insertion of residues G81-G83 in the S.aureus structure extends the turn between strands II and III of the n-terminal β-sheet. The insertion of V100 is in the turn between strand I of the central anti-parallel β-sheet and the central strand of the c-terminal mixed sheet. Insertion six occurs at the end of the central strand of the mix sheet and includes P106 and T107. These residues are positioned at the opening of the active site crevice and may be important determinates of S.aureus specificity. The subsequent conserved residues EGCLS form the other wall of the active site crevice. Residue C111 at the center of this sequence is one of the active site metal ligands. The conserved glutamic acid projects downward to form a part of the crevice wall and makes a conserved salt bridge with R124, which is found in the center of the first strand of the mix β-sheet. The insertion of A119 results in a slight bulge of the connecting strand (with respect to the E.coli structure) which precedes the first strand of the c-terminal mixed β-sheet. This seventh insertion, the sixth insertion (P106/T107) [both located in the thumb] and the c-terminal extension are all in close proximity and constitute a S.aureus specific surface.

From the simplest comparison of these two X-ray structures one is immediately struck by the obvious difference at the c-terminus (FIG. 11). The E.coli enzyme has a long protruding α-helix which abutts the protein surface behind the active site cavity. The c-terminus of the S.aureus enzyme does not contain an equivalent α-helix, but wraps around the lower aspect of the thumb region to make a short stretch of β-sheet, terminating near the opening of the active site cavity. This is the major topological difference between the two structures, otherwise the proteins follow the same pattern and direction of secondary structure. Superposition of the two proteins permits a more detailed comparison of the alignment of secondary structural elements (FIG. 12) and was the basis of the structure-based sequence alignment of FIG. 10. A superficial evaluation would suggest that the core α-helix and the surrounding β-sheet is the most closely conserved region of the two proteins. Loops near the surface tend to be the location of insertions as is discussed above.

It follows from the low sequence identity between these two proteins, that the lining of the active site cavity would not be identical between S.aureus and E.coli. This expectation is in fact born out by the present structure (FIG. 13). Analysis of the active site cavity suggests that 9 residue changes are found in the crevice and the annulus about the crevice. These changes are indicated in the table below (Table 4). Some particularly interesting changes include the replacement of R56 (S.aureus) for R97 (E.coli) where the arginine sidechain is conserved but changes the side of the cavity from which it projects. A number of subtle hydrophobic-hydrophobic changes are observed as are a number of polar-polar changes. TABLE 4 Difference in the active site residue between S. aureus and E. coli pdf. S. aureus E. coli S. aureus E. coli V59 I44 T107 E87 S57 E42 P106 — R56 E41 L105 I86 N117 R97 Y147 L125 I150 I128 V151 C129

The X-ray structure of the (S)-2-O-(H-phosphonoxy)-L-caproyl-L-leucyl-p-nitroanilide (PCLNA) with the E.coli pdf enzyme (Hao et al., Biochemistry, 38: 4712-19 (1999)) can be used to guide the identification of the subsites (active sites) within the enzyme which accommodate the substrate amino acid sidechains (Schechter et al., BBRC, 27:157-62 (1967). Using this scheme, the methionine analogue (caproyl), the P1 subsituent, would occupy the S1 subsite; leucine, P2, the S2 subsite; and the p-nitroanilide, P3, the S3 subsite. With the PCLNA inhibitor as a frame of reference, superposition (as above) with the present S.aureus pdf X-ray structure permits the general comparison of the S.aureus with the corresponding E.coli subsites. This comparison is schematically shown in FIG. 14. The β-sheet mainchain conformation of the inhibitor forces the inhibitor subsituents to adopt the typical down-up-down disposition observed for most peptidomimetic inhibitors. The P1 and P3 subsituents interact via the intra-molecular hydrophobic interface (between the caproyl and aromatic ring) to form a continuous surface which fills the S1 and S3 subsites. The P2 subsituent projects away from the protein surface toward solvent.

Comparison of the E.coli and S.aureus crystal structures indicates that six residues in the region of the active site are conserved. In fact, five are always conserved in pdf sequences (ETB, data not shown). The residues come from the three regions of greatest sequence identity; Gxglaa, EGCls, and IxxqHexdhl, where the capitization indicates a conserved residue in the active site crevice. The first glycine is the lone invariant amino acid on the right side of the cleft (FIG. 15). The glutamic-glycine-cysteine triplet forms the invariant left side of the crevice. Finally, isoleucine and histidine are found at the bottom of the active site crevice (FIG. 15). These conserved residues form a continuous invariant surface which extends from the methionine (caproyl) site (S1) and up the left wall of the crevice. The variable residues encircle the upper aspect of the crevice. The differences account for the subtle differences in crevice shape when the two enzymes are compared—and presumably will be important determinates for inhibitor specificity.

The S1 subsite has the greatest surface conservation between E.coli and S.aureus. This is due to the sequence conservation (outlined above) of the amino acids which form the bottom of the crevice—primarily H154, which also coordinates the metal ion, and I150. The long and fairly narrow hydrophobic subsite appears well-designed to cradle the preferred methionine residue. The rightside crevice wall is defined by V59(I, E.coli), Y147L, I150I, V151C, and L105I (FIG. 17). The subsite is an exclusive hydrophobic surface in E.coli; whereas, the hydroxyl group of Y147 introduces a potential hydrogen bonding group in the upper aspect of the rightside of the equivalent S. aureus subsite. The presence of the cysteine in the E.coli enyzme may contribute to the instability of the enzyme and may offer an advantage when working with S.aureus pdf.

The S2 subsite is quite different between the two enzymes (FIG. 18). In E.coli R97 projects over the central leftside of the crevice and with E42 slightly narrows the entrance to the subsite. The principle hydrophobic interaction of the P2, leucyl, is with L91 (L112, in S.aureus). This residue is always hydrophobic, but not strictly conserved among pdf from different bacteria. The subsite continues unobstructed across the protein surface and is completely accessible to bulk solvent. In S.aureus pdf the E.coli R97 is lost and replaced with R56, which projects from the leftside of the crevice. Also, on the leftside the E.coli E42 is replaced with S57. The sidechain hydroxyl project directly into the S2 subsite and may provide a handle for P2 specific inhibitors directed towards S.aureus. Finally, the S2 subsite in S.aureus is obstructed by R56 which projects across the subsite limiting its depth, and concomitantly providing additional hydrogen bonding determinates.

The S3 subsite is a broad somewhat flat hydrophobic surface in both enzymes (FIG. 19). Aside from an aliphatic contribution from E109, which is conserved among all pdf enzymes, there are no strictly conserved amino acids in the S3 subsite. The insertion of P106 broadens the subsite in the S.aureus species. The introduction of T107 for glutamatic acid is important as is the amino acid Y147 (as noted above). In the former case, the polar group projects into the subsite in the S.aureus protein and is available for a unique hydrogen bond. In addition the aromatic Y147 and the possible hydrogen bond from the hydroxyl differentiate the rightside of the S3 subsite. These differences between S.aureus and E.coli create distinct features for the S3 subsite, which may be exploited for bacteria-specific pdf inhibitors.

Three-Dimensional Configurations

The structure coordinates generated for S. aureus pdf or the S. aureus pdf/ligand complex or one of its active sites shown in Table 1 define a unique configuration of points in space. Those of skill in the art understand that a set of structure coordinates for protein or an protein/ligand complex, or a portion thereof, define a relative set of points that, in turn, define a configuration in three dimensions. A similar or identical configuration can be defined by an entirely different set of coordinates, provided the distances and angles between coordinates remain essentially the same. In addition, a scalable configuration of points can be defined by increasing or decreasing the distances between coordinates by a scalar factor while keeping the angles essentially the same.

The present invention thus includes the three-dimensional configuration of points derived from the structure coordinates of at least a portion of an S. aureus pdf molecule or molecular complex, as shown in Table 1, as well as structurally equivalent configurations, as described below. Preferably, the three-dimensional configuration includes points derived from structure coordinates representing the locations of a plurality of the amino acids defining the S. aureus pdf active site. In one embodiment, the three-dimensional configuration includes points derived from structure coordinates representing the locations the backbone atoms of a plurality of amino acids defining the S. aureus pdf active site, preferably Gly58, Gly60, Leu61, Gln65, Glu109, Gly110, Cys111, Leu112, Ile150, His154, Glu155, and His158; and more preferably Arg56, Ser57, Gly58, Val59, Gly60, Leu61, Gln65, Leu105, Pro106, Thr107, Gly108, Glu109, Gly110, Cys111, Leu112, Asn117, Tyr147, Ile150, Val151, His154, Glu155, and His158. In another embodiment, the three-dimensional configuration includes points derived from structure coordinates representing the locations of the side chain and the backbone atoms (other than hydrogens) of a plurality of the amino acids defining the S. aureus pdf active site, preferably Gly58, Gly60, Leu61, Gln65, Glu109, Gly110, Cys111, Leu112, Ile150, His154, Glu155, and His158; and more preferably Arg56, Ser57, Gly58, Val59, Gly60, Leu61, Gln65, Leu105, Pro106, Thr107, Gly108, Glu109, Gly110, Cys111, Leu112, Asn117, Tyr147, Ile150, Val151, His154, Glu155, and His158.

Likewise, the invention also includes the three-dimensional configuration of points derived from structure coordinates of molecules or molecular complexes that are structurally homologous to S. aureus pdf, as well as structurally equivalent configurations. Structurally homologous molecules or molecular complexes are defined below. Advantageously, structurally homologous molecules can be identified using the structure coordinates of S. aureus pdf (Table 1) according to a method of the invention.

The configurations of points in space derived from structure coordinates according to the invention can be visualized as, for example, a holographic image, a stereodiagram, a model or a computer-displayed image, and the invention thus includes such images, diagrams or models.

Structurally Equivalent Crystal Structures

Various computational analyses can be used to determine whether a molecule or the active site portion thereof is “structurally equivalent,” defined in terms of its three-dimensional structure, to all or part of S. aureus pdf or its active sites. Such analyses may be carried out in current software applications, such as the Molecular Similarity application of QUANTA (Molecular Simulations Inc., San Diego, Calif.) version 4.1, and as described in the accompanying User's Guide.

The Molecular Similarity application permits comparisons between different structures, different conformations of the same structure, and different parts of the same structure. The procedure used in Molecular Similarity to compare structures is divided into four steps: (1) load the structures to be compared; (2) define the atom equivalences in these structures; (3) perform a fitting operation; and (4) analyze the results.

Each structure is identified by a name. One structure is identified as the target (i.e., the fixed structure); all remaining structures are working structures (i.e., moving structures). Since atom equivalency within QUANTA is defined by user input, for the purpose of this invention equivalent atoms are defined as protein backbone atoms (N, Cα, C, and O) for all conserved residues between the two structures being compared. A conserved residue is defined as a residue that is structurally or functionally equivalent. Only rigid fitting operations are considered.

When a rigid fitting method is used, the working structure is translated and rotated to obtain an optimum fit with the target structure. The fitting operation uses an algorithm that computes the optimum translation and rotation to be applied to the moving structure, such that the root mean square difference of the fit over the specified pairs of equivalent atom is an absolute minimum. This number, given in angstroms, is reported by QUANTA.

For the purpose of this invention, any molecule or molecular complex or active site thereof, or any portion thereof, that has a root mean square deviation of conserved residue backbone atoms (N, Cα, C, O) of less than about 1.4 Å, when superimposed on the relevant backbone atoms described by the reference structure coordinates listed in Table 1, is considered “structurally equivalent” to the reference molecule. That is to say, the crystal structures of those portions of the two molecules are substantially identical, within acceptable error. Particularly preferred structurally equivalent molecules or molecular complexes are those that are defined by the entire set of structure coordinates in Table 1, ±a root mean square deviation from the conserved backbone atoms of those amino acids of not more than 1.4 Å. More preferably, the root mean square deviation is less than about 0.8 Å, and preferably less than about 0.35 Å.

The term “root mean square deviation” means the square root of the arithmetic mean of the squares of the deviations. It is a way to express the deviation or variation from a trend or object. For purposes of this invention, the “root mean square deviation” defines the variation in the backbone of a protein from the backbone of S. aureus pdf or an active site portion thereof, as defined by the structure coordinates of S. aureus pdf described herein.

Machine Readable Storage Media

Transformation of the structure coordinates for all or a portion of S. aureus pdf or the S. aureus pdf/ligand complex or one of its active sites, for structurally homologous molecules as defined below, or for the structural equivalents of any of these molecules or molecular complexes as defined above, into three-dimensional graphical representations of the molecule or complex can be conveniently achieved through the use of commercially-available software.

The invention thus further provides a machine-readable storage medium including a data storage material encoded with machine readable data which, when using a machine programmed with instructions for using said data, displays a graphical three-dimensional representation of any of the molecule or molecular complexes of this invention that have been described above. In a preferred embodiment, the machine-readable data storage medium includes a data storage material encoded with machine readable data which, when using a machine programmed with instructions for using said data, displays a graphical three-dimensional representation of a molecule or molecular complex including all or any parts of an S. aureus pdf active site or an S. aureus pdf-like active site, as defined above. In another preferred embodiment, the machine-readable data storage medium displays a graphical three-dimensional representation of a molecule or molecular complex defined by the structure coordinates of all of the amino acids in Table 1, ±a root mean square deviation from the backbone atoms of said amino acids of not more than 0.8 Å.

In an alternative embodiment, the machine-readable data storage medium includes a data storage material encoded with a first set of machine readable data which includes the Fourier transform of the structure coordinates set forth in Table 1, and which, when using a machine programmed with instructions for using said data, can be combined with a second set of machine readable data including the x-ray diffraction pattern of a molecule or molecular complex to determine at least a portion of the: structure coordinates corresponding to the second set of machine readable data.

For example, a system for reading a data storage medium may include a computer including a central processing unit (“CPU”), a working memory which may be, e.g., RAM (random access memory) or “core” memory, mass storage memory (such as one or more disk drives or CD-ROM drives), one or more display devices (e.g., cathode-ray tube (“CRT”) displays, light emitting diode (“LED”) displays, liquid cyrstal displays (“LCDs”), electroluminescent displays, vacuum fluorescent displays, field emission displays (“FEDs”), plasma displays, projection panels, etc.), one or more user input devices (e.g., keyboards, microphones, mice, touch screens, etc.), one or more input lines, and one or more output lines, all of which are interconnected by a conventional bidirectional system bus. The system may be a stand-alone computer, or may be networked (e.g., through local area networks, wide area networks, intranets, extranets, or the internet) to other systems (e.g., computers, hosts, servers, etc.). The system may also include additional computer controlled devices such as consumer electronics and appliances.

Input hardware may be coupled to the computer by input lines and may be implemented in a variety of ways. Machine-readable data of this invention may be inputted via the use of a modem or modems connected by a telephone line or dedicated data line. Alternatively or additionally, the input hardware may include CD-ROM drives or disk drives. In conjunction with a display terminal, a keyboard may also be used as an input device.

Output hardware may be coupled to the computer by output lines and may similarly be implemented by conventional devices. By way of example, the output hardware may include a display device for displaying a graphical representation of an active site of this invention using a program such as QUANTA as described herein. Output hardware might also include a printer, so that hard copy output may be produced, or a disk drive, to store system output for later use.

In operation, a CPU coordinates the use of the various input and output devices, coordinates data accesses from mass storage devices, accesses to and from working memory, and determines the sequence of data processing steps. A number of programs may be used to process the machine-readable data of this invention. Such programs are discussed in reference to the computational methods of drug discovery as described herein. References to components of the hardware system are included as appropriate throughout the following description of the data storage medium.

Machine-readable storage devices useful in the present invention include, but are not limited to, magnetic devices, electrical devices, optical devices, and combinations thereof. Examples of such data storage devices include, but are not limited to, hard disk devices, CD devices, digital video disk devices, floppy disk devices, removable hard disk devices, magneto-optic disk devices, magnetic tape devices, flash memory devices, bubble memory devices, holographic storage devices, and any other mass storage peripheral device. It should be understood that these storage devices include necessary hardware (e.g., drives, controllers, power supplies, etc.) as well as any necessary media (e.g., disks, flash cards, etc.) to enable the storage of data.

Structurally Homologous Molecules, Molecular Complexes, and Crystal Structures

The structure coordinates set forth in Table 1 can be used to aid in obtaining structural information about another crystallized molecule or molecular complex. A “molecular complex” means a protein in covalent or non-covalent association with a chemical entity or compound. The method of the invention allows determination of at least a portion of the three-dimensional structure of molecules or molecular complexes which contain one or more structural features that are similar to structural features of S. aureus pdf. These molecules are referred to herein as “structurally homologous” to S. aureus pdf. Similar structural features can include, for example, regions of amino acid identity, conserved active site or binding site motifs, and similarly arranged secondary structural elements (e.g., α helices and β sheets). Optionally, structural homology is determined by aligning the residues of the two amino acid sequences to optimize the number of identical amino acids along the lengths of their sequences; gaps in either or both sequences are permitted in making the alignment in order to optimize the number of identical amino acids, although the amino acids in each sequence must nonetheless remain in their proper order. Preferably, two amino acid sequences are compared using the Blastp program, version 2.0.9, of the BLAST 2 search algorithm, as described by Tatusova et al., FEMS Microbiol Lett., 174:247-50 (1999), and available at http://www.ncbi.nlm.nih.gov/gorf/bl2.html. Preferably, the default values for all BLAST 2 search parameters are used, including matrix=BLOSUM62; open gap penalty=1 1, extension gap penalty=1, gap x_dropoff=50, expect=10, wordsize=3, and filter on. In the comparison of two amino acid sequences using the BLAST search algorithm, structural similarity is referred to as “identity.” Preferably, a structurally homologous molecule is a protein that has an amino acid sequence sharing at least 65% identity with the amino acid sequence of S. aureus pdf (SEQ ID NO: 1). More preferably, a protein that is structurally homologous to S. aureus pdf includes at least one contiguous stretch of at least 50 amino acids that shares at least 80% amino acid sequence identity with the analogous portion of S. aureus pdf. Methods for generating structural information about the structurally homologous molecule or molecular complex are well-known and include, for example, molecular replacement techniques.

Therefore, in another embodiment this invention provides a method of utilizing molecular replacement to obtain structural information about a molecule or molecular complex whose structure is unknown including the steps of:

-   -   (a) crystallizing the molecule or molecular complex of unknown         structure;     -   (b) generating an x-ray diffraction pattern from said         crystallized molecule or molecular complex; and     -   (c) applying at least a portion of the structure coordinates set         forth in Table 1 to the x-ray diffraction pattern to generate a         three-dimensional electron density map of the molecule or         molecular complex whose structure is unknown.

By using molecular replacement, all or part of the structure coordinates of S. aureus pdf or the S. aureus pdf/ligand complex as provided by this invention (and set forth in Table 1) can be used to determine the structure of a crystallized molecule or molecular complex whose structure is unknown more quickly and efficiently than attempting to determine such information ab initio.

Molecular replacement provides an accurate estimation of the phases for an unknown structure. Phases are a factor in equations used to solve crystal structures that cannot be determined directly. Obtaining accurate values for the phases, by methods other than molecular replacement, is a time-consuming process that involves iterative cycles of approximations and refinements and greatly hinders the solution of crystal structures. However, when the crystal structure of a protein containing at least a structurally homologous portion has been solved, the phases from the known structure provide a satisfactory estimate of the phases for the unknown structure.

Thus, this method involves generating a preliminary model of a molecule or molecular complex whose structure coordinates are unknown, by orienting and positioning the relevant portion of S. aureus pdf or the S. aureus pdf/ligand complex according to Table 1 within the unit cell of the crystal of the unknown molecule or molecular complex so as best to account for the observed x-ray diffraction pattern of the crystal of the molecule or molecular complex whose structure is unknown. Phases can then be calculated from this model and combined with the observed x-ray diffraction pattern amplitudes to generate an electron density map of the structure whose coordinates are unknown. This, in turn, can be subjected to any well-known model building and structure refinement techniques to provide a final, accurate structure of the unknown crystallized molecule or molecular complex (E. Lattman, “Use of the Rotation and Translation Functions,” in Meth. Enzymol., 115:55-77 (1985); M. G. Rossman, ed., “The Molecular Replacement Method,” Int. Sci. Rev. Ser., No. 13, Gordon & Breach, New York (1972)).

Structural information about a portion of any crystallized molecule or molecular complex that is sufficiently structurally homologous to a portion of S. aureus pdf can be resolved by this method. In addition to a molecule that shares one or more structural features with S. aureus pdf as described above, a molecule that has similar bioactivity, such as the same catalytic activity, substrate specificity or ligand binding activity as S. aureus pdf, may also be sufficiently structurally homologous to S. aureus pdf to permit use of the structure coordinates of S. aureus pdf to solve its crystal structure.

In a preferred embodiment, the method of molecular replacement is utilized to obtain structural information about a molecule or molecular complex, wherein the molecule or molecular complex includes at least one S. aureus pdf subunit or homolog. A “subunit” of S. aureus pdf is an S. aureus pdf molecule that has been truncated at the N-terminus or the C-terminus, or both. In the context of the present invention, a “homolog” of S. aureus pdf is a protein that contains one or more amino acid substitutions, deletions, additions, or rearrangements with respect to the amino acid sequence of S. aureus pdf, but that, when folded into its native conformation, exhibits or is reasonably expected to exhibit at least a portion of the tertiary (three-dimensional) structure of S. aureus pdf. For example, structurally homologous molecules can contain deletions or additions of one or more contiguous or noncontiguous amino acids, such as a loop or a domain. Structurally homologous molecules also include “modified” S. aureus pdf molecules that have been chemically or enzymatically derivatized at one or more constituent amino acid, including side chain modifications, backbone modifications, and N- and C-terminal modifications including acetylation, hydroxylation, methylation, amidation, and the attachment of carbohydrate or lipid moieties, cofactors, and the like.

A heavy atom derivative of S. aureus pdf is also included as an S. aureus pdf homolog. The term “heavy atom derivative” refers to derivatives of S. aureus pdf produced by chemically modifying a crystal of S. aureus pdf. In practice, a crystal is soaked in a solution containing heavy metal atom salts, or organometallic compounds, e.g., lead chloride, gold thiomalate, thiomersal or uranyl acetate, which can diffuse through the crystal and bind to the surface of the protein. The location(s) of the bound heavy metal atom(s) can be determined by x-ray diffraction analysis of the soaked crystal. This information, in turn, is used to generate the phase information used to construct three-dimensional structure of the protein (T. L. Blundell and N. L. Johnson, Protein Crystallography, Academic Press (1976)).

Because S. aureus pdf can crystallize in more than one crystal form, the structure coordinates of S. aureus pdf as provided by this invention are particularly useful in solving the structure of other crystal forms of S. aureus pdf or S. aureus pdf complexes.

The structure coordinates of S. aureus pdf in Table 1 are also particularly useful to solve the structure of crystals of S. aureus pdf, S. aureus pdf mutants or S. aureus pdf homologs co-complexed with a variety of chemical entities. This approach enables the determination of the optimal sites for interaction between chemical entities, including candidate S. aureus pdf modifiers and S. aureus pdf. Potential sites for modification within the various binding site of the molecule can also be identified. This information provides an additional tool for determining the most efficient binding interactions, for example, increased hydrophobic interactions, between S. aureus pdf and a chemical entity. For example, high resolution x-ray diffraction data collected from crystals exposed to different types of solvent allows the determination of where each type of solvent molecule resides. Small molecules that bind tightly to those sites can then be designed and synthesized and tested for their potential modification of S. aureus pdf.

All of the complexes referred to above may be studied using well-known x-ray diffraction techniques and may be refined versus x-ray data to an R value of about 0.20 or less using computer software, such as X-PLOR (Yale University, (1992), distributed by Molecular Simulations, Inc.; see, e.g., Blundell & Johnson, supra; Meth. Enzymol., Vol. 114 & 115, H. W. Wyckoff et al., eds., Academic Press (1985)). This information may thus be used to optimize known modifiers of S. aureus pdf activity, and more importantly, to design new modifiers of S. aureus pdf activity.

The invention also includes the unique three-dimensional configuration defined by a set of points defined by the structure coordinates for a molecule or molecular complex structurally homologous to S. aureus pdf as determined using the method of the present invention, structurally equivalent configurations, and magnetic storage media including such set of structure coordinates.

Further, the invention includes structurally homologous molecules as identified using the method of the invention.

Homology Modeling

Using homology modeling, a computer model of an S. aureus pdf homolog can be built or refined without crystallizing the homolog. First, a preliminary model of the S. aureus pdf homolog is created by sequence alignment with S. aureus pdf, secondary structure prediction, the screening of structural libraries, or any combination of those techniques. Computational software may be used to carry out the sequence alignments and the secondary structure predictions. Structural incoherences, e.g., structural fragments around insertions and deletions, can be modeled by screening a structural library for peptides of the desired length and with a suitable conformation. For prediction of the side chain conformation, a side chain rotamer library may be employed. Where the S. aureus pdf homolog has been crystallized, the final homology model can be used to solve the crystal structure of the homolog by molecular replacement, as described above. Next, the preliminary model is subjected to energy minimization to yield an energy minimized model. The energy minimized model may contain regions where stereochemistry restraints are violated, in which case such regions are remodeled to obtain a final homology model. The homology model is positioned according to the results of molecular replacement, and subjected to further refinement including molecular dynamics calculations.

Rational Drug Design

Computational techniques can be used to screen, identify, select and design chemical entities capable of associating with S. aureus pdf or structurally homologous molecules. Knowledge of the structure coordinates for S. aureus pdf permits the design and/or identification of synthetic compounds and/or other molecules which have a shape complementary to the conformation of the S. aureus pdf binding site. In particular, computational techniques can be used to identify or design chemical entities that are potential modifiers of S. aureus pdf activity, such as inhibitors, agonists and antagonists, that associate with an S. aureus pdf active site or an S. aureus pdf-like active site. Potential modifiers may bind to or interfere with all or a portion of the active site of S. aureus pdf, and can be competitive, non-competitive, or uncompetitive inhibitors; or interfere with dimerization by binding at the interface between the two monomers. Once identified and screened for biological activity, these inhibitors/agonists/antagonists may be used therapeutically or prophylactically to block S. aureus pdf activity and, thus, block bacterial growth. Structure-activity data for analogs of ligands that bind to or interfere with S. aureus pdf or S. aureus pdf-like active sites can also be obtained computationally.

The term “chemical entity,” as used herein, refers to chemical compounds, complexes of two or more chemical compounds, and fragments of such compounds or complexes. Chemical entities that are determined to associate with S. aureus pdf are potential drug candidates. Data stored in a machine-readable storage medium that displays a graphical three-dimensional representation of the structure of S. aureus pdf or a structurally homologous molecule, as identified herein, or portions thereof may thus be advantageously used for drug discovery. The structure coordinates of the chemical entity are used to generate a three-dimensional image that can be computationally fit to the three-dimensional image of S. aureus pdf or a structurally homologous molecule. The three-dimensional molecular structure encoded by the data in the data storage medium can then be computationally evaluated for its ability to associate with chemical entities. When the molecular structures encoded by the data is displayed in a graphical three-dimensional representation on a computer screen, the protein structure can also be visually inspected for potential association with chemical entities.

One embodiment of the method of drug design involves evaluating the potential association of a known chemical entity with S. aureus pdf or a structurally homologous molecule, particularly with an S. aureus pdf active site or S. aureus pdf-like active site. The method of drug design thus includes computationally evaluating the potential of a selected chemical entity to associate with any of the molecules or molecular complexes set forth above. This method includes the steps of: (a) employing computational means to perform a fitting operation between the selected chemical entity and a active site of the molecule or molecular complex; and (b) analyzing the results of said fitting operation to quantify the association between the chemical entity and the active site.

In another embodiment, the method of drug design involves computer-assisted design of chemical entities that associate with S. aureus pdf, its homologs, or portions thereof. Chemical entities can be designed in a step-wise fashion, one fragment at a time, or may be designed as a whole or “de novo.”

To be a viable drug candidate, the chemical entity identified or designed according to the method must be capable of structurally associating with at least part of an S. aureus pdf or S. aureus pdf-like active sites, and must be able, sterically and energetically, to assume a conformation that allows it to associate with the S. aureus pdf or S. aureus pdf-like active site. Non-covalent molecular interactions important in this association include hydrogen bonding, van der Waals interactions, hydrophobic interactions, and electrostatic interactions. Conformational considerations include the overall three-dimensional structure and orientation of the chemical entity in relation to the active site, and the spacing between various functional groups of an entity that directly interact with the S. aureus pdf-like active site or homologs thereof.

Optionally, the potential binding of a chemical entity to an S. aureus pdf or S. aureus pdf-like active site is analyzed using computer modeling techniques prior to the actual synthesis and testing of the chemical entity. If these computational experiments suggest insufficient interaction and association between it and the S. aureus pdf or S. aureus pdf-like active site, testing of the entity is obviated. However, if computer modeling indicates a strong interaction, the molecule may then be synthesized and tested for its ability to bind to or interfere with an S. aureus pdf or S. aureus pdf-like active site. Binding assays to determine if a compound actually binds to S. aureus pdf can also be performed and are well known in the art. Binding assays may employ kinetic or thermodynamic methodology using a wide variety of techniques including, but not limited to, microcalorimetry, circular dichroism, capillary zone electrophoresis, nuclear magnetic resonance spectroscopy, fluorescence spectroscopy, and combinations thereof.

One skilled in the art may use one of several methods to screen chemical entities or fragments for their ability to associate with an S. aureus pdf or S. aureus pdf-like active site. This process may begin by visual inspection of, for example, an S. aureus pdf or S. aureus pdf-like active site on the computer screen based on the S. aureus pdf structure coordinates in Table 1 or other coordinates which define a similar shape generated from the machine-readable storage medium. Selected fragments or chemical entities may then be positioned in a variety of orientations, or docked, within the active site. Docking may be accomplished using software such as QUANTA and SYBYL, followed by energy minimization and molecular dynamics with standard molecular mechanics forcefields, such as CHARMM and AMBER.

Specialized computer programs may also assist in the process of selecting fragments or chemical entities. Examples include GRID (P. J. Goodford, J. Med. Chem., 28:849-57 (1985); available from Oxford University, Oxford, UK); MCSS (A. Miranker et al., Proteins: Struct. Funct. Gen., 11:29-34 (1991); available from Molecular Simulations, San Diego, Calif.); AUTODOCK (D. S. Goodsell et al., Proteins: Struct. Funct. Genet., 8:195-202 (1990); available from Scripps Research Institute, La Jolla, Calif.); and DOCK (I. D. Kuntz et al., J. Mol. Biol., 161:269-88 (1982); available from University of California, San Francisco, Calif.).

Once suitable chemical entities or fragments have been selected, they can be assembled into a single compound or complex. Assembly may be preceded by visual inspection of the relationship of the fragments to each other on the three-dimensional image displayed on a computer screen in relation to the structure coordinates of S. aureus pdf. This would be followed by manual model building using software such as QUANTA or SYBYL (Tripos Associates, St. Louis, Mo.).

Useful programs to aid one of skill in the art in connecting the individual chemical entities or fragments include, without limitation, CAVEAT (P. A. Bartlett et al., in Molecular Recognition in Chemical and Biological Problems, Special Publ., Royal Chem. Soc., 78:182-96 (1989); G. Lauri et al., J. Comput. Aided Mol. Des., 8:51-66 (1994); available from the University of California, Berkeley, Calif.); 3D database systems such as ISIS (available from MDL Information Systems, San Leandro, Calif.; reviewed in Y. C. Martin, J. Med. Chem. 35:2145-54 (1992)); and HOOK (M. B. Eisen et al., Proteins: Struc., Funct., Genet., 19:199-221 (1994); available from Molecular Simulations, San Diego, Calif.).

S. aureus pdf binding compounds may be designed “de novo” using either an empty binding site or optionally including some portion(s) of a known modifier(s). There are many de novo ligand design methods including, without limitation, LUDI (H.-J. Bohm, J. Comp. Aid. Molec. Design., 6:61-78 (1992); available from Molecular Simulations Inc., San Diego, Calif.); LEGEND (Y. Nishibata et al., Tetrahedron, 47:8985 (1991); available from Molecular Simulations Inc., San Diego, Calif.); LeapFrog (available from Tripos Associates, St. Louis, Mo.); and SPROUT (V. Gillet et al., J. Comput. Aided Mol. Design, 7:127-53 (1993); available from the University of Leeds, UK).

Once a compound has been designed or selected by the above methods, the efficiency with which that entity may bind to or interfere with an S. aureus pdf or S. aureus pdf-like active site may be tested and optimized by computational evaluation. For example, an effective S. aureus pdf or S. aureus pdf-like active site modifier must preferably demonstrate a relatively small difference in energy between its bound and free states (i.e., a small deformation energy of binding). Thus, the most efficient S. aureus pdf or S. aureus pdf-like active site modifiers should preferably be designed with a deformation energy of binding of not greater than about 10 kcal/mole; more preferably, not greater than 7 kcal/mole. S. aureus pdf or S. aureus pdf-like active site modifiers may interact with the active site in more than one conformation that is similar in overall binding energy. In those cases, the deformation energy of binding is taken to be the difference between the energy of the free entity and the average energy of the conformations observed when the modifier binds to the protein.

An entity designed or selected as binding to or interfering with an S. aureus pdf or S. aureus pdf-like active site may be further computationally optimized so that in its bound state it would preferably lack repulsive electrostatic interaction with the target enzyme and with the surrounding water molecules. Such non-complementary electrostatic interactions include repulsive charge-charge, dipole-dipole, and charge-dipole interactions.

Specific computer software is available in the art to evaluate compound deformation energy and electrostatic interactions. Examples of programs designed for such uses include: Gaussian 94, revision C (M. J. Frisch, Gaussian, Inc., Pittsburgh, Pa. (1995)); AMBER, version 4.1 (P. A. Kollman, University of California at San Francisco, (1995)); QUANTA/CHARMM (Molecular Simulations, Inc., San Diego, Calif. (1995)); Insight II/Discover (Molecular Simulations, Inc., San Diego, Calif. (1995)); DelPhi (Molecular Simulations, Inc., San Diego, Calif. (1995)); and AMSOL (Quantum Chemistry Program Exchange, Indiana University). These programs may be implemented, for instance, using a Silicon Graphics workstation such as an Indigo² with “IMPACT” graphics. Other hardware systems and software packages will be known to those skilled in the art.

Another approach encompassed by this invention is the computational screening of small molecule databases for chemical entities or compounds that can bind in whole, or in part, to a S. aureus pdf or S. aureus pdf-like active site. In this screening, the quality of fit of such entities to the binding site may be judged either by shape complementarity or by estimated interaction energy (E. C. Meng et al., J. Comp. Chem., 13:505-24 (1992)).

This invention also enables the development of chemical entities that can isomerize to short-lived reaction intermediates in the chemical reaction of a substrate or other compound that binds to or with S. aureus pdf. Time-dependent analysis of structural changes in S. aureus pdf during its interaction with other molecules is carried out. The reaction intermediates of S. aureus pdf can also be deduced from the reaction product in co-complex with S. aureus pdf. Such information is useful to design improved analogs of known modifiers of S. aureus pdf activity or to design novel classes of modifiers based on the reaction intermediates of the S. aureus pdf and modifier co-complex. This provides a novel route for designing S. aureus pdf modifiers with both high specificity and stability.

Yet another approach to rational drug design involves probing the S. aureus pdf crystal of the invention with molecules including a variety of different functional groups to determine optimal sites for interaction between candidate S. aureus pdf modifiers and the protein. For example, high resolution x-ray diffraction data collected from crystals soaked in or co-crystallized with other molecules allows the determination of where each type of solvent molecule sticks. Molecules that bind tightly to those sites can then be further modified and synthesized and tested for their hepes protease inhibitor activity (J. Travis, Science, 262:1374 (1993)).

In a related approach, iterative drug design is used to identify modifiers of S. aureus pdf activity. Iterative drug design is a method for optimizing associations between a protein and a compound by determining and evaluating the three-dimensional structures of successive sets of protein/compound complexes. In iterative drug design, crystals of a series of protein/compound complexes are obtained and then the three-dimensional structures of each complex is solved. Such an approach provides insight into the association between the proteins and compounds of each complex. This is accomplished by selecting compounds with inhibitory activity, obtaining crystals of this new protein/compound complex, solving the three dimensional structure of the complex, and comparing the associations between the new protein/compound complex and previously solved protein/compound complexes. By observing how changes in the compound affected the protein/compound associations, these associations may be optimized.

Pharmaceutical Compositions

Pharmaceutical compositions of this invention include a potential modifier of S. aureus pdf activity identified according to the invention, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle. The term “pharmaceutically acceptable carrier” refers to a carrier(s) that is “acceptable” in the sense of being compatible with the other ingredients of a composition and not deleterious to the recipient thereof. Optionally, the pH of the formulation is adjusted with pharmaceutically acceptable acids, bases, or buffers to enhance the stability of the formulated compound or its delivery form.

Methods of making and using such pharmaceutical compositions are also included in the invention. The pharmaceutical compositions of the invention can be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally, or via an implanted reservoir. Oral administration or administration by injection is preferred. The term parenteral as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, intra-articular, intrasynovial, intrasternal, intrathecal, intralesional, and intracranial injection or infusion techniques.

Dosage levels of between about 0.01 and about 100 mg/kg body weight per day, preferably between about 0.5 and about 75 mg/kg body weight per day of the S. aureus pdf inhibitory compounds described herein are useful for the prevention and treatment of S. aureus pdf mediated disease. Typically, the pharmaceutical compositions of this invention will be administered from about 1 to about 5 times per day or alternatively, as a continuous infusion. Such administration can be used as a chronic or acute therapy. The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. A typical preparation will contain from about 5% to about 95% active compound (w/w). Preferably, such preparations contain from about 20% to about 80% active compound.

In order that this invention be more fully understood, the following examples are set forth. These examples are for the purpose of illustration only and are not to be construed as limiting the scope of the invention in any way.

EXAMPLES Example 1 Analysis of the Structure of S. aureus pdf

Cloning and Expression

The plasmid containing the pdf insert was purified and used to transform a competent strain of E. coli JM109. This cDNA clone used for protein expression and purification (R127K H186Q, highlighted in FIG. 3) contained two mutations. The second mutation is confirmed to be in the HIS6 tag (near the c-terminus) and has no effect on Km or Kcat. The gene encodes a total of 189 residues including a c-terminal hexahis tag.

The pdf protein was expressed using LB with ampicillin (100 mg/L) in both the seed and production media. LB was prepared using Bacto-tryptone (10 g), Bacto yeast (5 g), and NaCl (5 g) added per L of deioninzed water. The pH of the media was adjusted to 7.5 before sterilization with KOH. The LB broth was auotclaved for 20 minutes in 100 ml volumes in 500 ml wide mouth fermentation flasks. Ampicillin was filter sterilized and added just before innoculation. The 100 ml seed stock fermentations were carried out in 500 ml wide mouth flasks and were innoculated from agar cultures and were incubated overnight at 37° C. with agitation at 200 revolutions per minute (rpm). The seed fermentations were used to inoculate at 2% the 100 ml production fermentations which were also carried out in 500 ml wide mouth flasks. These fermentations were incubated with agitation at 200 rpm for slightly longer than 2 hours and were then induced (OD 660 nm reached 0.6). IPTG was added to a final concentration of 0.4 mM. The induced fermentations were continued for an additional 3.5 hours until the OD reached 3.0. Multiple fermentations produced a final harvest of 4-6 liters for purification.

For expression of selenomethionyl-Pdf, M9 glucose was utilized in 100 ml volumes containing ampicillin, thiamin, and PAS trace metal solution at 100 mg, 5 mg and 0.3 ml per liter of deionized water, respectively. Multiple shake flasks were used to attain the desired fermentation volume. Since JM109 is not a methionine auxotroph, incorporation of selenomethionine was accomplished through down regulation of methionine biosynthesis just prior to induction (Van Duyne, Standaert, 1993). The culture was grown in 500 ml wide mouth fermentation flasks at 37° C. with an agitation rate of 200 rpm until A600 reached ca. 0.5 unit. At this point, the following filter sterilized amino acids were added to achieve down-regulation. DL-selenomethione, L-lysine, L-threonine and L-phenylalanine were added to final concentrations of 120 micrograms/ml. L-leucine, L-isoleucine and L-valine were added to final concentrations of 60 micrograms/ml. After 15-20 minutes, protein expression was induced by the addition of filter sterilized IPTG added to a final concentration of 0.4 mM. Growth of the culture was continued as described for an additional 3 hours when A600 reached ca. 2 units. Cells were then harvested by centrifugation and stored at −80° C.

Purification

Cell paste from a two liter E.coli fermentation expressing S.aureus pdf was lysed in 50 mM Tris-HCl pH=8.0 with lysozyme dissolved at 1 mg/ml. The suspension sat on ice for 10 minutes and large strand DNA was broken by repeatedly shearing with a syringe and 19 gauge Needle. Cell extract was collected and centrifuged at 20500 rpm for 40-45 minutes at 5° C. Ni-NTA resin from Qiagen was equilibrated in lysis buffer (without lysozyme) and stirred into the cell extract. The suspension was poured into a column, washed expensively with lysis buffer and pdf was eluted with lysis buffer containing 200 mM imidazole. This protein designated as pdf1 was used for the first crystallization efforts, but required further purification (FIG. 4).

The eluate from the nickel column was concentrated by ultrafiltration with an Amicon stirred cell under nitrogen at room temperature. Two forms of pdf were resolved by anionic (Q fast flow, Pharmacia) exchange chromatography (without baseline resolution) as follows. A concentrated sample was injected onto a 1 mL column equilibrated with 25mM Tris-HCl, pH=8.0. Proteins were resolved with a linear gradient of NaCl. The two forms of pdf were collected separately for further analysis. No differences in SDS-PAGE moblilty or purity were observed. The first fraction had optimal activity while the second fraction had much less specific activity. Protein eluted in the early fraction of the gradient was collected and further concentrated in a stirred cell to the desired volume. Further purified pdf is referred to as pdf2, and improved purification is verified by Isoelectric focussing. Pdf was either delivered for crystallization experiments at this time, or was mixed with 50% glycerol and stored at −20° C. Enzyme assays have demonstrated that pdf is stable for over one year when stored in 50% glycerol at −20° C.

Selenomethionine pdf was purified for crystallization efforts as described above with the inclusion of 5 mM BME to reduce the chance of selenomethionine oxidation.

Protein Preparation

Protein was delivered immediately following concentration of peak material from the anion exchange column. The buffer contained 25 mM Tris pH=8.0 and approximately 50 mM NaCl. Protein was adjusted to 30 mg/ml and exchanged into buffer containing 25 mM Tris pH=8.0. Later batches of protein were received at a protein concentration of 60 mg/ml. This protein was diluted in half with water and frozen immediately in 50 microliter aliquots for later experiments.

Crystallization of S.aureus pdf

The first batch of pdf2 was received for crystallization. Crystallization experiments began with commercially available, random sparse matrix screens. Drops of 1 μL protein and 1 μL well solutions were set up in hanging drop vapor diffusion experiments at room temperature. Crystals grew in one week from 4 separate well conditions 6,15,18 and 22 of Hampton Crystal Screen I (Jancarik et al., J. Appl. Cryst., 24:409-11 (1991)). Follow-up grid screens were simultaneously set up to optimize each crystallization condition and are described below.

Hampton Research Crystal Screen I, #6

Hampton Screen I, condition 6 contains 30% PEG 4000, 0.2M MgCl₂ and 0.1M Tris pH=8.5. Original crystals grew as long thin needle clusters. Sitting drop vapor diffusion experiments were set up by mixing 2 microliters pdf+2 microliters reservoir solution. Crystals were optimized through a series of grid screens varying both PEG 4000 and MgCl₂ concentrations. Results from these screens produced larger rod crystals.

Micro-seeding was utilized in an attempt to grow individual crystals. Seed stocks were made by breaking off a large rod crystal and crushing it in 10 microliters of matching well solution. Serial dilutions of seed stocks were made to 10⁻⁴. Freshly mixed drops of protein and well solution containing 0.1M Tris pH=8.5, 0.075M MgCl₂ and varying amounts of PEG 4000 were seeded at setup with a cat whisker by successively streaking the whisker across one row. Single, chunky crystals grew within two weeks up to 0.35×0.35×0.7 micrometer. Large crystals often contained a channel down the middle of the crystal. Crystals were successfully stabilized and slowly transferred into a cryo-preservation solution containing 25% PEG 4000, 0.1M Tris pH=8.5, 0.1M MgCl₂ and 25% glycerol. Crystals were frozen in liquid nitrogen for cryogenic data collection.

Hampton Research Crystal Screen I, #15

Condition # 15 of Crystal Screen I was the second solution to produce crystals in the original screens. This solution contains 30% PEG 8000, 0.2M ammonium sulfate (A/S) and 0.1M Cacodylic acid pH=6.5. The original hit contained twinned crystalline rods that spread throughout the drop. The crystals were improved by varying both PEG 8000 and ammonium sulfate. Crystals improved significantly through micro-seeding. Crystals could be easily transferred to stabilization solution and slowly soaked into cryo-protective solution containing 22% PEG 8000, 0.2M ammonium sulfate, 0.1M cacodylic acid pH=6.5 and 25% glycerol for freezing.

Hampton Research Crystal Screen I, #18

A third solution to yield crystals was condition # 18 of Crystal Screen I. The solution is 20% PEG 8000, 0.1 m Na cacodylate pH=6.5 and 0.2M Mg acetate. Crystals grew as small rods that were very difficult to optimize. Seeding enabled the growth of a few large crystals, but crystals were very fragile. In many cases, crystals could not be stabilized without major crystal cracking. Despite these difficulties, a couple crystals were successfully soaked into cryo-solution containing 20% PEG 8000, 0.1 M NaCacodylate pH=6.5 and 0.2M MgAcetate and 25% glycerol and frozen for data collection.

Hampton Research Crystal Screen I, #22

Crystals also appeared in condition #22 which contains 30% PEG 4000, 0.1M Tris pH=8.5 and 0.2M sodium acetate. Crystals also grew as rod clusters and were optimized as described above for condition #6. Tweaking of the PEG 400 and Na acetate as well as micro-seeding produced large single rods grown from the bridge. Crystals were slowly soaked into cryo-solution of 0.3M Na acetate, 24% PEG 4000, 0.1M Tris pH=8.5 and 25% glycerol. Crystals diffracted well to 2.0 Å.

Selenomethionine pdf

Se-methionine pdf was prepared and initial crystallization experiments were set up in each of the four conditions as described above. An additional 5 mM BME was added to the reservoir solutions to reduce the chance of oxidation. Crystals from condition #6 were optimized through micro-seeding and produced sizable crystals. Crystals were prepared for low temperature data collection.

Data Collection, Space Group Determination

A crystal was grown from 28% PEG 8000, 0.1M cacodylic acid pH=6.5 and 0.1M ammonium sulfate and measured 0.1×0.1×0.5 micrometer. This crystal was the result of the follow up experiments from the Hampton I #15 hits. The crystal was frozen as described above for low temperature data collection. Data was collected on a single Hi Star at a detector distance of 18 cm and a temperature of 100° K. Frames of 300 seconds, 0.25° omega oscillation, and 2θ=15 were collected. Data was not processed because the crystal appeared obviously twinned.

Another crystal was grown from 16% PEG 8000, 0.1M Cacodylic Acid pH=6.5 and 0.4M Mg Acetate. This crystal was the result of the follow up experiments from the Hampton I #18 hits. The crystal was frozen and data was collected on the APS 17-ID beamline. The crystal diffracted to around 1.9 Å and about 400 frames of 0.5 degree oscillation data were collected (Table 5). The space group is C222₁ with unit cell parameters of a=94.296 Å, b=120.85 Å, c=47.88 Å, and α=β=γ=90°. Data collection ended since we were at the end of the run and the crystal was recovered at APS and refrozen for additional data collection. Data collection was continued on this crystal. Data was collected on a single Hi Star at detector distance of 12 cm and 300 seconds per frame. The 2θ angle was set to 15° with an omega oscillation of 0.25°. Several water flow problems were encountered during data collection. This data was complete to around 2.7 Å (100% observed) with the I/sigma dropping below 2.0 for the higher resolution data. This data was not used for calculations. Molecular replacement was attempted using this data, but was unsuccessful.

A Se-methionine crystal was grown from 22.5% PEG 4000, 0.1M Tris pH=8.5 and 0.075M MgCl₂. This crystal was the result of the follow up experiments from the Hampton I #6 hits. Data was collected on a dual Hi Star at 12 cm and 100° K. Each frame oscillated 0.25° omega for 200 seconds at 2θ=−25°. Data collection statistics are summarized in Table 6. The space group is C222₁ with unit cell parameters of a=94.469 Å, b=121.965 Å, c=47.58 Å, and α=β=γ=90°. This crystal diffracted to around 2.0 Å resolution. This data set was used for molecular replacement studies, but these also failed to produce a good solution. This data suggested that a good data set could be obtained from these Se-Methionine crystals at APS.

Preliminary co-crystallization experiments began in an attempt to obtain a pdf complex with several leads as determined from screens. A crystal was grown in the presence of 10% DMSO and 2 mM of a potential inhibitor as well as the reservoir solution containing 20% PEG 4000, 0.1M Tris pH=8.5 and 0.1M MgCl₂. This crystal was the result of the follow up experiments from the Hampton I #6 hits. The crystal measured 0.28×0.28×0.98 micrometer and was frozen for low temperature data collection. Data was collected on a dual Hi Star at 100° K. The detector distance was 12 cm and 2θ=30°. Each frame of 0.25° omega oscillation was exposed for 200 seconds. The crystal diffracted to 1.9 Å and was of the C222₁ space group with unit cell parameters of a=94.95 Å, b=122.08 Å, c=47.73 Å, and α=β=γ=90°. Data statistics are summarized in Table 7. This data was used for refinement after the pdf structure was solved by MAD phasing, but a bound inhibitor was not observed.

Additional Se-methionine crystals were prepared for MAD data collection at APS. A crystal grew from 19% PEG 4000, 0.075M MgCl₂ and 0.1 m Tris pH=8.5. This crystal was the result of the follow up experiments from the Hampton I #6 hits. A total of 3 data sets were collected on the 17-ID beamline at APS. The crystal to detector distance was 15 cm, 2θ=0 and each frame of 0.5° was exposed for 0.5 seconds. The ring current was 96.4 mA. A low data set was collected at a low λ=1.03321, an edge data set was collected at the adsorption edge of λ=0.0.97939, and a peak data set was collected at λ=0.97928. Data collection statistics are summarized in Table 8. The space group is C222₁ with unit cell parameters of a=94.113 Å, b=121.873 Å, c=47.579 Å, and α=β=γ=90°. TABLE 5 Data collection statistics. Å Obs Theory % Redund Rsym Pairs % Rshell % 2 s to 4.090 2042 2343 87.15 3.86 0.0651863 79.51 0.065 85.08 2.9 to 3.247 4094 4584 89.31 3.99 0.0673737 81.52 0.069 62.43 4.1 to 2.837 6182 6780 91.18 4.07 0.0675683 83.82 0.067 42.23 5.8 to 2.578 8269 8975 92.13 4.11 0.0697634 85.06 0.079 26.72 7.8 to 2.393 10326 11156 92.56 4.13 0.0719571 85.79 0.093 21.02 11.4 to 2.252 12312 13339 92.30 4.08 0.07411360 85.16 0.114 17.26 12.4 to 2.139 14308 15515 92.22 3.96 0.07713141 84.70 0.126 14.22 15.7 to 2.046 16170 17685 91.43 3.82 0.07914655 82.87 0.146 12.01 18.3 to 1.967 17759 19839 89.52 3.70 0.08115709 79.18 0.195 8.90 22.9 to 1.899 19024 22028 86.36 3.60 0.08316453 74.69 0.242 6.89 28.1

TABLE 6 Data collection statistics for data with I/sigma greater than 2. Ref Resolution Å Possible Ref Observed observations R-factor I/sigma 3.76 3005 2791 21889 8.88 58.19 2.98 2871 2629 23125 9.73 43.57 2.61 2852 2453 18757 14.62 22.66 2.37 2843 2340 11384 11.83 13.50 2.20 2811 2148 9136 23.25 9.48 2.07 2809 1427 4412 15.93 6.45 17191 13788 88703 10.29 28.55

TABLE 7 Data collection statistics for data with I/sigma greater than 2. Ref Resolution Å Possible Ref Observed observations R-factor I/sigma 3.61 3392 3160 21173 2.27 70.5 2.87 3259 3117 15625 3.99 37.7 2.51 3214 2881 8737 6.74 16.4 2.28 3201 2686 6898 9.37 10.8 2.11 3209 2520 5961 10.51 8.87 2.00 3176 1945 4074 11.24 6.90 19451 16309 62468 3.70 27.7

TABLE 8 Data collection statistics. Coverage Statistics Shell Angstrms #Obs Theory % Compl Redund Rsym Pairs % Pairs Rshell #Sigma % <2 s stats low to 4.091 2265 2343 96.67 4.46 0.028 2072 88.43 0.028 84.43 2.0 to 3.247 4503 4588 98.15 4.82 0.030 4249 92.61 0.032 64.10 2.4 to 2.837 6720 6792 98.94 5.10 0.033 6444 94.88 0.041 38.38 4.0 to 2.578 8925 8992 99.25 5.27 0.035 8646 96.15 0.048 26.64 5.6 to 2.393 11131 11185 99.52 5.35 0.037 10850 97.00 0.053 20.55 8.2 to 2.252 13312 13363 99.62 5.23 0.038 12969 97.05 0.056 17.44 10.4 to 2.139 15489 15533 99.72 5.07 0.039 14978 96.43 0.062 14.57 13.6 to 2.046 17604 17725 99.32 4.92 0.040 16869 95.17 0.067 12.58 15.0 to 1.967 19626 19868 98.78 4.74 0.041 18446 92.84 0.081 9.67 18.8 to 1.899 21519 22066 97.52 4.54 0.042 19661 89.10 0.107 7.97 22.2 stats edge to 4.091 2249 2343 95.99 3.74 0.034 1577 67.31 0.034 81.38 2.1 to 3.247 4478 4588 97.60 4.17 0.037 3455 75.31 0.039 60.12 2.6 to 2.837 6688 6792 98.47 4.51 0.043 5468 80.51 0.061 33.75 5.2 to 2.578 8892 8992 98.89 4.76 0.048 7550 83.96 0.081 22.55 7.3 to 2.393 11088 11185 99.13 4.94 0.053 9682 86.56 0.095 16.88 10.6 to 2.252 13278 13363 99.36 5.03 0.057 11842 88.62 0.101 14.05 12.9 to 2.139 15478 15533 99.65 4.97 0.060 13963 89.89 0.107 11.68 17.4 to 2.046 17649 17725 99.57 4.86 0.062 15967 90.08 0.113 10.17 18.8 to 1.967 19761 19868 99.46 4.76 0.064 17876 89.97 0.129 7.54 24.6 to 1.899 21904 22066 99.27 4.62 0.065 19621 88.92 0.152 5.87 29.9 stats peak to 4.091 2280 2343 97.31 3.60 0.038 1594 68.03 0.038 81.02 2.3 to 3.247 4480 4588 97.65 4.04 0.040 3446 75.11 0.041 59.39 3.0 to 2.837 6677 6792 98.31 4.41 0.046 5373 79.11 0.063 33.15 5.9 to 2.578 8881 8992 98.77 4.67 0.051 7393 82.22 0.081 22.29 7.5 to 2.393 11072 11185 98.99 4.87 0.056 9452 84.51 0.095 16.80 10.8 to 2.252 13247 13363 99.13 4.97 0.060 11527 86.26 0.105 13.87 13.5 to 2.139 15449 15533 99.46 4.92 0.063 13605 87.59 0.116 11.72 17.7 to 2.046 17637 17725 99.50 4.81 0.066 15657 88.33 0.123 10.11 19.0 to 1.967 19798 19868 99.65 4.70 0.069 17642 88.80 0.143 7.63 24.5 to 1.899 22008 22066 99.74 4.56 0.071 19528 88.50 0.168 6.04 29.2 Phase Determination and Refinement

The structure of S.aureus pdf was determined by multiple anomalous dispersion (MAD) using synchrotron radiation. The MAD data set included data to 1.9 Å resolution. Anomalous difference Patterson maps revealed the expected six selenium sites for a single protein molecule in the asymmetric unit. An excellent well-phased map to 1.9 Å resolution was produced into which the protein model could be easily built. However, XPLOR refinement of this model did not result in a model with an R-factor below 30%. This was difficult to understand since the overall map quality was excellent and there was little remaining difference density unaccounted for. This refinement effort was eventually discontinued in favor of a second data set. The 2.0 Å resolution data from the pdf crystal was used for the refinement of the structure. These data did refine well and a final R-factor of 18.6% for this model with good geometry was obtained (Table 9).

The X-ray data for the MAD phasing of pdf was collected at the Advanced Photon Source and consisted of three separate wavelength experiments centered about the Selenium edge (low, 1.03321 Å; edge, 0.97939 Å; high, 0.97928 Å). Each of the data sets were indexed and integrated separately. The data sets were scaled together using the program SCALEIT in the CCP4 Program Suite (Collaborative Computational Project N4, Acta Cryst., D50:760-63 (1994)). Patterson maps revealed six selenium sites whose locations were determined and refined by direct methods using SHELX (Sheldrick et al., Acta Cryst., B51:423-31 (1995)). Heavy atom refinement and phase calculations were carried out using MLPHARE from CCP4 with all the data from 10 to 1.9 Å resolution. The resulting electron density map was readily interpreted and a model built. A density modified map was also calculated (MLPHARE), but the maps were not very different. Model building was done with the program CHAIN (Sack, J. Mol. Graphics, 6:224-25 (1988)) and LORE (Finzel, Meth. Enzymol., 277:230-42 (1997)). Initial refinement was carried out with XPLOR (Brunger A T. X-PLOR version 3.1: Asystem for X-ray crystallography and NMR. New Haven: Yale Univ. Press, (1992)). However, the R-factor failed to fall below 30% after several cycles and with the inclusion of many waters. At that point the refinement of this data set was discontinued in favor of another data set. TABLE 9 Data collection and phasing statistics λ 1.03321 Å λ 0.97939 Å λ 0.97928 Å Resolution 1.9 Å 1.9 Å 1.9 Å Average redundancy 4.5 4.5 4.5 # unique reflections 21519 21904 22008 % completeness 97.5% 99.3% 99.7% R_(sym) ^(†) 0.042 0.065 0.071 R_(sym) (1.96-1.89 shell) 0.107 0.152 0.168 R_(cullis) acentrics 1.70 0.87 0.57 (19034 refs) (18878 refs) (18899 refs) R_(cullis) anomalous 0.98 0.64 0.58 (19178 refs) (18418 refs) (18679 refs) Phasing Power Centrics — 0.70 1.83 Acentrics — 0.80 2.15 Mean FOM overall centric acentric Before solvent flattening 0.714 0.627 0.724 (21048 ref) (2014 refs) (19034 refs) After solvent flattening 0.788 — — Refinement of the Data Set.

This data was used for the further refinement of the native pdf structure. The partially refined model derived from the MAD map was rotated to an arbitrary initial position, stripped of water and cations, and used for molecular replacement (XPLOR). The rotation solutions were filtered with PC-refinement (Brunger, Acta Crystallogr., A46:46-47 (1990)). The highest rotation function peak also resulted in the hghest PC-filtered peak (PC=0.194). The position of the rotated monomer was obtained by a translation search (again the highest peak in the map and 15.6 sigma above the mean). The solution obtained was consistent with the position of the molecule in the MAD map and had an initial R-factor of 39.6% for data from 20-2.5 Å resolution (9235 reflections). This structure was further refined with XPLOR positional refinement and waters and a Zinc atom incorporated into the model. The R-factor dropped to 21% with a Free-R-factor of just over 25%. A final cycle of refinement and rebuilding was employed using PROLSQ (Hendrickson et al., “Stereochemically restrained crystallographic least-squares refinement of macromolecule structures” in Biomolecular Structure, Function and Evolution, (R. Srinivasan, ed. 43-57) Pergamon Press, Oxford UK (1980)) which resulted in a final R-factor of 18.62% for 16266 reflections, 10-2.0 Å resolution data. The final agreement statistics (Table 10) and Ramachandran plot revealed a well-refined structure and are included below. Additional statistics were generated with PROCHECK (Laskowski et al., J. Appl. Cryst., 26:283-91 (1993)). A comparison of the initial MAD map and the final refined map was produced in CHAIN. TABLE 10 Final model agreement statistics for PDF data set. Resolution: 2.00 Angstrom R-value: 18.62% for 16,266 reflections (2 sigma) Atoms 1725 (305 waters); 1 Zinc Mean B-factor 15.0 Å² Final Model rmsd from expected for restraint class: Distances: 1-2 bonds 0.018 (0.030) 1-3 bond angle 0.031 (0.040) 1-4 torsional 0.029 (0.050) Planes peptides 0.016 (0.030) Other 0.014 (0.030) chiral volumes 0.204 (0.250) NonBonded 1-4 0.174 (0.300) H-bond 0.204 (0.300) other 0.172 (0.300) Thermal 1-2 mainchain 1.033 (1.500) 1-3 1.676 (3.000) 1-2 sidechain 2.109 (2.000) 1-3 sidechain 3.293 (4.000) Comparison of S.aureus and E.coli pdf Structures.

The final S.aureus pdf and the E.coli pdf complex with (S)-2-O—(H-phosphonoxy)-L-caproyl-L-leucyl-p-nitroanilide (PCLNA) (Hao et al., Biochemistry, 38: 4712-19 (1999)) were compared using SUPERPDB (Finzel, unpublished). FIGS. 6 and 11 were produced with MOLSCRIPT (Kraulis, J. Appl. Cryst., 24:946-50 (1991)) and Raster 3D (Merritt et al., Acta Cryst., D50:869-73 (1994)). FIGS. 8, 9, 12 and 13 were prepared with MOSAIC2. FIGS. 7 and 14 were prepared with CHAIN using PLOT.

The complete disclosure of all patents, patent applications including provisional applications, and publications, and electronically available material (e.g., GenBank amino acid and nucleotide sequence submissions) cited herein are incorporated by reference. The foregoing detailed description and examples have been given for clarity of understanding only. No unnecessary limitations are to be understood therefrom. The invention is not limited to the exact details shown and described; many variations will be apparent to one skilled in the art and are intended to be included within the invention defined by the claims.

SEQUENCE LISTING FREE TEXT

-   SEQ ID NO:1 Staphylococcus aureus peptide deformylase with     C-terminal 6×His tag -   SEQ ID NO:2 Escherichia coli peptide deformylase -   SEQ ID NO:3 Haemophilis influenzae peptide deformylase -   SEQ ID NO:4 Bacillus subtilis peptide deformylase -   SEQ ID NO:5 Mycoplasma pneumoniae peptide deformylase

SEQ ID NO:6 Staphylococcus aureus def1 gene (Pseudo pdf) TABLE 1 Structure Coordinates for S. aureus pdf CRYST1 94.950 122.080 47.730 90.00 90.00 90.00 SCALE1    0.010532 0.000000 0.000000    0.00000 SCALE2    0.000000 0.008191 0.000000    0.00000 SCALE3    0.000000 0.000000 0.020951    0.00000 ATOM 1 N MET 1 34.916 34.289 28.962 1.00 19.94 ATOM 2 CA MET 1 34.532 33.707 30.269 1.00 17.68 ATOM 3 CB MET 1 34.906 34.864 31.043 1.00 22.02 ATOM 4 CG MET 1 34.249 35.660 31.315 1.00 26.50 ATOM 5 SD MET 1 34.946 36.841 32.629 1.00 21.74 ATOM 6 CE MET 1 34.539 36.320 34.127 1.00 24.64 ATOM 7 C MET 1 33.437 33.258 30.418 1.00 14.02 ATOM 8 O MET 1 32.276 33.920 29.938 1.00 26.24 ATOM 9 N LEU 2 32.981 31.938 30.879 1.00 7.75 ATOM 10 CA LEU 2 31.816 31.467 31.565 1.00 8.41 ATOM 11 CB LEU 2 32.031 30.005 32.023 1.00 8.48 ATOM 12 CG LEU 2 32.268 28.961 30.866 1.00 7.73 ATOM 13 CD1 LEU 2 32.614 27.626 31.509 1.00 9.08 ATOM 14 CD2 LEU 2 30.932 28.747 30.133 1.00 8.57 ATOM 15 C LEU 2 31.402 32.379 32.708 1.00 9.38 ATOM 16 O LEU 2 32.278 32.943 33.415 1.00 10.57 ATOM 17 N THR 3 30.099 32.656 32.839 1.00 9.70 ATOM 18 CA THR 3 29.624 33.466 33.943 1.00 10.89 ATOM 19 CB THR 3 29.238 34.900 33.661 1.00 10.34 ATOM 20 OG1 THR 3 28.067 34.943 32.811 1.00 13.27 ATOM 21 CG2 THR 3 30.363 35.684 33.051 1.00 9.36 ATOM 22 C THR 3 28.428 32.714 34.511 1.00 12.61 ATOM 23 O THR 3 28.150 31.586 34.034 1.00 12.67 ATOM 24 N MET 4 27.740 33.297 35.478 1.00 13.52 ATOM 25 CA MET 4 26.570 32.603 36.027 1.00 12.96 ATOM 26 CB MET 4 26.007 33.362 37.225 1.00 12.16 ATOM 27 CG MET 4 26.954 33.492 38.401 1.00 12.58 ATOM 28 SD MET 4 27.512 31.883 38.995 1.00 12.58 ATOM 29 CE MET 4 25.972 31.153 39.545 1.00 11.19 ATOM 30 C MET 4 25.497 32.343 34.975 1.00 13.01 ATOM 31 O MET 4 24.627 31.474 35.142 1.00 11.54 ATOM 32 N LYS 5 25.475 33.147 33.917 1.00 13.68 ATOM 33 CA LYS 5 24.490 32.976 32.902 1.00 14.22 ATOM 34 CB LYS 5 24.163 34.124 31.992 1.00 16.93 ATOM 35 CG LYS 5 25.243 34.788 31.252 1.00 18.60 ATOM 36 CD LYS 5 24.807 35.647 30.112 1.00 19.21 ATOM 37 CE LYS 5 23.755 36.633 30.201 1.00 17.56 ATOM 38 NZ LYS 5 23.653 37.497 28.989 1.00 17.28 ATOM 39 C LYS 5 24.684 31.690 32.119 1.00 13.07 ATOM 40 O LYS 5 23.720 31.241 31.521 1.00 12.87 ATOM 41 N ASP 6 25.880 31.127 32.131 1.00 12.68 ATOM 42 CA ASP 6 26.110 29.855 31.443 1.00 10.98 ATOM 43 CB ASP 6 27.608 29.644 31.134 1.00 11.64 ATOM 44 CG ASP 6 28.053 30.725 30.147 1.00 12.48 ATOM 45 OD1 ASP 6 27.837 30.487 28.933 1.00 13.27 ATOM 46 OD2 ASP 6 28.505 31.815 30.591 1.00 11.62 ATOM 47 C ASP 6 25.640 28.730 32.353 1.00 11.50 ATOM 48 O ASP 6 25.445 27.605 31.881 1.00 11.74 ATOM 49 N ILE 7 25.501 29.000 33.628 1.00 11.13 ATOM 50 CA ILE 7 25.098 27.943 34.547 1.00 11.49 ATOM 51 CB ILE 7 25.811 28.121 35.898 1.00 11.70 ATOM 52 CG1 ILE 7 27.331 27.997 35.581 1.00 11.93 ATOM 53 CD1 ILE 7 28.288 28.140 36.663 1.00 12.02 ATOM 54 CG2 ILE 7 25.417 27.057 36.887 1.00 11.40 ATOM 55 C ILE 7 23.634 27.664 34.603 1.00 11.29 ATOM 56 O ILE 7 22.817 28.487 34.999 1.00 12.63 ATOM 57 N ILE 8 23.245 26.433 34.193 1.00 10.48 ATOM 58 CA ILE 8 21.856 26.026 34.213 1.00 9.51 ATOM 59 CB ILE 8 21.513 24.909 33.253 1.00 8.83 ATOM 60 CG1 ILE 8 22.221 23.575 33.487 1.00 7.90 ATOM 61 CD1 ILE 8 21.762 22.525 32.454 1.00 7.81 ATOM 62 CG2 ILE 8 21.684 25.377 31.803 1.00 9.89 ATOM 63 C ILE 8 21.433 25.703 35.643 1.00 10.40 ATOM 64 O ILE 8 22.205 25.174 36.456 1.00 9.94 ATOM 65 N ARG 9 20.182 26.031 35.987 1.00 11.42 ATOM 66 CA ARG 9 19.665 25.850 37.329 1.00 12.02 ATOM 67 CB ARG 9 19.009 27.157 37.828 1.00 10.73 ATOM 68 CG ARG 9 19.850 28.421 37.618 1.00 11.22 ATOM 69 CD ARG 9 21.253 28.290 38.166 1.00 11.70 ATOM 70 NE ARG 9 22.124 29.328 37.705 1.00 14.84 ATOM 71 CZ ARG 9 22.235 30.599 38.010 1.00 15.66 ATOM 72 NH1 ARG 9 21.529 31.122 38.991 1.00 18.52 ATOM 73 NH2 ARG 9 22.902 31.393 37.188 1.00 14.81 ATOM 74 C ARG 9 18.764 24.658 37.504 1.00 12.31 ATOM 75 O ARG 9 18.267 24.036 36.555 1.00 14.42 ATOM 76 N ASP 10 18.518 24.283 38.736 1.00 12.74 ATOM 77 CA ASP 10 17.674 23.150 39.113 1.00 13.72 ATOM 78 CB ASP 10 17.681 22.953 40.600 1.00 14.31 ATOM 79 CG ASP 10 16.924 21.758 41.104 1.00 14.46 ATOM 80 OD1 ASP 10 17.107 20.628 40.640 1.00 14.86 ATOM 81 OD2 ASP 10 16.146 21.966 42.029 1.00 16.72 ATOM 82 C ASP 10 16.285 23.236 38.506 1.00 14.81 ATOM 83 O ASP 10 15.531 24.212 38.663 1.00 15.66 ATOM 84 N GLY 11 15.932 22.174 37.772 1.00 14.39 ATOM 85 CA GLY 11 14.636 22.169 37.079 1.00 15.06 ATOM 86 C GLY 11 14.962 22.038 35.578 1.00 15.47 ATOM 87 O GLY 11 14.116 21.564 34.841 1.00 16.98 ATOM 88 N HIS 12 16.200 22.335 35.197 1.00 16.07 ATOM 89 CA HIS 12 16.564 22.199 33.771 1.00 15.33 ATOM 90 CB HIS 12 17.798 22.984 33.422 1.00 14.11 ATOM 91 CG HIS 12 18.137 23.113 31.958 1.00 12.04 ATOM 92 ND1 HIS 12 18.258 22.085 31.076 1.00 10.56 ATOM 93 CE1 HIS 12 18.600 22.523 29.883 1.00 9.61 ATOM 94 NE2 HIS 12 18.767 23.826 29.977 1.00 11.37 ATOM 95 CD2 HIS 12 18.457 24.243 31.262 1.00 11.65 ATOM 96 C HIS 12 16.780 20.692 33.515 1.00 15.36 ATOM 97 O HIS 12 17.443 19.998 34.299 1.00 14.84 ATOM 98 N PRO 13 16.209 20.178 32.431 1.00 14.53 ATOM 99 CA PRO 13 16.296 18.798 32.066 1.00 14.20 ATOM 100 CB PRO 13 15.436 18.664 30.843 1.00 14.95 ATOM 101 CG PRO 13 15.070 20.047 30.408 1.00 15.00 ATOM 102 CD PRO 13 15.333 20.975 31.520 1.00 14.75 ATOM 103 C PRO 13 17.704 18.221 31.869 1.00 13.44 ATOM 104 O PRO 13 17.920 17.049 32.297 1.00 13.01 ATOM 105 N THR 14 18.641 18.885 31.313 1.00 12.25 ATOM 106 CA THR 14 20.006 18.412 31.110 1.00 12.11 ATOM 107 CB THR 14 20.879 19.447 30.442 1.00 12.39 ATOM 108 OG1 THR 14 20.324 19.703 29.186 1.00 14.02 ATOM 109 CG2 THR 14 22.327 19.047 30.251 1.00 11.43 ATOM 110 C THR 14 20.616 17.961 32.443 1.00 11.87 ATOM 111 O THR 14 21.340 16.974 32.439 1.00 12.53 ATOM 112 N LEU 15 20.236 18.589 33.544 1.00 11.35 ATOM 113 CA LEU 15 20.691 18.204 34.862 1.00 10.88 ATOM 114 CB LEU 15 20.289 19.242 35.945 1.00 9.29 ATOM 115 CG LEU 15 20.941 20.618 35.797 1.00 10.23 ATOM 116 CD1 LEU 15 20.421 21.579 36.861 1.00 9.66 ATOM 117 CD2 LEU 15 22.486 20.500 35.940 1.00 8.87 ATOM 118 C LEU 15 20.276 16.823 35.350 1.00 10.52 ATOM 119 O LEU 15 20.887 16.276 36.276 1.00 10.57 ATOM 120 N ARG 16 19.281 16.212 34.728 1.00 12.62 ATOM 121 CA ARG 16 18.760 14.908 35.102 1.00 12.70 ATOM 122 CB ARG 16 17.252 15.021 35.435 1.00 11.19 ATOM 123 CG ARG 16 16.965 15.901 36.689 1.00 12.05 ATOM 124 CD ARG 16 17.589 15.300 37.922 1.00 12.29 ATOM 125 NE ARG 16 17.174 15.869 39.202 1.00 14.07 ATOM 126 CZ ARG 16 17.503 15.282 40.354 1.00 14.85 ATOM 127 NH1 ARG 16 18.257 14.175 40.357 1.00 13.47 ATOM 128 NH2 ARG 16 17.016 15.724 41.537 1.00 14.89 ATOM 129 C ARG 16 19.050 13.808 34.098 1.00 13.29 ATOM 130 O ARG 16 18.686 12.615 34.267 1.00 12.21 ATOM 131 N GLN 17 19.716 14.156 33.007 1.00 14.43 ATOM 132 CA GLN 17 20.112 13.203 31.993 1.00 14.49 ATOM 133 CB GLN 17 20.423 13.917 30.676 1.00 15.50 ATOM 134 CG GLN 17 19.172 14.623 30.150 1.00 19.61 ATOM 135 CD GLN 17 19.464 15.367 28.883 1.00 22.76 ATOM 136 OE1 GLN 17 20.585 15.845 28.654 1.00 25.94 ATOM 137 NE2 GLN 17 18.516 15.484 27.983 1.00 25.81 ATOM 138 C GLN 17 21.414 12.531 32.438 1.00 14.27 ATOM 139 O GLN 17 22.117 12.968 33.350 1.00 13.89 ATOM 140 N LYS 18 21.716 11.457 31.735 1.00 14.65 ATOM 141 CA LYS 18 22.963 10.724 31.984 1.00 13.90 ATOM 142 CB LYS 18 22.734 9.222 32.030 1.00 15.80 ATOM 143 CG LYS 18 24.083 8.533 32.321 1.00 19.05 ATOM 144 CD LYS 18 23.986 7.048 32.414 1.00 21.35 ATOM 145 CE LYS 18 25.337 6.413 32.686 1.00 22.45 ATOM 146 NZ LYS 18 25.078 4.922 32.839 1.00 26.17 ATOM 147 C LYS 18 23.980 11.178 30.950 1.00 12.55 ATOM 148 O LYS 18 23.801 10.968 29.753 1.00 14.36 ATOM 149 N ALA 19 25.068 11.839 31.353 1.00 10.71 ATOM 150 CA ALA 19 26.065 12.355 30.478 1.00 10.46 ATOM 151 CB ALA 19 27.088 13.257 31.241 1.00 9.78 ATOM 152 C ALA 19 26.749 11.295 29.636 1.00 11.00 ATOM 153 O ALA 19 26.983 10.143 30.034 1.00 12.01 ATOM 154 N ALA 20 27.080 11.667 28.404 1.00 10.99 ATOM 155 CA ALA 20 27.720 10.828 27.437 1.00 9.79 ATOM 156 CB ALA 20 27.497 11.492 26.021 1.00 8.56 ATOM 157 C ALA 20 29.232 10.755 27.581 1.00 9.39 ATOM 158 O ALA 20 29.876 11.797 27.803 1.00 8.57 ATOM 159 N GLU 21 29.758 9.569 27.411 1.00 9.74 ATOM 160 CA GLU 21 31.202 9.379 27.439 1.00 11.72 ATOM 161 CB GLU 21 31.512 7.905 27.257 1.00 17.23 ATOM 162 CG GLU 21 31.202 6.871 28.231 1.00 22.07 ATOM 163 CD GLU 21 32.063 6.663 29.432 1.00 26.07 ATOM 164 OE1 GLU 21 33.305 6.831 29.247 1.00 28.08 ATOM 165 OE2 GLU 21 31.599 6.155 30.497 1.00 27.56 ATOM 166 C GLU 21 31.861 10.115 26.238 1.00 11.80 ATOM 167 O GLU 21 31.417 10.185 25.089 1.00 11.59 ATOM 168 N LEU 22 33.013 10.661 26.528 1.00 11.07 ATOM 169 CA LEU 22 33.838 11.349 25.587 1.00 11.81 ATOM 170 CB LEU 22 34.811 12.325 26.236 1.00 9.69 ATOM 171 CG LEU 22 34.424 13.644 26.794 1.00 8.78 ATOM 172 CD1 LEU 22 34.103 14.677 25.719 1.00 8.17 ATOM 173 CD2 LEU 22 33.310 13.559 27.815 1.00 8.71 ATOM 174 C LEU 22 34.675 10.321 24.815 1.00 13.30 ATOM 175 O LEU 22 35.079 9.332 25.372 1.00 13.83 ATOM 176 N GLU 23 34.852 10.597 23.535 1.00 16.09 ATOM 177 CA GLU 23 35.751 9.770 22.737 1.00 17.85 ATOM 178 CB GLU 23 35.257 9.636 21.289 1.00 23.31 ATOM 179 CG GLU 23 33.952 8.895 21.273 1.00 29.61 ATOM 180 CD GLU 23 33.367 8.488 19.961 1.00 34.86 ATOM 181 OE1 GLU 23 33.510 9.170 18.922 1.00 37.14 ATOM 182 OE2 GLU 23 32.683 7.419 19.974 1.00 37.69 ATOM 183 C GLU 23 37.087 10.532 22.787 1.00 16.82 ATOM 184 O GLU 23 37.021 11.729 22.817 1.00 16.18 ATOM 185 N LEU 24 38.209 9.855 22.917 1.00 18.03 ATOM 186 CA LEU 24 39.524 10.444 22.930 1.00 17.31 ATOM 187 CB LEU 24 40.436 9.892 24.031 1.00 16.16 ATOM 188 CG LEU 24 43.230 10.220 25.490 1.00 16.48 ATOM 189 CD1 LEU 24 40.257 11.765 25.662 1.00 17.54 ATOM 190 CD2 LEU 24 38.965 9.743 26.117 1.00 15.61 ATOM 191 C LEU 24 40.173 10.220 21.558 1.00 17.41 ATOM 192 O LEU 24 39.995 9.166 20.916 1.00 19.08 ATOM 193 N PRO 25 40.912 11.204 21.075 1.00 15.93 ATOM 194 CA PRO 25 41.141 12.448 21.731 1.00 14.52 ATOM 195 CB PRO 25 42.287 13.063 20.900 1.00 14.29 ATOM 196 CG PRO 25 42.036 12.531 19.526 1.00 15.30 ATOM 197 CD PRO 25 41.604 11.109 19.738 1.00 15.06 ATOM 198 C PRO 25 39.995 13.443 21.653 1.00 13.35 ATOM 199 O PRO 25 39.177 13.401 20.754 1.00 13.89 ATOM 200 N LEU 26 39.985 14.367 22.602 1.00 13.79 ATOM 201 CA LEU 26 38.996 15.418 22.666 1.00 12.59 ATOM 202 CB LEU 26 39.082 16.256 23.904 1.00 12.08 ATOM 203 CG LEU 26 38.886 15.669 25.289 1.00 12.93 ATOM 204 CD1 LEU 26 38.866 16.788 26.340 1.00 10.60 ATOM 205 CD2 LEU 26 37.642 14.803 25.381 1.00 12.07 ATOM 206 C LEU 26 39.100 16.326 21.409 1.00 12.36 ATOM 207 O LEU 26 40.197 16.480 20.886 1.00 12.03 ATOM 208 N THR 27 37.963 16.834 20.967 1.00 12.65 ATOM 209 CA THR 27 37.963 17.766 19.832 1.00 14.54 ATOM 210 CB THR 27 36.532 18.035 19.308 1.00 15.30 ATOM 211 OG1 THR 27 35.727 18.682 20.310 1.00 15.81 ATOM 212 CG2 THR 27 35.847 16.719 18.948 1.00 14.42 ATOM 213 C THR 27 38.493 19.093 20.391 1.00 15.69 ATOM 214 O THR 27 38.511 19.249 21.642 1.00 15.10 ATOM 215 N LYS 28 38.949 20.026 19.593 1.00 17.11 ATOM 216 CA LYS 28 39.461 21.322 20.062 1.00 16.59 ATOM 217 CB LYS 28 39.640 22.170 18.785 1.00 21.45 ATOM 218 CG LYS 28 40.041 23.601 18.941 1.00 24.97 ATOM 219 CD LYS 28 41.424 23.746 19.542 1.00 28.58 ATOM 220 CE LYS 28 41.893 25.200 19.520 1.00 29.78 ATOM 221 NZ LYS 28 43.362 25.231 19.863 1.00 30.20 ATOM 222 C LYS 28 38.449 22.070 20.922 1.00 15.27 ATOM 223 O LYS 28 38.795 22.754 21.899 1.00 14.45 ATOM 224 N GLU 29 37.202 21.988 20.547 1.00 14.88 ATOM 225 CA GLU 29 36.095 22.628 21.221 1.00 14.47 ATOM 226 CB GLU 29 34.832 22.548 20.375 1.00 20.18 ATOM 227 CG GLU 29 33.633 23.176 21.057 1.00 25.80 ATOM 228 CD GLU 29 32.326 22.956 20.331 1.00 30.91 ATOM 229 OE1 GLU 29 32.201 21.989 19.520 1.00 32.53 ATOM 230 OE2 GLU 29 31.389 23.743 20.643 1.00 32.71 ATOM 231 C GLU 29 35.873 22.024 22.595 1.00 13.31 ATOM 232 O GLU 29 35.595 22.749 23.545 1.00 11.60 ATOM 233 N GLU 30 35.940 20.686 22.711 1.00 12.75 ATOM 234 CA GLU 30 35.795 20.032 24.009 1.00 10.36 ATOM 235 CB GLU 30 35.700 18.517 23.814 1.00 10.77 ATOM 236 CG GLU 30 34.365 18.110 23.139 1.00 12.50 ATOM 237 CD GLU 30 34.397 16.669 22.642 1.00 11.90 ATOM 238 OE1 GLU 30 35.467 16.104 22.370 1.00 12.79 ATOM 239 OE2 GLU 30 33.310 16.151 22.474 1.00 14.28 ATOM 240 C GLU 30 36.936 20.426 24.950 1.00 9.86 ATOM 241 O GLU 30 36.678 20.595 26.156 1.00 9.16 ATOM 242 N LYS 31 38.154 20.617 24.466 1.00 9.50 ATOM 243 CA LYS 31 39.272 21.016 25.315 1.00 10.37 ATOM 244 CB LYS 31 40.624 20.903 24.615 1.00 10.65 ATOM 245 CG LYS 31 40.935 19.492 24.109 1.00 10.14 ATOM 246 CD LYS 31 42.376 19.413 23.639 1.00 12.65 ATOM 247 CE LYS 31 42.773 18.053 23.142 1.00 13.40 ATOM 248 NZ LYS 31 44.122 17.978 22.539 1.00 16.75 ATOM 249 C LYS 31 39.056 22.437 25.839 1.00 11.34 ATOM 250 O LYS 31 39.219 22.729 27.019 1.00 10.78 ATOM 251 N GLU 32 38.652 23.343 24.963 1.00 12.34 ATOM 252 CA GLU 32 38.358 24.725 25.267 1.00 13.73 ATOM 253 CB GLU 32 37.914 25.458 23.995 1.00 18.88 ATOM 254 CG GLU 32 38.998 25.596 22.948 1.00 25.82 ATOM 255 CD GLU 32 38.508 26.242 21.661 1.00 31.02 ATOM 256 OE1 GLU 32 37.329 26.619 21.506 1.00 34.16 ATOM 257 OE2 GLU 32 39.333 26.362 20.729 1.00 33.69 ATOM 258 C GLU 32 37.266 24.829 26.333 1.00 12.41 ATOM 259 O GLU 32 37.312 25.639 27.241 1.00 11.77 ATOM 260 N THR 33 36.250 23.978 26.208 1.00 12.31 ATOM 261 CA THR 33 35.163 23.899 27.157 1.00 12.37 ATOM 262 CB THR 33 34.104 22.861 26.725 1.00 13.11 ATOM 263 OG1 THR 33 33.517 23.349 25.513 1.00 15.23 ATOM 264 CG2 THR 33 33.023 22.657 27.752 1.00 11.29 ATOM 265 C THR 33 35.681 23.524 28.559 1.00 11.41 ATOM 266 O THR 33 35.365 24.208 29.497 1.00 10.34 ATOM 267 N LEU 34 36.486 22.474 28.658 1.00 11.17 ATOM 268 CA LEU 34 37.030 22.021 29.928 1.00 10.16 ATOM 269 CB LEU 34 37.678 20.654 29.693 1.00 9.41 ATOM 270 CG LEU 34 38.102 19.874 30.942 1.00 8.70 ATOM 271 CD1 LEU 34 36.909 19.607 31.858 1.00 5.18 ATOM 272 CD2 LEU 34 38.697 18.541 30.452 1.00 8.15 ATOM 273 C LEU 34 37.960 23.036 30.557 1.00 10.05 ATOM 274 O LEU 34 37.967 23.258 31.785 1.00 10.33 ATOM 275 N ILE 35 38.761 23.700 29.745 1.00 9.38 ATOM 276 CA ILE 35 39.669 24.770 30.298 1.00 9.27 ATOM 277 CB ILE 35 40.619 25.168 29.153 1.00 9.96 ATOM 278 CG1 ILE 35 41.392 23.960 28.683 1.00 11.21 ATOM 279 CD1 ILE 35 42.276 24.096 27.476 1.00 10.72 ATOM 280 CG2 ILE 35 41.467 26.360 29.493 1.00 10.81 ATOM 281 C ILE 35 38.843 25.908 30.801 1.00 8.81 ATOM 282 O ILE 35 39.131 26.555 31.836 1.00 9.47 ATOM 283 N ALA 36 37.769 26.277 30.047 1.00 8.60 ATOM 284 CA ALA 36 36.878 27.369 30.469 1.00 8.07 ATOM 285 CB ALA 36 35.833 27.665 29.390 1.00 8.37 ATOM 286 C ALA 36 36.161 27.045 31.767 1.00 8.14 ATOM 287 O ALA 36 35.768 27.917 32.560 1.00 8.12 ATOM 288 N MET 37 35.881 25.724 31.941 1.00 8.77 ATOM 289 CA MET 37 35.248 25.210 33.136 1.00 9.24 ATOM 290 CB MET 37 34.795 23.764 33.059 1.00 8.72 ATOM 291 CG MET 37 33.559 23.483 32.224 1.00 6.71 ATOM 292 SD MET 37 33.335 21.789 31.709 1.00 6.53 ATOM 293 CE MET 37 33.342 20.932 33.251 1.00 4.67 ATOM 294 C MET 37 36.195 25.410 34.333 1.00 9.17 ATOM 295 O MET 37 35.692 25.892 35.376 1.00 8.49 ATOM 296 N ARG 38 37.452 25.050 34.165 1.00 8.88 ATOM 297 CA ARG 38 38.401 25.295 35.266 1.00 8.29 ATOM 298 CB ARG 38 39.761 24.673 34.946 1.00 6.27 ATOM 299 CG ARG 38 40.886 25.129 35.854 1.00 6.22 ATOM 300 CD ARG 38 42.253 24.472 35.513 1.00 6.20 ATOM 301 NE ARG 38 43.275 24.989 36.431 1.00 8.87 ATOM 302 CZ ARG 38 43.890 26.160 36.395 1.00 10.20 ATOM 303 NH1 ARG 38 43.647 27.040 35.409 1.00 11.24 ATOM 304 NH2 ARG 38 44.784 26.493 37.315 1.00 11.77 ATOM 305 C ARG 38 38.583 26.825 35.430 1.00 9.07 ATOM 306 O ARG 38 38.763 27.261 36.567 1.00 9.36 ATOM 307 N GLU 39 38.575 27.572 34.337 1.00 8.69 ATOM 308 CA GLU 39 38.771 29.029 34.403 1.00 9.54 ATOM 309 CB GLU 39 39.029 29.643 33.049 1.00 10.78 ATOM 310 CG GLU 39 39.650 31.040 33.051 1.00 14.31 ATOM 311 CD GLU 39 41.070 30.997 33.632 1.00 17.29 ATOM 312 OE1 GLU 39 41.712 29.936 33.706 1.00 17.09 ATOM 313 OE2 GLU 39 41.577 32.041 34.079 1.00 19.58 ATOM 314 C GLU 39 37.629 29.691 35.178 1.00 8.74 ATOM 315 O GLU 39 37.872 30.680 35.887 1.00 8.33 ATOM 316 N PHE 40 36.424 29.202 35.067 1.00 8.68 ATOM 317 CA PHE 40 35.267 29.674 35.808 1.00 8.98 ATOM 318 CB PHE 40 33.969 28.890 35.546 1.00 6.33 ATOM 319 CG PHE 40 32.816 29.364 36.423 1.00 7.37 ATOM 320 CD1 PHE 40 32.004 30.431 36.041 1.00 6.34 ATOM 321 CE1 PHE 40 30.944 30.806 36.826 1.00 7.39 ATOM 322 CZ PHE 40 30.729 30.221 38.073 1.00 8.75 ATOM 323 CE2 PHE 40 31.553 29.164 38.474 1.00 7.42 ATOM 324 CD2 PHE 40 32.570 28.749 37.650 1.00 5.86 ATOM 325 C PHE 40 35.567 29.539 37.321 1.00 9.68 ATOM 326 O PHE 40 35.299 30.458 38.106 1.00 8.96 ATOM 327 N LEU 41 36.096 28.389 37.716 1.00 8.34 ATOM 328 CA LEU 41 36.407 28.121 39.108 1.00 7.20 ATOM 329 CB LEU 41 36.736 26.662 39.311 1.00 5.79 ATOM 330 CG LEU 41 35.632 25.661 38.986 1.00 4.96 ATOM 331 CD1 LEU 41 36.180 24.230 39.076 1.00 4.68 ATOM 332 CD2 LEU 41 34.592 25.769 40.118 1.00 5.67 ATOM 333 C LEU 41 37.487 29.057 39.633 1.00 6.55 ATOM 334 O LEU 41 37.318 29.593 40.732 1.00 6.21 ATOM 335 N VAL 42 38.543 29.226 38.866 1.00 6.90 ATOM 336 CA VAL 42 39.620 30.141 39.229 1.00 8.11 ATOM 337 CB VAL 42 40.640 30.109 38.086 1.00 11.15 ATOM 338 CG1 VAL 42 41.734 31.155 38.206 1.00 13.45 ATOM 339 CG2 VAL 42 41.304 28.748 37.976 1.00 11.23 ATOM 340 C VAL 42 38.991 31.513 39.408 1.00 8.71 ATOM 341 O VAL 42 39.122 32.126 40.489 1.00 10.31 ATOM 342 N ASN 43 38.252 32.049 38.442 1.00 8.34 ATOM 343 CA ASN 43 37.596 33.354 38.565 1.00 8.46 ATOM 344 CB ASN 43 36.811 33.707 37.239 1.00 8.52 ATOM 345 CG ASN 43 37.814 34.020 36.161 1.00 9.24 ATOM 346 OD1 ASN 43 38.937 34.339 36.546 1.00 10.81 ATOM 347 ND2 ASN 43 37.464 33.943 34.891 1.00 10.73 ATOM 348 C ASN 43 36.632 33.504 39.695 1.00 9.08 ATOM 349 O ASN 43 36.559 34.588 40.314 1.00 8.98 ATOM 350 N SER 44 35.887 32.473 40.035 1.00 9.07 ATOM 351 CA SER 44 34.906 32.506 41.091 1.00 10.54 ATOM 352 CB SER 44 33.940 31.317 41.107 1.00 9.94 ATOM 353 OG SER 44 34.463 30.152 41.665 1.00 10.32 ATOM 354 C SER 44 35.612 32.595 42.463 1.00 11.84 ATOM 355 O SER 44 35.022 33.048 43.445 1.00 13.02 ATOM 356 N GLN 45 36.866 32.177 42.517 1.00 12.29 ATOM 357 CA GLN 45 37.648 32.199 43.727 1.00 12.76 ATOM 358 CB GLN 45 38.552 30.951 43.870 1.00 13.51 ATOM 359 CG GLN 45 37.711 29.688 44.112 1.00 12.21 ATOM 360 CD GLN 45 38.518 28.436 44.161 1.00 13.51 ATOM 361 OE1 GLN 45 39.733 28.479 44.331 1.00 15.12 ATOM 362 NE2 GLN 45 37.819 27.301 43.898 1.00 11.45 ATOM 363 C GLN 45 38.451 33.491 43.882 1.00 14.04 ATOM 364 O GLN 45 38.996 33.746 44.942 1.00 14.63 ATOM 365 N ASP 46 38.518 34.305 42.869 1.00 14.76 ATOM 366 CA ASP 46 39.203 35.595 42.881 1.00 17.02 ATOM 367 CB ASP 46 39.977 35.835 41.627 1.00 20.12 ATOM 368 CG ASP 46 40.799 37.118 41.646 1.00 23.64 ATOM 369 OD1 ASP 46 40.229 38.095 42.163 1.00 23.90 ATOM 370 OD2 ASP 46 41.954 37.141 41.179 1.00 26.97 ATOM 371 C ASP 46 38.159 36.639 43.278 1.00 16.96 ATOM 372 O ASP 46 37.141 36.906 42.690 1.00 15.76 ATOM 373 N GLU 47 38.383 37.201 44.471 1.00 18.61 ATOM 374 CA GLU 47 37.524 38.172 45.105 1.00 20.77 ATOM 375 CB GLU 47 38.318 38.747 46.281 1.00 26.35 ATOM 376 CG GLU 47 37.601 39.794 47.124 1.00 31.95 ATOM 377 CD GLU 47 38.607 40.361 48.151 1.00 35.24 ATOM 378 OE1 GLU 47 39.590 41.011 47.707 1.00 36.36 ATOM 379 OE2 GLU 47 38.401 40.085 49.347 1.00 37.08 ATOM 380 C GLU 47 37.043 39.303 44.202 1.00 20.14 ATOM 381 O GLU 47 35.844 39.612 44.172 1.00 19.26 ATOM 382 N GLU 48 37.975 39.957 43.516 1.00 19.74 ATOM 383 CA GLU 48 37.697 41.040 42.619 1.00 20.15 ATOM 384 CB GLU 48 39.015 41.724 42.176 1.00 26.28 ATOM 385 CG GLU 48 38.788 42.838 41.175 1.00 33.55 ATOM 386 CD GLU 48 39.965 43.661 40.716 1.00 38.79 ATOM 387 OE1 GLU 48 41.131 43.498 41.173 1.00 40.40 ATOM 388 OE2 GLU 48 39.734 44.559 39.829 1.00 39.98 ATOM 389 C GLU 48 36.940 40.613 41.365 1.00 17.56 ATOM 390 O GLU 48 35.980 41.201 40.970 1.00 15.31 ATOM 391 N ILE 49 37.483 39.560 40.714 1.00 17.33 ATOM 392 CA ILE 49 36.899 39.040 39.494 1.00 15.12 ATOM 393 CB ILE 49 37.765 38.038 38.757 1.00 16.13 ATOM 394 CG1 ILE 49 39.111 38.674 38.292 1.00 16.15 ATOM 395 CD1 ILE 49 40.129 37.587 37.857 1.00 13.47 ATOM 396 CG2 ILE 49 36.997 37.575 37.496 1.00 16.11 ATOM 397 C ILE 49 35.503 38.558 39.794 1.00 13.80 ATOM 398 O ILE 49 34.619 38.936 39.034 1.00 14.67 ATOM 399 N ALA 50 35.287 37.841 40.890 1.00 12.57 ATOM 400 CA ALA 50 33.952 37.373 41.233 1.00 12.32 ATOM 401 CB ALA 50 33.951 36.441 42.447 1.00 10.25 ATOM 402 C ALA 50 33.017 38.526 41.500 1.00 12.90 ATOM 403 O ALA 50 31.824 38.435 41.186 1.00 12.81 ATOM 404 N LYS 51 33.530 39.604 42.123 1.00 14.84 ATOM 405 CA LYS 51 32.621 40.724 42.364 1.00 17.61 ATOM 406 CB LYS 51 33.059 41.746 43.393 1.00 23.09 ATOM 407 CG LYS 51 33.488 41.245 44.742 1.00 29.47 ATOM 408 CD LYS 51 32.742 40.030 45.276 1.00 35.11 ATOM 409 CE LYS 51 31.236 40.116 45.393 1.00 38.34 ATOM 410 NZ LYS 51 30.581 38.814 45.690 1.00 39.45 ATOM 411 C LYS 51 32.262 41.424 41.035 1.00 16.20 ATOM 412 O LYS 51 31.066 41.571 40.745 1.00 17.61 ATOM 413 N ARG 52 33.240 41.788 40.263 1.00 15.36 ATOM 414 CA ARG 52 33.029 42.487 38.995 1.00 15.36 ATOM 415 CB ARG 52 34.299 42.597 38.210 1.00 15.92 ATOM 416 CG ARG 52 34.190 43.493 36.961 1.00 20.56 ATOM 417 CD ARG 52 35.484 43.366 36.171 1.00 25.75 ATOM 418 NE ARG 52 36.584 43.664 37.113 1.00 30.94 ATOM 419 CZ ARG 52 37.845 43.340 36.840 1.00 34.86 ATOM 420 NH1 ARG 52 38.178 42.759 35.680 1.00 36.86 ATOM 421 NH2 ARG 52 38.734 43.409 37.825 1.00 36.03 ATOM 422 C ARG 52 32.016 41.733 38.124 1.00 15.87 ATOM 423 O ARG 52 31.146 42.328 37.514 1.00 15.88 ATOM 424 N TYR 53 32.184 40.394 38.051 1.00 15.45 ATOM 425 CA TYR 53 31.314 39.566 37.273 1.00 14.70 ATOM 426 CB TYR 53 32.073 38.518 36.434 1.00 15.59 ATOM 427 CG TYR 53 32.954 39.236 35.446 1.00 16.81 ATOM 428 CD1 TYR 53 32.407 39.794 34.291 1.00 17.94 ATOM 429 CE1 TYR 53 33.218 40.509 33.416 1.00 19.07 ATOM 430 CZ TYR 53 34.568 40.622 33.684 1.00 19.48 ATOM 431 OH TYR 53 35.396 41.309 32.827 1.00 22.92 ATOM 432 CE2 TYR 53 35.110 40.078 34.818 1.00 19.01 ATOM 433 CD2 TYR 53 34.301 39.379 35.692 1.00 18.15 ATOM 434 C TYR 53 30.181 38.907 37.974 1.00 14.36 ATOM 435 O TYR 53 29.510 38.141 37.274 1.00 15.28 ATOM 436 N GLY 54 29.926 39.126 39.252 1.00 14.71 ATOM 437 CA GLY 54 28.814 38.492 39.937 1.00 15.24 ATOM 438 C GLY 54 28.886 36.981 39.985 1.00 16.54 ATOM 439 O GLY 54 27.879 36.281 39.822 1.00 19.66 ATOM 440 N LEU 55 30.071 36.433 40.235 1.00 15.81 ATOM 441 CA LEU 55 30.300 35.000 40.253 1.00 14.58 ATOM 442 CB LEU 55 31.684 34.640 39.689 1.00 10.75 ATOM 443 CG LEU 55 32.128 35.125 38.328 1.00 8.84 ATOM 444 CD1 LEU 55 33.483 34.650 37.920 1.00 6.15 ATOM 445 CD2 LEU 55 31.095 34.816 37.227 1.00 8.13 ATOM 446 C LEU 55 30.165 34.407 41.645 1.00 14.82 ATOM 447 O LEU 55 30.668 34.952 42.634 1.00 15.45 ATOM 448 N ARG 56 29.397 33.312 41.702 1.00 13.86 ATOM 449 CA ARG 56 29.268 32.583 42.994 1.00 14.05 ATOM 450 CB ARG 56 27.988 31.773 42.901 1.00 12.84 ATOM 451 CG ARG 56 27.702 30.880 44.040 1.00 12.65 ATOM 452 CD ARG 56 26.371 30.171 43.928 1.00 13.01 ATOM 453 NE ARG 56 26.264 29.199 44.998 1.00 13.72 ATOM 454 CZ ARG 56 25.247 28.411 45.241 1.00 12.53 ATOM 455 NH1 ARG 56 24.176 28.440 44.495 1.00 10.89 ATOM 456 NH2 ARG 56 25.422 27.610 46.289 1.00 14.43 ATOM 457 C ARG 56 30.501 31.671 43.133 1.00 14.45 ATOM 458 O ARG 56 30.849 30.913 42.200 1.00 14.08 ATOM 459 N SER 57 31.222 31.754 44.225 1.00 13.89 ATOM 460 CA SER 57 32.426 30.929 44.412 1.00 15.05 ATOM 461 CB SER 57 33.023 31.247 45.792 1.00 15.54 ATOM 462 OG SER 57 34.277 30.604 45.995 1.00 17.22 ATOM 463 C SER 57 32.107 29.424 44.362 1.00 14.39 ATOM 464 O SER 57 31.028 29.003 44.817 1.00 14.42 ATOM 465 N GLY 58 32.997 28.630 43.816 1.00 13.20 ATOM 466 CA GLY 58 32.724 27.157 43.793 1.00 10.96 ATOM 467 C GLY 58 34.050 26.420 43.697 1.00 8.84 ATOM 468 O GLY 58 35.027 27.045 43.316 1.00 9.13 ATOM 469 N VAL 59 34.082 25.126 43.982 1.00 8.47 ATOM 470 CA VAL 59 35.220 24.274 43.887 1.00 7.38 ATOM 471 CB VAL 59 35.731 23.702 45.248 1.00 6.40 ATOM 472 CG1 VAL 59 36.137 24.837 46.154 1.00 2.67 ATOM 473 CG2 VAL 59 34.729 22.751 45.834 1.00 6.06 ATOM 474 C VAL 59 35.111 23.138 42.895 1.00 6.56 ATOM 475 O VAL 59 36.087 22.423 42.623 1.00 5.81 ATOM 476 N GLY 60 33.901 22.917 42.339 1.00 5.18 ATOM 477 CA GLY 60 33.686 21.922 41.328 1.00 3.01 ATOM 478 C GLY 60 32.684 22.363 40.281 1.00 4.83 ATOM 479 O GLY 60 31.831 23.228 40.563 1.00 7.05 ATOM 480 N LEU 61 32.723 21.833 39.071 1.00 4.97 ATOM 481 CA LEU 61 31.800 22.185 38.012 1.00 5.34 ATOM 482 CB LEU 61 32.356 23.451 37.250 1.00 4.23 ATOM 483 CG LEU 61 31.400 24.019 36.212 1.00 4.22 ATOM 484 CD1 LEU 61 30.116 24.482 36.841 1.00 2.46 ATOM 485 CD2 LEU 61 32.030 25.178 35.413 1.00 4.72 ATOM 486 C LEU 61 31.694 21.018 37.026 1.00 5.60 ATOM 487 O LEU 61 32.750 20.517 36.638 1.00 6.42 ATOM 488 N ALA 62 30.504 20.552 36.686 1.00 5.63 ATOM 489 CA ALA 62 30.418 19.406 35.741 1.00 4.65 ATOM 490 CB ALA 62 29.619 18.292 36.364 1.00 2.45 ATOM 491 C ALA 62 29.793 19.935 34.451 1.00 5.95 ATOM 492 O ALA 62 28.964 20.817 34.490 1.00 6.05 ATOM 493 N ALA 63 30.228 19.393 33.287 1.00 6.80 ATOM 494 CA ALA 63 29.749 19.839 31.985 1.00 6.73 ATOM 495 CB ALA 63 30.529 19.136 30.903 1.00 4.62 ATOM 496 C ALA 63 28.270 19.965 31.891 1.00 8.06 ATOM 497 O ALA 63 27.704 20.987 31.462 1.00 7.93 ATOM 498 N PRO 64 27.455 19.043 32.424 1.00 9.12 ATOM 499 CA PRO 64 25.985 19.168 32.412 1.00 8.90 ATOM 500 CB PRO 64 25.605 17.981 33.293 1.00 8.17 ATOM 501 CG PRO 64 26.622 16.974 32.833 1.00 7.79 ATOM 502 CD PRO 64 27.917 17.751 32.936 1.00 8.59 ATOM 503 C PRO 64 25.470 20.474 32.967 1.00 10.82 ATOM 504 O PRO 64 24.417 21.004 32.529 1.00 12.14 ATOM 505 N GLN 65 26.166 21.045 33.961 1.00 9.00 ATOM 506 CA GLN 65 25.887 22.265 34.602 1.00 9.54 ATOM 507 CB GLN 65 26.745 22.513 35.855 1.00 7.85 ATOM 508 CG GLN 65 26.491 21.503 36.986 1.00 7.50 ATOM 509 CD GLN 65 27.298 21.965 38.217 1.00 7.64 ATOM 510 OE1 GLN 65 28.430 21.506 38.343 1.00 6.16 ATOM 511 NE2 GLN 65 26.694 22.855 39.036 1.00 5.03 ATOM 512 C GLN 65 25.965 23.523 33.712 1.00 9.56 ATOM 513 O GLN 65 25.400 24.560 34.092 1.00 9.71 ATOM 514 N ILE 66 26.607 23.468 32.580 1.00 9.17 ATOM 515 CA ILE 66 26.768 24.427 31.569 1.00 8.61 ATOM 516 CB ILE 66 28.175 24.958 31.202 1.00 7.57 ATOM 517 CG1 ILE 66 29.148 23.899 30.706 1.00 7.91 ATOM 518 CD1 ILE 66 30.433 24.581 30.125 1.00 7.44 ATOM 519 CG2 ILE 66 28.749 25.769 32.340 1.00 7.53 ATOM 520 C ILE 66 26.068 23.881 30.298 1.00 9.39 ATOM 521 O ILE 66 26.309 24.232 29.163 1.00 10.40 ATOM 522 N ASN 67 25.126 22.986 30.510 1.00 10.49 ATOM 523 CA ASN 67 24.266 22.369 29.557 1.00 11.57 ATOM 524 CB ASN 67 23.399 23.500 28.929 1.00 12.56 ATOM 525 CG ASN 67 22.171 22.934 28.230 1.00 12.16 ATOM 526 OD1 ASN 67 21.751 21.813 28.405 1.00 12.53 ATOM 527 ND2 ASN 67 21.492 23.785 27.485 1.00 14.18 ATOM 528 C ASN 67 24.980 21.596 28.464 1.00 11.97 ATOM 529 O ASN 67 24.610 21.590 27.263 1.00 12.28 ATOM 530 N ILE 68 26.093 21.000 28.821 1.00 10.89 ATOM 531 CA ILE 68 26.918 20.161 27.888 1.00 10.88 ATOM 532 CB ILE 68 28.298 20.745 27.721 1.00 10.24 ATOM 533 CG1 ILE 68 28.286 22.078 26.953 1.00 9.48 ATOM 534 CD1 ILE 68 29.646 22.766 26.933 1.00 7.35 ATOM 535 CG2 ILE 68 29.224 19.745 26.992 1.00 9.60 ATOM 536 C ILE 68 26.868 18.749 28.499 1.00 10.44 ATOM 537 O ILE 68 27.477 18.497 29.537 1.00 9.24 ATOM 538 N SER 69 26.091 17.859 27.888 1.00 10.07 ATOM 539 CA SER 69 25.867 16.541 28.468 1.00 10.16 ATOM 540 CB SER 69 24.475 16.071 28.036 1.00 8.68 ATOM 541 OG SER 69 23.982 14.974 28.781 1.00 9.95 ATOM 542 C SER 69 26.972 15.562 28.156 1.00 10.74 ATOM 543 O SER 69 26.778 14.529 27.532 1.00 11.54 ATOM 544 N LYS 70 28.184 15.911 28.570 1.00 10.10 ATOM 545 CA LYS 70 29.409 15.153 28.370 1.00 9.96 ATOM 546 CB LYS 70 30.368 15.890 27.428 1.00 10.10 ATOM 547 CG LYS 70 29.624 16.156 26.075 1.00 13.10 ATOM 548 CD LYS 70 30.666 16.689 25.078 1.00 15.02 ATOM 549 CE LYS 70 30.002 16.829 23.705 1.00 15.43 ATOM 550 NZ LYS 70 30.955 17.277 22.697 1.00 17.50 ATOM 551 C LYS 70 30.082 14.848 29.722 1.00 9.28 ATOM 552 O LYS 70 29.937 15.649 30.656 1.00 10.48 ATOM 553 N ARG 71 30.789 13.750 29.827 1.00 7.46 ATOM 554 CA ARG 71 31.383 13.295 31.076 1.00 7.42 ATOM 555 CB ARG 71 31.426 11.762 31.151 1.00 5.24 ATOM 556 CG ARG 71 30.124 11.043 30.888 1.00 4.69 ATOM 557 CD ARG 71 30.141 9.561 31.166 1.00 3.45 ATOM 558 NE ARG 71 30.097 9.086 32.533 1.00 5.53 ATOM 559 CZ ARG 71 29.004 9.030 33.279 1.00 6.30 ATOM 560 NH1 ARG 71 27.846 9.361 32.738 1.00 6.87 ATOM 561 NH2 ARG 71 28.983 8.718 34.567 1.00 9.93 ATOM 562 C ARG 71 32.756 13.852 31.351 1.00 7.34 ATOM 563 O ARG 71 33.782 13.219 31.176 1.00 7.04 ATOM 564 N MET 72 32.764 15.142 31.733 1.00 8.16 ATOM 565 CA MET 72 33.929 15.899 32.038 1.00 7.49 ATOM 566 CB MET 72 34.226 16.975 30.968 1.00 11.49 ATOM 567 CG MET 72 34.482 16.514 29.597 1.00 14.92 ATOM 568 SD MET 72 34.929 17.771 28.426 1.00 14.46 ATOM 569 CE MET 72 33.462 18.708 28.193 1.00 15.90 ATOM 570 C MET 72 33.639 16.756 33.276 1.00 6.05 ATOM 571 O MET 72 32.583 17.367 33.360 1.00 5.46 ATOM 572 N ILE 73 34.610 16.921 34.129 1.00 5.83 ATOM 573 CA ILE 73 34.470 17.767 35.294 1.00 4.01 ATOM 574 CB ILE 73 34.134 16.939 36.559 1.00 4.50 ATOM 575 CG1 ILE 73 35.208 15.825 36.788 1.00 3.12 ATOM 576 CD1 ILE 73 35.070 15.150 38.142 1.00 3.42 ATOM 577 CG2 ILE 73 32.758 16.373 36.503 1.00 3.16 ATOM 578 C ILE 73 35.728 18.596 35.564 1.00 4.80 ATOM 579 O ILE 73 36.814 18.324 35.070 1.00 4.39 ATOM 580 N ALA 74 35.570 19.655 36.382 1.00 4.79 ATOM 581 CA ALA 74 36.744 20.441 36.785 1.00 5.15 ATOM 582 CB ALA 74 36.868 21.730 36.054 1.00 5.71 ATOM 583 C ALA 74 36.659 20.559 38.308 1.00 4.79 ATOM 584 O ALA 74 35.592 20.723 38.844 1.00 4.28 ATOM 585 N VAL 75 37.774 20.324 39.020 1.00 6.37 ATOM 586 CA VAL 75 37.811 20.449 40.484 1.00 6.45 ATOM 587 CB VAL 75 37.984 19.144 41.290 1.00 5.03 ATOM 588 CG1 VAL 75 38.075 19.427 42.796 1.00 2.00 ATOM 589 CG2 VAL 75 36.744 18.271 41.056 1.00 3.76 ATOM 590 C VAL 75 38.918 21.416 40.854 1.00 7.44 ATOM 591 O VAL 75 40.043 21.229 40.321 1.00 8.86 ATOM 592 N LEU 76 38.635 22.413 41.703 1.00 6.88 ATOM 593 CA LEU 76 39.681 23.368 42.027 1.00 7.77 ATOM 594 CB LEU 76 39.537 24.660 41.205 1.00 7.33 ATOM 595 CG LEU 76 40.640 25.705 41.437 1.00 4.71 ATOM 596 CD1 LEU 76 41.961 25.218 40.861 1.00 3.93 ATOM 597 CD2 LEU 76 40.257 27.038 40.857 1.00 7.52 ATOM 598 C LEU 76 39.614 23.683 43.527 1.00 8.83 ATOM 599 O LEU 76 38.896 24.560 43.956 1.00 10.55 ATOM 600 N ILE 77 40.247 22.867 44.342 1.00 8.82 ATOM 601 CA ILE 77 40.215 23.024 45.796 1.00 11.03 ATOM 602 CB ILE 77 40.001 21.637 46.472 1.00 10.29 ATOM 603 CG1 ILE 77 38.674 21.025 46.000 1.00 9.23 ATOM 604 CD1 ILE 77 38.561 19.534 46.388 1.00 7.45 ATOM 605 CG2 ILE 77 39.946 21.906 48.012 1.00 11.93 ATOM 606 C ILE 77 41.570 23.599 46.247 1.00 11.22 ATOM 607 O ILE 77 42.605 22.996 46.058 1.00 11.78 ATOM 608 N PRO 78 41.549 24.801 46.769 1.00 12.81 ATOM 609 CA PRO 78 42.755 25.478 47.215 1.00 13.82 ATOM 610 CB PRO 78 42.281 26.881 47.476 1.00 13.82 ATOM 611 CG PRO 78 40.832 26.828 47.688 1.00 13.52 ATOM 612 CD PRO 78 40.323 25.600 47.015 1.00 13.68 ATOM 613 C PRO 78 43.384 24.865 48.463 1.00 14.04 ATOM 614 O PRO 78 42.729 24.162 49.225 1.00 13.74 ATOM 615 N ASP 79 44.663 25.190 48.665 1.00 15.66 ATOM 616 CA ASP 79 45.421 24.733 49.796 1.00 16.97 ATOM 617 CB ASP 79 46.815 25.342 49.773 1.00 17.17 ATOM 618 CG ASP 79 47.725 24.835 50.845 1.00 19.81 ATOM 619 OD1 ASP 79 47.281 24.237 51.833 1.00 21.59 ATOM 620 OD2 ASP 79 48.968 24.997 50.743 1.00 23.71 ATOM 621 C ASP 79 44.730 25.095 51.103 1.00 19.47 ATOM 622 O ASP 79 44.386 26.257 51.328 1.00 19.81 ATOM 623 N ASP 80 44.523 24.114 51.958 1.00 21.56 ATOM 624 CA ASP 80 43.899 24.283 53.240 1.00 24.85 ATOM 625 CB ASP 80 43.294 22.944 53.706 1.00 27.72 ATOM 626 CG ASP 80 44.345 21.869 53.833 1.00 30.53 ATOM 627 OD1 ASP 80 44.094 20.790 54.401 1.00 32.70 ATOM 628 OD2 ASP 80 45.490 22.015 53.347 1.00 30.54 ATOM 629 C ASP 80 44.898 24.740 54.318 1.00 26.28 ATOM 630 O ASP 80 44.491 25.228 55.374 1.00 27.81 ATOM 631 N GLY 81 46.168 24.602 54.112 1.00 26.90 ATOM 632 CA GLY 81 47.214 24.943 55.079 1.00 27.17 ATOM 633 C GLY 81 48.062 23.658 55.240 1.00 27.82 ATOM 634 O GLY 81 49.259 23.728 55.546 1.00 28.21 ATOM 635 N SER 82 47.391 22.520 54.989 1.00 27.02 ATOM 636 CA SER 82 48.108 21.246 55.049 1.00 26.04 ATOM 637 CB SER 82 47.248 20.019 54.796 1.00 25.15 ATOM 638 OG SER 82 46.765 20.059 53.446 1.00 26.13 ATOM 639 C SER 82 49.127 21.195 53.882 1.00 24.89 ATOM 640 O SER 82 50.066 20.426 53.980 1.00 25.62 ATOM 641 N GLY 83 48.917 22.012 52.872 1.00 23.48 ATOM 642 CA GLY 83 49.841 21.974 51.719 1.00 21.77 ATOM 643 C GLY 83 49.163 21.092 50.638 1.00 19.26 ATOM 644 O GLY 83 49.801 20.902 49.631 1.00 20.21 ATOM 645 N LYS 84 47.972 20.576 50.867 1.00 16.73 ATOM 646 CA LYS 84 47.296 19.797 49.836 1.00 14.79 ATOM 647 CB LYS 84 46.528 18.644 50.415 1.00 16.65 ATOM 648 CG LYS 84 47.294 17.703 51.325 1.00 20.53 ATOM 649 CD LYS 84 46.320 16.536 51.571 1.00 26.25 ATOM 650 CE LYS 84 46.765 15.630 52.681 1.00 29.35 ATOM 651 NZ LYS 84 46.698 16.382 53.997 1.00 31.51 ATOM 652 C LYS 84 46.305 20.645 49.058 1.00 13.36 ATOM 653 O LYS 84 45.482 21.354 49.657 1.00 13.57 ATOM 654 N SER 85 46.334 20.575 47.727 1.00 12.20 ATOM 655 CA SER 85 45.399 21.352 46.904 1.00 10.79 ATOM 656 CB SER 85 45.910 22.713 46.473 1.00 10.03 ATOM 657 OG SER 85 46.979 22.545 45.587 1.00 12.27 ATOM 658 C SER 85 45.052 20.517 45.660 1.00 9.97 ATOM 659 O SER 85 45.892 19.710 45.314 1.00 9.45 ATOM 660 N TYR 86 43.855 20.667 45.136 1.00 8.93 ATOM 661 CA TYR 86 43.370 19.823 44.040 1.00 8.91 ATOM 662 CB TYR 86 42.190 18.985 44.568 1.00 9.61 ATOM 663 CG TYR 86 42.612 18.127 45.766 1.00 11.87 ATOM 664 CD1 TYR 86 42.525 18.675 47.031 1.00 12.22 ATOM 665 CE1 TYR 86 42.968 17.980 48.146 1.00 14.09 ATOM 666 CZ TYR 86 43.464 16.693 47.998 1.00 13.74 ATOM 667 OH TYR 86 43.877 16.050 49.147 1.00 14.04 ATOM 668 CE2 TYR 86 43.587 16.139 46.747 1.00 13.17 ATOM 669 CD2 TYR 86 43.136 16.849 45.631 1.00 12.81 ATOM 670 C TYR 86 42.937 20.636 42.843 1.00 8.39 ATOM 671 O TYR 86 42.041 21.470 42.905 1.00 11.10 ATOM 672 N ASP 87 43.597 20.487 41.740 1.00 7.58 ATOM 673 CA ASP 87 43.388 21.198 40.491 1.00 7.93 ATOM 674 CB ASP 87 44.561 22.172 40.249 1.00 7.54 ATOM 675 CG ASP 87 44.336 23.088 39.060 1.00 9.36 ATOM 676 OD1 ASP 87 43.367 22.912 38.300 1.00 9.22 ATOM 677 OD2 ASP 87 45.098 24.043 38.908 1.00 12.88 ATOM 678 C ASP 87 43.369 20.124 39.392 1.00 6.63 ATOM 679 O ASP 87 44.445 19.695 38.965 1.00 7.41 ATOM 680 N TYR 88 42.204 19.657 39.046 1.00 7.18 ATOM 681 CA TYR 88 42.058 18.612 38.048 1.00 7.88 ATOM 682 CB TYR 88 41.775 17.252 38.727 1.00 8.03 ATOM 683 CG TYR 88 42.918 16.706 39.528 1.00 7.31 ATOM 684 CD1 TYR 88 43.051 16.986 40.887 1.00 7.10 ATOM 685 CE1 TYR 88 44.093 16.455 41.622 1.00 5.16 ATOM 686 CZ TYR 88 45.017 15.649 40.992 1.00 5.90 ATOM 687 OH TYR 88 46.088 15.153 41.721 1.00 7.39 ATOM 688 CE2 TYR 88 44.955 15.404 39.643 1.00 6.03 ATOM 689 CD2 TYR 88 43.866 15.894 38.917 1.00 6.97 ATOM 690 C TYR 88 40.939 18.810 37.051 1.00 8.22 ATOM 691 O TYR 88 39.816 19.193 37.355 1.00 9.63 ATOM 692 N MET 89 41.231 18.498 35.814 1.00 8.89 ATOM 693 CA MET 89 40.233 18.533 34.736 1.00 8.17 ATOM 694 CB MET 89 40.600 19.441 33.591 1.00 7.98 ATOM 695 CG MET 89 40.522 20.918 33.852 1.00 8.05 ATOM 696 SD MET 89 41.005 21.973 32.496 1.00 8.41 ATOM 697 CE MET 89 42.746 21.671 32.340 1.00 7.64 ATOM 698 C MET 89 40.203 17.038 34.319 1.00 5.98 ATOM 699 O MET 89 41.212 16.525 33.797 1.00 6.63 ATOM 700 N LEU 90 39.123 16.386 34.611 1.00 4.43 ATOM 701 CA LEU 90 39.050 14.952 34.284 1.00 5.33 ATOM 702 CB LEU 90 38.707 14.179 35.541 1.00 6.25 ATOM 703 CG LEU 90 39.564 14.222 36.755 1.00 6.92 ATOM 704 CD1 LEU 90 39.034 13.233 37.827 1.00 4.71 ATOM 705 CD2 LEU 90 41.018 13.889 36.453 1.00 6.93 ATOM 706 C LEU 90 38.027 14.648 33.196 1.00 4.75 ATOM 707 O LEU 90 36.963 15.237 33.151 1.00 5.61 ATOM 708 N VAL 91 38.354 13.719 32.340 1.00 4.98 ATOM 709 CA VAL 91 37.487 13.246 31.253 1.00 4.58 ATOM 710 CB VAL 91 38.323 13.299 29.938 1.00 4.51 ATOM 711 CG1 VAL 91 37.590 12.571 28.815 1.00 6.97 ATOM 712 CG2 VAL 91 38.589 14.718 29.522 1.00 2.32 ATOM 713 C VAL 91 37.137 11.805 31.576 1.00 5.04 ATOM 714 O VAL 91 38.003 11.030 31.991 1.00 5.81 ATOM 715 N ASN 92 35.842 11.420 31.481 1.00 5.85 ATOM 716 CA ASN 92 35.357 10.088 31.747 1.00 6.19 ATOM 717 CB ASN 92 35.743 9.111 30.644 1.00 7.29 ATOM 718 CG ASN 92 35.308 9.457 29.252 1.00 7.92 ATOM 719 OD1 ASN 92 34.247 10.045 29.090 1.00 7.73 ATOM 720 ND2 ASN 92 36.092 9.017 28.271 1.00 10.17 ATOM 721 C ASN 92 35.756 9.501 33.083 1.00 8.19 ATOM 722 O ASN 92 36.265 8.363 33.177 1.00 9.98 ATOM 723 N PRO 93 35.644 10.283 34.153 1.00 8.97 ATOM 724 CD PRO 93 35.059 11.684 34.132 1.00 7.81 ATOM 725 CA PRO 93 35.996 9.859 35.482 1.00 8.04 ATOM 726 CB PRO 93 35.928 11.155 36.272 1.00 7.31 ATOM 727 CG PRO 93 34.802 11.890 35.596 1.00 7.53 ATOM 728 C PRO 93 35.074 8.770 35.997 1.00 9.49 ATOM 729 O PRO 93 33.852 8.750 35.756 1.00 9.28 ATOM 730 N LYS 94 35.690 7.828 36.740 1.00 9.93 ATOM 731 CA LYS 94 34.921 6.724 37.302 1.00 9.81 ATOM 732 CB LYS 94 34.975 5.537 36.280 1.00 13.20 ATOM 733 CG LYS 94 33.920 4.483 36.579 1.00 18.63 ATOM 734 CD LYS 94 34.020 3.251 35.668 1.00 23.45 ATOM 735 CE LYS 94 32.846 2.297 35.911 1.00 25.89 ATOM 736 NZ LYS 94 32.998 1.075 35.012 1.00 28.49 ATOM 737 C LYS 94 35.539 6.242 38.610 1.00 8.51 ATOM 738 O LYS 94 36.749 6.036 38.748 1.00 6.81 ATOM 739 N ILE 95 34.686 6.078 39.604 1.00 7.95 ATOM 740 CA ILE 95 35.040 5.534 40.910 1.00 6.10 ATOM 741 CB ILE 95 34.014 5.898 41.954 1.00 5.18 ATOM 742 CG1 ILE 95 34.046 7.444 42.211 1.00 6.06 ATOM 743 CD1 ILE 95 32.837 7.904 43.045 1.00 5.94 ATOM 744 CG2 ILE 95 34.329 5.157 43.281 1.00 5.58 ATOM 745 C ILE 95 35.166 3.997 40.716 1.00 6.29 ATOM 746 O ILE 95 34.198 3.309 40.347 1.00 5.34 ATOM 747 N VAL 96 36.391 3.492 40.859 1.00 4.94 ATOM 748 CA VAL 96 36.632 2.073 40.636 1.00 5.84 ATOM 749 CB VAL 96 37.831 1.745 39.776 1.00 5.80 ATOM 750 CG1 VAL 96 37.679 2.310 38.351 1.00 6.24 ATOM 751 CG2 VAL 96 39.165 2.258 40.318 1.00 5.22 ATOM 752 C VAL 96 36.608 1.295 41.950 1.00 5.83 ATOM 753 O VAL 96 36.279 0.126 41.914 1.00 5.47 ATOM 754 N SER 97 36.847 1.959 43.077 1.00 5.14 ATOM 755 CA SER 97 36.830 1.376 44.383 1.00 5.56 ATOM 756 CB SER 97 38.128 0.683 44.766 1.00 3.06 ATOM 757 OG SER 97 39.236 1.451 44.594 1.00 6.94 ATOM 758 C SER 97 36.592 2.485 45.447 1.00 6.21 ATOM 759 O SER 97 36.842 3.650 45.154 1.00 5.16 ATOM 760 N HIS 98 36.080 2.045 46.577 1.00 5.51 ATOM 761 CA HIS 98 35.807 2.912 47.695 1.00 6.19 ATOM 762 CB HIS 98 34.521 3.705 47.410 1.00 5.68 ATOM 763 CG HIS 98 33.314 2.839 47.189 1.00 3.10 ATOM 764 ND1 HIS 98 32.540 2.415 48.249 1.00 5.80 ATOM 765 CE1 HIS 98 31.533 1.690 47.820 1.00 3.91 ATOM 766 NE2 HIS 98 31.630 1.631 46.504 1.00 4.11 ATOM 767 CD2 HIS 98 32.731 2.333 46.100 1.00 2.55 ATOM 768 C HIS 98 35.718 2.187 49.043 1.00 6.46 ATOM 769 O HIS 98 35.484 0.998 49.174 1.00 5.57 ATOM 770 N SER 99 35.882 2.968 50.123 1.00 6.76 ATOM 771 CA SER 99 35.744 2.476 51.476 1.00 6.43 ATOM 772 CB SER 99 36.188 3.588 52.459 1.00 7.38 ATOM 773 OG SER 99 35.341 4.757 52.354 1.00 7.60 ATOM 774 C SER 99 34.290 2.177 51.765 1.00 6.67 ATOM 775 O SER 99 33.365 2.734 51.153 1.00 7.55 ATOM 776 N VAL 100 34.005 1.310 52.714 1.00 6.58 ATOM 777 CA VAL 100 32.615 1.043 53.160 1.00 6.28 ATOM 778 CB VAL 100 32.598 −0.278 53.971 1.00 6.35 ATOM 779 CG1 VAL 100 31.215 −0.420 54.605 1.00 6.97 ATOM 780 CG2 VAL 100 32.745 −1.461 52.932 1.00 6.04 ATOM 781 C VAL 100 32.175 2.219 54.062 1.00 6.51 ATOM 782 O VAL 100 31.049 2.745 54.044 1.00 6.77 ATOM 783 N GLN 101 33.124 2.741 54.816 1.00 7.40 ATOM 784 CA GLN 101 32.865 3.871 55.734 1.00 9.68 ATOM 785 CB GLN 101 34.012 4.032 56.704 1.00 9.29 ATOM 786 CG GLN 101 33.909 5.192 57.649 1.00 9.97 ATOM 787 CD GLN 101 35.017 5.329 58.642 1.00 10.63 ATOM 788 OE1 GLN 101 36.190 5.548 58.257 1.00 13.55 ATOM 789 NE2 GLN 101 34.656 5.267 59.887 1.00 11.28 ATOM 790 C GLN 101 32.569 5.189 54.993 1.00 9.37 ATOM 791 O GLN 101 33.236 5.551 54.068 1.00 7.54 ATOM 792 N GLU 102 31.480 5.845 55.472 1.00 9.24 ATOM 793 CA GLU 102 31.008 7.074 54.921 1.00 9.90 ATOM 794 CB GLU 102 29.464 7.141 55.018 1.00 11.63 ATOM 795 CG GLU 102 28.763 6.013 54.261 1.00 12.22 ATOM 796 CD GLU 102 27.278 6.126 54.402 1.00 14.95 ATOM 797 OE1 GLU 102 26.805 6.596 55.462 1.00 18.92 ATOM 798 OE2 GLU 102 26.511 5.770 53.500 1.00 16.02 ATOM 799 C GLU 102 31.533 8.340 55.593 1.00 10.50 ATOM 800 O GLU 102 32.169 8.275 56.630 1.00 11.22 ATOM 801 N ALA 103 31.273 9.485 54.974 1.00 9.97 ATOM 802 CA ALA 103 31.699 10.772 55.541 1.00 9.74 ATOM 803 CB ALA 103 33.049 11.245 55.034 1.00 8.10 ATOM 804 C ALA 103 30.644 11.816 55.123 1.00 9.71 ATOM 805 O ALA 103 30.011 11.529 54.129 1.00 9.34 ATOM 806 N TYR 104 30.556 12.936 55.808 1.00 9.87 ATOM 807 CA TYR 104 29.585 13.984 55.438 1.00 11.04 ATOM 808 CB TYR 104 28.192 13.707 56.083 1.00 11.01 ATOM 809 CG TYR 104 28.273 13.737 57.596 1.00 12.87 ATOM 810 CD1 TYR 104 27.958 14.884 58.330 1.00 14.01 ATOM 811 CE1 TYR 104 28.088 14.909 59.727 1.00 13.96 ATOM 812 CZ TYR 104 28.519 13.774 60.389 1.00 14.95 ATOM 813 OH TYR 104 28.676 13.775 61.757 1.00 15.04 ATOM 814 CE2 TYR 104 28.796 12.619 59.685 1.00 13.61 ATOM 815 CD2 TYR 104 28.665 12.589 58.310 1.00 13.25 ATOM 816 C TYR 104 30.135 15.342 55.885 1.00 10.66 ATOM 817 O TYR 104 30.942 15.394 56.853 1.00 11.97 ATOM 818 N LEU 105 29.819 16.416 55.227 1.00 10.31 ATOM 819 CA LEU 105 30.271 17.775 55.675 1.00 10.31 ATOM 820 CB LEU 105 30.363 18.745 54.499 1.00 8.28 ATOM 821 CG LEU 105 31.202 18.355 53.295 1.00 7.12 ATOM 822 CD1 LEU 105 31.189 19.393 52.190 1.00 5.52 ATOM 823 CD2 LEU 105 32.669 18.076 53.663 1.00 5.12 ATOM 824 C LEU 105 29.156 18.174 56.667 1.00 10.48 ATOM 825 O LEU 105 27.977 17.998 56.358 1.00 10.24 ATOM 826 N PRO 106 29.469 18.627 57.865 1.00 11.95 ATOM 827 CA PRO 106 28.454 18.963 58.863 1.00 12.84 ATOM 828 CB PRO 106 29.276 19.275 60.093 1.00 13.00 ATOM 829 CG PRO 106 30.549 19.799 59.534 1.00 14.02 ATOM 830 CD PRO 106 30.826 18.911 58.327 1.00 13.21 ATOM 831 C PRO 106 27.479 20.038 58.465 1.00 13.69 ATOM 832 O PRO 106 26.376 20.106 59.000 1.00 14.91 ATOM 833 N THR 107 27.838 20.930 57.523 1.00 14.66 ATOM 834 CA THR 107 26.983 21.976 57.008 1.00 16.19 ATOM 835 CB THR 107 27.799 23.235 56.607 1.00 21.67 ATOM 836 OG1 THR 107 28.885 22.852 55.716 1.00 25.40 ATOM 837 CG2 THR 107 28.349 23.915 57.844 1.00 24.07 ATOM 838 C THR 107 26.199 21.591 55.752 1.00 13.84 ATOM 839 O THR 107 25.549 22.430 55.155 1.00 14.95 ATOM 840 N GLY 108 26.232 20.326 55.368 1.00 11.38 ATOM 841 CA GLY 108 25.547 19.869 54.176 1.00 8.51 ATOM 842 C GLY 108 26.402 20.337 53.000 1.00 7.43 ATOM 843 O GLY 108 27.611 20.629 53.127 1.00 7.41 ATOM 844 N GLU 109 25.808 20.388 51.837 1.00 6.61 ATOM 845 CA GLU 109 26.466 20.806 50.634 1.00 7.52 ATOM 846 CB GLU 109 26.686 19.615 49.685 1.00 7.66 ATOM 847 CG GLU 109 27.582 18.521 50.288 1.00 5.52 ATOM 848 CD GLU 109 27.731 17.381 49.320 1.00 7.26 ATOM 849 OE1 GLU 109 27.368 17.478 48.139 1.00 7.28 ATOM 850 OE2 GLU 109 28.195 16.298 49.739 1.00 8.58 ATOM 851 C GLU 109 25.653 21.884 49.896 1.00 8.48 ATOM 852 O GLU 109 24.554 22.191 50.241 1.00 10.22 ATOM 853 N GLY 110 26.303 22.414 48.883 1.00 10.01 ATOM 854 CA GLY 110 25.702 23.424 47.989 1.00 10.84 ATOM 855 C GLY 110 26.178 23.098 46.548 1.00 11.21 ATOM 856 O GLY 110 27.056 22.281 46.342 1.00 11.00 ATOM 857 N CYS 111 25.608 23.776 45.582 1.00 11.21 ATOM 858 CA CYS 111 25.870 23.582 44.163 1.00 10.09 ATOM 859 C CYS 111 25.533 24.848 43.352 1.00 10.36 ATOM 860 O CYS 111 24.562 25.536 43.627 1.00 10.29 ATOM 861 CB CYS 111 24.923 22.434 43.721 1.00 9.84 ATOM 862 SG CYS 111 25.048 21.924 42.045 1.00 8.95 ATOM 863 N LEU 112 26.398 25.177 42.403 1.00 11.20 ATOM 864 CA LEU 112 26.170 26.384 41.550 1.00 11.83 ATOM 865 CB LEU 112 27.411 26.486 40.666 1.00 12.57 ATOM 866 CG LEU 112 28.708 26.878 41.352 1.00 15.06 ATOM 867 CD1 LEU 112 29.871 26.352 40.469 1.00 15.77 ATOM 868 CD2 LEU 112 28.926 28.394 41.340 1.00 15.61 ATOM 869 C LEU 112 24.851 26.350 40.836 1.00 11.60 ATOM 870 O LEU 112 24.228 27.383 40.488 1.00 11.36 ATOM 871 N SER 113 24.310 25.146 40.587 1.00 11.85 ATOM 872 CA SER 113 23.048 24.950 39.917 1.00 11.15 ATOM 873 CB SER 113 23.025 23.699 39.049 1.00 10.66 ATOM 874 OG SER 113 23.968 23.793 37.992 1.00 7.38 ATOM 875 C SER 113 21.886 24.945 40.885 1.00 12.54 ATOM 876 O SER 113 20.731 24.917 40.427 1.00 14.05 ATOM 877 N VAL 114 22.143 24.975 42.198 1.00 11.90 ATOM 878 CA VAL 114 21.022 25.016 43.143 1.00 11.54 ATOM 879 CB VAL 114 21.067 23.872 44.160 1.00 9.05 ATOM 880 CG1 VAL 114 19.777 23.919 45.007 1.00 10.95 ATOM 881 CG2 VAL 114 21.080 22.538 43.409 1.00 9.28 ATOM 882 C VAL 114 21.005 26.402 43.818 1.00 11.42 ATOM 883 O VAL 114 21.854 26.663 44.630 1.00 11.25 ATOM 884 N ASP 115 20.077 27.277 43.466 1.00 12.74 ATOM 885 CA ASP 115 20.012 28.618 43.985 1.00 15.39 ATOM 886 CB ASP 115 19.029 29.540 43.310 1.00 17.73 ATOM 887 CG ASP 115 19.300 29.933 41.893 1.00 20.05 ATOM 888 OD1 ASP 115 20.331 29.598 41.312 1.00 18.80 ATOM 889 OD2 ASP 115 18.380 30.637 41.372 1.00 22.85 ATOM 890 C ASP 115 19.789 28.760 45.492 1.00 16.27 ATOM 891 O ASP 115 20.405 29.626 46.099 1.00 17.11 ATOM 892 N ASP 116 18.857 28.001 46.028 1.00 17.25 ATOM 893 CA ASP 116 18.590 28.081 47.461 1.00 18.90 ATOM 894 CB ASP 116 17.117 27.717 47.739 1.00 21.30 ATOM 895 CG ASP 116 16.153 28.650 47.041 1.00 24.14 ATOM 896 OD1 ASP 116 16.391 29.883 47.008 1.00 23.07 ATOM 897 OD2 ASP 116 15.132 28.134 46.495 1.00 26.77 ATOM 898 C ASP 116 19.444 27.106 48.249 1.00 19.20 ATOM 899 O ASP 116 19.738 26.025 47.744 1.00 19.78 ATOM 900 N ASN 117 19.869 27.534 49.428 1.00 18.50 ATOM 901 CA ASN 117 20.571 26.691 50.352 1.00 18.69 ATOM 902 CB ASN 117 21.143 27.363 51.585 1.00 19.43 ATOM 903 CG ASN 117 22.487 28.000 51.304 1.00 22.50 ATOM 904 OD1 ASN 117 23.330 27.263 50.736 1.00 23.16 ATOM 905 ND2 ASN 117 22.749 29.225 51.663 1.00 22.67 ATOM 906 C ASN 117 19.655 25.543 50.781 1.00 19.22 ATOM 907 O ASN 117 18.465 25.737 51.042 1.00 20.65 ATOM 908 N VAL 118 20.216 24.324 50.775 1.00 18.92 ATOM 909 CA VAL 118 19.445 23.151 51.178 1.00 18.04 ATOM 910 CB VAL 118 19.364 22.090 50.077 1.00 18.23 ATOM 911 CG1 VAL 118 18.474 20.906 50.480 1.00 15.62 ATOM 912 CG2 VAL 118 18.797 22.712 48.813 1.00 18.51 ATOM 913 C VAL 118 20.133 22.575 52.422 1.00 17.95 ATOM 914 O VAL 118 21.338 22.351 52.430 1.00 17.23 ATOM 915 N ALA 119 19.326 22.435 53.478 1.00 17.06 ATOM 916 CA ALA 119 19.833 21.907 54.727 1.00 17.10 ATOM 917 CB ALA 119 18.932 22.450 55.851 1.00 17.38 ATOM 918 C ALA 119 19.739 20.368 54.722 1.00 16.72 ATOM 919 O ALA 119 18.760 19.858 54.161 1.00 16.13 ATOM 920 N GLY 120 20.718 19.683 55.320 1.00 15.41 ATOM 921 CA GLY 120 20.621 18.216 55.347 1.00 14.28 ATOM 922 C GLY 120 21.960 17.576 55.058 1.00 13.76 ATOM 923 O GLY 120 22.737 18.067 54.234 1.00 14.66 ATOM 924 N LEU 121 22.244 16.452 55.717 1.00 12.70 ATOM 925 CA LEU 121 23.529 15.767 55.522 1.00 11.00 ATOM 926 CB LEU 121 23.882 15.004 56.781 1.00 10.76 ATOM 927 CG LEU 121 23.943 15.759 58.103 1.00 9.49 ATOM 928 CD1 LEU 121 24.449 14.822 59.193 1.00 7.07 ATOM 929 CD2 LEU 121 24.866 16.971 57.969 1.00 8.49 ATOM 930 C LEU 121 23.528 14.851 54.310 1.00 9.73 ATOM 931 O LEU 121 22.575 14.134 53.975 1.00 10.55 ATOM 932 N VAL 122 24.614 14.916 53.575 1.00 9.32 ATOM 933 CA VAL 122 24.834 14.130 52.353 1.00 8.52 ATOM 934 CB VAL 122 25.063 15.033 51.127 1.00 6.54 ATOM 935 CG1 VAL 122 25.255 14.183 49.858 1.00 6.34 ATOM 936 CG2 VAL 122 23.909 15.992 50.882 1.00 7.19 ATOM 937 C VAL 122 26.025 13.196 52.613 1.00 8.38 ATOM 938 O VAL 122 27.194 13.572 52.554 1.00 7.49 ATOM 939 N HIS 123 25.693 11.961 52.933 1.00 8.70 ATOM 940 CA HIS 123 26.619 10.910 53.254 1.00 9.15 ATOM 941 CB HIS 123 25.995 9.863 54.141 1.00 8.55 ATOM 942 CG HIS 123 25.490 10.280 55.476 1.00 8.68 ATOM 943 ND1 HIS 123 24.164 10.635 55.678 1.00 8.01 ATOM 944 CE1 HIS 123 23.986 10.913 56.974 1.00 7.33 ATOM 945 NE2 HIS 123 25.156 10.789 57.597 1.00 9.84 ATOM 946 CD2 HIS 123 26.079 10.374 56.687 1.00 8.51 ATOM 947 C HIS 123 27.238 10.273 51.992 1.00 8.74 ATOM 948 O HIS 123 26.548 9.818 51.133 1.00 9.79 ATOM 949 N ARG 124 28.544 10.295 51.908 1.00 8.30 ATOM 950 CA ARG 124 29.327 9.808 50.787 1.00 7.51 ATOM 951 CB ARG 124 29.950 11.016 50.038 1.00 6.35 ATOM 952 CG ARG 124 28.857 11.950 49.441 1.00 6.41 ATOM 953 CD ARG 124 29.525 12.993 48.565 1.00 6.17 ATOM 954 NE ARG 124 28.611 13.914 47.957 1.00 6.87 ATOM 955 CZ ARG 124 27.747 13.824 46.996 1.00 8.12 ATOM 956 NH1 ARG 124 27.516 12.728 46.252 1.00 6.27 ATOM 957 NH2 ARG 124 27.033 14.909 46.631 1.00 7.84 ATOM 958 C ARG 124 30.408 8.871 51.264 1.00 7.13 ATOM 959 O ARG 124 30.496 8.686 52.482 1.00 7.16 ATOM 960 N HIS 125 31.238 8.287 50.388 1.00 8.38 ATOM 961 CA HIS 125 32.302 7.401 50.830 1.00 9.33 ATOM 962 CB HIS 125 32.816 6.389 49.794 1.00 9.69 ATOM 963 CG HIS 125 31.660 5.665 49.141 1.00 7.74 ATOM 964 ND1 HIS 125 30.806 4.831 49.778 1.00 8.49 ATOM 965 CE1 HIS 125 29.907 4.383 48.933 1.00 7.96 ATOM 966 NE2 HIS 125 30.208 4.908 47.725 1.00 9.47 ATOM 967 CD2 HIS 125 31.289 5.714 47.836 1.00 8.48 ATOM 968 C HIS 125 33.495 8.241 51.292 1.00 9.98 ATOM 969 O HIS 125 33.868 9.228 50.668 1.00 11.12 ATOM 970 N ASN 126 34.083 7.837 52.420 1.00 8.74 ATOM 971 CA ASN 126 35.193 8.623 52.953 1.00 8.54 ATOM 972 CB ASN 126 35.428 8.115 54.411 1.00 8.14 ATOM 973 CG ASN 126 36.416 9.019 55.101 1.00 8.88 ATOM 974 OD1 ASN 126 36.270 10.238 54.953 1.00 10.54 ATOM 975 ND2 ASN 126 37.448 8.494 55.731 1.00 9.56 ATOM 976 C ASN 126 36.402 8.566 52.090 1.00 8.32 ATOM 977 O ASN 126 37.199 9.515 51.941 1.00 9.13 ATOM 978 N LYS 127 36.595 7.416 51.408 1.00 8.46 ATOM 979 CA LYS 127 37.733 7.182 50.536 1.00 6.93 ATOM 980 CB LYS 127 38.785 6.232 51.138 1.00 8.23 ATOM 981 CG LYS 127 39.335 6.671 52.443 1.00 13.12 ATOM 982 CD LYS 127 40.489 5.811 52.965 1.00 16.68 ATOM 983 CE LYS 127 40.871 6.388 54.335 1.00 21.82 ATOM 984 NZ LYS 127 41.984 5.677 54.991 1.00 26.43 ATOM 985 C LYS 127 37.279 6.566 49.206 1.00 5.67 ATOM 986 O LYS 127 36.408 5.710 49.137 1.00 5.09 ATOM 987 N ILE 128 37.890 7.084 48.137 1.00 6.06 ATOM 988 CA ILE 128 37.584 6.599 46.802 1.00 5.35 ATOM 989 CB ILE 128 36.554 7.482 46.060 1.00 3.79 ATOM 990 CG1 ILE 128 37.101 8.916 45.871 1.00 2.49 ATOM 991 CD1 ILE 128 36.165 9.779 45.033 1.00 4.28 ATOM 992 CG2 ILE 128 35.180 7.503 46.769 1.00 2.00 ATOM 993 C ILE 128 38.855 6.553 45.951 1.00 4.84 ATOM 994 O ILE 128 39.849 7.235 46.194 1.00 3.72 ATOM 995 N THR 129 38.812 5.755 44.906 1.00 4.26 ATOM 996 CA THR 129 39.886 5.639 43.932 1.00 5.44 ATOM 997 CB THR 129 40.600 4.262 43.874 1.00 5.74 ATOM 998 OG1 THR 129 41.384 4.124 45.083 1.00 6.67 ATOM 999 CG2 THR 129 41.546 4.171 42.697 1.00 3.87 ATOM 1000 C THR 129 39.130 5.882 42.610 1.00 5.76 ATOM 1001 O THR 129 38.104 5.237 42.387 1.00 4.96 ATOM 1002 N ILE 130 39.584 6.856 41.882 1.00 6.40 ATOM 1003 CA ILE 130 39.076 7.252 40.599 1.00 7.37 ATOM 1004 CB ILE 130 38.692 8.769 40.544 1.00 7.11 ATOM 1005 CG1 ILE 130 37.391 8.969 41.370 1.00 7.19 ATOM 1006 CD1 ILE 130 36.998 10.444 41.506 1.00 10.30 ATOM 1007 CG2 ILE 130 38.474 9.320 39.150 1.00 7.49 ATOM 1008 C ILE 130 40.132 7.022 39.492 1.00 7.21 ATOM 1009 O ILE 130 41.291 7.322 39.617 1.00 6.63 ATOM 1010 N LYS 131 39.603 6.521 38.372 1.00 7.02 ATOM 1011 CA LYS 131 40.359 6.352 37.170 1.00 8.19 ATOM 1012 CB LYS 131 40.513 4.982 36.602 1.00 11.33 ATOM 1013 CG LYS 131 41.314 3.971 37.416 1.00 13.57 ATOM 1014 CD LYS 131 41.458 2.749 36.505 1.00 17.15 ATOM 1015 CE LYS 131 42.455 1.746 37.039 1.00 20.87 ATOM 1016 NZ LYS 131 42.779 0.788 35.929 1.00 25.22 ATOM 1017 C LYS 131 39.709 7.288 36.109 1.00 6.91 ATOM 1018 O LYS 131 38.489 7.342 36.009 1.00 5.90 ATOM 1019 N ALA 132 40.583 8.053 35.447 1.00 6.42 ATOM 1020 CA ALA 132 40.013 8.945 34.400 1.00 5.33 ATOM 1021 CB ALA 132 39.562 10.235 35.083 1.00 2.00 ATOM 1022 C ALA 132 41.063 9.240 33.354 1.00 5.57 ATOM 1023 O ALA 132 42.191 8.728 33.449 1.00 6.67 ATOM 1024 N LYS 133 40.734 10.026 32.341 1.00 6.83 ATOM 1025 CA LYS 133 41.758 10.489 31.375 1.00 7.84 ATOM 1026 CB LYS 133 41.311 10.463 29.904 1.00 9.83 ATOM 1027 CG LYS 133 40.878 9.164 29.336 1.00 11.29 ATOM 1028 CD LYS 133 41.983 8.133 29.442 1.00 14.36 ATOM 1029 CE LYS 133 41.577 6.842 28.727 1.00 16.88 ATOM 1030 NZ LYS 133 42.601 5.811 29.133 1.00 17.94 ATOM 1031 C LYS 133 41.887 12.006 31.643 1.00 6.97 ATOM 1032 O LYS 133 40.940 12.600 32.143 1.00 7.81 ATOM 1033 N ASP 134 42.949 12.623 31.268 1.00 8.29 ATOM 1034 CA ASP 134 43.141 14.055 31.363 1.00 7.39 ATOM 1035 CB ASP 134 44.519 14.454 31.823 1.00 8.51 ATOM 1036 CG ASP 134 45.717 14.189 30.975 1.00 8.37 ATOM 1037 OD1 ASP 134 46.894 14.220 31.413 1.00 8.77 ATOM 1038 OD2 ASP 134 45.585 13.946 29.746 1.00 9.62 ATOM 1039 C ASP 134 42.752 14.675 30.015 1.00 9.13 ATOM 1040 O ASP 134 42.283 13.980 29.053 1.00 10.00 ATOM 1041 N ILE 135 42.905 15.962 29.856 1.00 8.82 ATOM 1042 CA ILE 135 42.538 16.710 28.635 1.00 9.79 ATOM 1043 CB ILE 135 42.652 18.224 28.949 1.00 10.08 ATOM 1044 CG1 ILE 135 41.900 19.058 27.938 1.00 9.25 ATOM 1045 CD1 ILE 135 41.972 20.551 28.227 1.00 9.86 ATOM 1046 CG2 ILE 135 44.134 18.642 28.921 1.00 10.69 ATOM 1047 C ILE 135 43.229 16.263 27.395 1.00 9.88 ATOM 1048 O ILE 135 42.729 16.310 26.254 1.00 10.08 ATOM 1049 N GLU 136 44.447 15.717 27.490 1.00 9.82 ATOM 1050 CA GLU 136 45.211 15.168 26.423 1.00 9.97 ATOM 1051 CB GLU 136 46.721 15.501 26.503 1.00 9.18 ATOM 1052 CG GLU 136 47.025 16.963 26.269 1.00 11.11 ATOM 1053 CD GLU 136 46.573 17.426 24.871 1.00 11.43 ATOM 1054 OE1 GLU 136 46.759 16.636 23.938 1.00 12.83 ATOM 1055 OE2 GLU 136 46.039 18.527 24.823 1.00 12.16 ATOM 1056 C GLU 136 45.033 13.647 26.240 1.00 9.67 ATOM 1057 O GLU 136 45.793 13.083 25.431 1.00 10.16 ATOM 1058 N GLY 137 44.149 12.996 26.990 1.00 8.60 ATOM 1059 CA GLY 137 43.916 11.554 26.862 1.00 7.80 ATOM 1060 C GLY 137 44.812 10.661 27.640 1.00 6.10 ATOM 1061 O GLY 137 44.951 9.443 27.445 1.00 6.27 ATOM 1062 N ASN 138 45.611 11.224 28.533 1.00 6.53 ATOM 1063 CA ASN 138 46.540 10.485 29.348 1.00 7.17 ATOM 1064 CB ASN 138 47.859 11.112 29.564 1.00 6.62 ATOM 1065 CG ASN 138 48.666 11.343 28.324 1.00 6.41 ATOM 1066 OD1 ASN 138 48.891 10.474 27.473 1.00 7.83 ATOM 1067 ND2 ASN 138 49.080 12.589 28.118 1.00 5.84 ATOM 1068 C ASN 138 45.702 9.938 30.557 1.00 8.75 ATOM 1069 O ASN 138 44.731 10.431 30.900 1.00 9.34 ATOM 1070 N ASP 139 46.289 8.893 31.200 1.00 9.51 ATOM 1071 CA ASP 139 45.642 8.232 32.304 1.00 9.46 ATOM 1072 CB ASP 139 46.137 6.738 32.368 1.00 9.74 ATOM 1073 CG ASP 139 45.953 6.042 31.034 1.00 10.25 ATOM 1074 OD1 ASP 139 45.029 6.416 30.295 1.00 10.01 ATOM 1075 OD2 ASP 139 46.802 5.192 30.714 1.00 10.42 ATOM 1076 C ASP 139 45.931 8.866 33.648 1.00 8.48 ATOM 1077 O ASP 139 47.094 9.212 33.934 1.00 8.89 ATOM 1078 N ILE 140 44.896 9.015 34.458 1.00 8.07 ATOM 1079 CA ILE 140 45.072 9.590 35.799 1.00 9.43 ATOM 1080 CB ILE 140 44.435 10.979 35.964 1.00 12.18 ATOM 1081 CG1 ILE 140 44.723 11.979 34.883 1.00 15.73 ATOM 1082 CD1 ILE 140 46.188 12.373 34.669 1.00 17.79 ATOM 1083 CG2 ILE 140 44.881 11.612 37.311 1.00 13.76 ATOM 1084 C ILE 140 44.358 8.632 36.775 1.00 8.12 ATOM 1085 O ILE 140 43.265 8.238 36.565 1.00 7.55 ATOM 1086 N GLN 141 44.992 8.330 37.908 1.00 8.68 ATOM 1087 CA GLN 141 44.370 7.492 38.929 1.00 8.09 ATOM 1088 CB GLN 141 44.930 6.081 39.016 1.00 10.14 ATOM 1089 CG GLN 141 44.139 5.210 39.984 1.00 13.25 ATOM 1090 CD GLN 141 44.556 3.767 40.096 1.00 14.70 ATOM 1091 OE1 GLN 141 45.723 3.425 40.103 1.00 16.12 ATOM 1092 NE2 GLN 141 43.607 2.851 40.176 1.00 14.82 ATOM 1093 C GLN 141 44.575 8.281 40.247 1.00 6.14 ATOM 1094 O GLN 141 45.713 8.595 40.573 1.00 7.17 ATOM 1095 N LEU 142 43.498 8.589 40.928 1.00 4.24 ATOM 1096 CA LEU 142 43.540 9.376 42.127 1.00 4.16 ATOM 1097 CB LEU 142 42.641 10.638 42.092 1.00 3.14 ATOM 1098 CG LEU 142 42.865 11.671 40.964 1.00 4.72 ATOM 1099 CD1 LEU 142 42.418 11.139 39.628 1.00 7.12 ATOM 1100 CD2 LEU 142 42.191 12.984 41.303 1.00 5.38 ATOM 1101 C LEU 142 43.024 8.590 43.362 1.00 4.55 ATOM 1102 O LEU 142 42.026 7.918 43.302 1.00 3.43 ATOM 1103 N ARG 143 43.706 8.838 44.442 1.00 5.60 ATOM 1104 CA ARG 143 43.254 8.230 45.735 1.00 6.45 ATOM 1105 CB ARG 143 44.406 7.410 46.295 1.00 6.30 ATOM 1106 CG ARG 143 44.572 6.089 45.510 1.00 6.38 ATOM 1107 CD ARG 143 45.870 5.421 45.955 1.00 7.24 ATOM 1108 NE ARG 143 46.994 6.164 45.399 1.00 8.41 ATOM 1109 CZ ARG 143 47.487 6.175 44.186 1.00 7.10 ATOM 1110 NH1 ARG 143 47.010 5.371 43.229 1.00 10.56 ATOM 1111 NH2 ARG 143 48.441 6.994 43.872 1.00 6.66 ATOM 1112 C ARG 143 42.862 9.416 46.587 1.00 6.59 ATOM 1113 O ARG 143 43.759 10.213 46.872 1.00 8.32 ATOM 1114 N LEU 144 41.608 9.616 46.887 1.00 6.29 ATOM 1115 CA LEU 144 41.146 10.800 47.621 1.00 7.40 ATOM 1116 CB LEU 144 40.077 11.501 46.737 1.00 8.55 ATOM 1117 CG LEU 144 40.603 12.027 45.375 1.00 8.47 ATOM 1118 CD1 LEU 144 39.402 12.282 44.481 1.00 6.95 ATOM 1119 CD2 LEU 144 41.379 13.312 45.591 1.00 5.70 ATOM 1120 C LEU 144 40.470 10.405 48.909 1.00 9.13 ATOM 1121 O LEU 144 39.953 9.293 49.040 1.00 8.94 ATOM 1122 N LYS 145 40.423 11.365 49.832 1.00 10.82 ATOM 1123 CA LYS 145 39.801 11.116 51.142 1.00 11.39 ATOM 1124 CB LYS 145 40.924 10.619 52.041 1.00 13.95 ATOM 1125 CG LYS 145 40.646 10.374 53.458 1.00 18.80 ATOM 1126 CD LYS 145 41.861 9.909 54.232 1.00 25.06 ATOM 1127 CE LYS 145 42.963 10.908 54.354 1.00 31.66 ATOM 1128 NZ LYS 145 43.539 11.396 53.059 1.00 37.64 ATOM 1129 C LYS 145 39.188 12.388 51.720 1.00 9.96 ATOM 1130 O LYS 145 39.596 13.478 51.389 1.00 9.17 ATOM 1131 N GLY 146 38.108 12.225 52.519 1.00 8.79 ATOM 1132 CA GLY 146 37.456 13.328 53.137 1.00 8.43 ATOM 1133 C GLY 146 36.897 14.360 52.201 1.00 8.40 ATOM 1134 O GLY 146 36.151 14.060 51.254 1.00 8.45 ATOM 1135 N TYR 147 37.263 15.616 52.405 1.00 8.09 ATOM 1136 CA TYR 147 36.779 16.715 51.642 1.00 7.87 ATOM 1137 CB TYR 147 37.196 18.074 52.234 1.00 9.36 ATOM 1138 CG TYR 147 36.595 19.261 51.474 1.00 11.07 ATOM 1139 CD1 TYR 147 35.277 19.634 51.672 1.00 11.07 ATOM 1140 CE1 TYR 147 34.748 20.679 50.935 1.00 13.45 ATOM 1141 CZ TYR 147 35.529 21.400 50.057 1.00 13.62 ATOM 1142 OH TYR 147 35.036 22.483 49.389 1.00 13.97 ATOM 1143 CE2 TYR 147 36.866 21.045 49.873 1.00 13.40 ATOM 1144 CD2 TYR 147 37.362 19.974 50.592 1.00 12.10 ATOM 1145 C TYR 147 36.885 16.626 50.152 1.00 5.90 ATOM 1146 O TYR 147 35.845 16.786 49.504 1.00 4.84 ATOM 1147 N PRO 148 38.043 16.403 49.590 1.00 7.00 ATOM 1148 CA PRO 148 38.156 16.303 48.132 1.00 7.78 ATOM 1149 CB PRO 148 39.605 16.180 47.837 1.00 7.31 ATOM 1150 CG PRO 148 40.271 15.930 49.125 1.00 8.35 ATOM 1151 CD PRO 148 39.340 16.286 50.255 1.00 7.21 ATOM 1152 C PRO 148 37.394 15.074 47.639 1.00 7.01 ATOM 1153 O PRO 148 36.995 15.119 46.479 1.00 8.08 ATOM 1154 N ALA 149 37.271 14.025 48.435 1.00 5.19 ATOM 1155 CA ALA 149 36.571 12.828 48.000 1.00 4.31 ATOM 1156 CB ALA 149 36.715 11.666 48.983 1.00 2.00 ATOM 1157 C ALA 149 35.079 13.175 47.824 1.00 3.82 ATOM 1158 O ALA 149 34.463 12.772 46.850 1.00 3.79 ATOM 1159 N ILE 150 34.535 13.957 48.742 1.00 4.49 ATOM 1160 CA ILE 150 33.146 14.400 48.705 1.00 5.37 ATOM 1161 CB ILE 150 32.790 15.107 50.026 1.00 7.40 ATOM 1162 CG2 ILE 150 31.624 16.049 49.837 1.00 7.23 ATOM 1163 CG1 ILE 150 32.660 14.085 51.137 1.00 8.06 ATOM 1164 CD1 ILE 150 32.623 14.512 52.578 1.00 7.31 ATOM 1165 C ILE 150 32.925 15.337 47.504 1.00 4.53 ATOM 1166 O ILE 150 31.943 15.147 46.813 1.00 3.53 ATOM 1167 N VAL 151 33.896 16.213 47.249 1.00 4.55 ATOM 1168 CA VAL 151 33.781 17.130 46.083 1.00 4.71 ATOM 1169 CB VAL 151 34.800 18.238 46.088 1.00 4.83 ATOM 1170 CG1 VAL 151 34.777 19.142 44.820 1.00 4.32 ATOM 1171 CG2 VAL 151 34.475 19.164 47.311 1.00 5.52 ATOM 1172 C VAL 151 33.820 16.304 44.795 1.00 5.66 ATOM 1173 O VAL 151 32.961 16.581 43.957 1.00 6.35 ATOM 1174 N PHE 152 34.749 15.379 44.629 1.00 4.24 ATOM 1175 CA PHE 152 34.658 14.562 43.361 1.00 4.96 ATOM 1176 CB PHE 152 35.902 13.806 43.085 1.00 4.05 ATOM 1177 CG PHE 152 37.140 14.561 42.669 1.00 6.55 ATOM 1178 CD1 PHE 152 37.911 15.246 43.583 1.00 7.52 ATOM 1179 CE1 PHE 152 39.104 15.892 43.234 1.00 6.30 ATOM 1180 CZ PHE 152 39.474 15.858 41.904 1.00 4.29 ATOM 1181 CE2 PHE 152 38.732 15.203 40.973 1.00 3.38 ATOM 1182 CD2 PHE 152 37.586 14.528 41.355 1.00 4.89 ATOM 1183 C PHE 152 33.386 13.735 43.308 1.00 4.69 ATOM 1184 O PHE 152 32.812 13.579 42.203 1.00 5.23 ATOM 1185 N GLN 153 32.847 13.159 44.374 1.00 4.19 ATOM 1186 CA GLN 153 31.588 12.395 44.269 1.00 5.10 ATOM 1187 CB GLN 153 31.284 11.638 45.555 1.00 4.46 ATOM 1188 CG GLN 153 32.324 10.564 45.854 1.00 5.68 ATOM 1189 CD GLN 153 32.214 9.837 47.177 1.00 7.54 ATOM 1190 OE1 GLN 153 31.475 8.874 47.401 1.00 9.94 ATOM 1191 NE2 GLN 153 33.031 10.289 48.117 1.00 5.48 ATOM 1192 C GLN 153 30.446 13.259 43.812 1.00 5.17 ATOM 1193 O GLN 153 29.581 12.883 42.981 1.00 6.71 ATOM 1194 N HIS 154 30.385 14.471 44.338 1.00 4.09 ATOM 1195 CA HIS 154 29.340 15.431 43.990 1.00 4.25 ATOM 1196 CB HIS 154 29.636 16.731 44.863 1.00 3.87 ATOM 1197 CG HIS 154 28.693 17.851 44.588 1.00 3.28 ATOM 1198 ND1 HIS 154 27.711 18.274 45.436 1.00 5.34 ATOM 1199 CE1 HIS 154 27.004 19.245 44.925 1.00 4.80 ATOM 1200 NE2 HIS 154 27.491 19.463 43.683 1.00 6.11 ATOM 1201 GD2 HIS 154 28.529 18.603 43.465 1.00 5.20 ATOM 1202 C HIS 154 29.391 15.728 42.477 1.00 3.83 ATOM 1203 O HIS 154 28.401 15.710 41.793 1.00 3.56 ATOM 1204 N GLU 155 30.571 16.019 41.951 1.00 4.91 ATOM 1205 CA GLU 155 30.779 16.302 40.553 1.00 7.09 ATOM 1206 CB GLU 155 32.150 16.925 40.264 1.00 7.65 ATOM 1207 CG GLU 155 32.331 18.281 41.029 1.00 6.88 ATOM 1208 CD GLU 155 31.161 19.223 40.725 1.00 8.48 ATOM 1209 OE1 GLU 155 30.644 19.235 39.570 1.00 6.97 ATOM 1210 OE2 GLU 155 30.704 19.907 41.673 1.00 9.81 ATOM 1211 C GLU 155 30.481 15.079 39.675 1.00 6.80 ATOM 1212 O GLU 155 29.815 15.254 38.625 1.00 7.83 ATOM 1213 N ILE 156 30.914 13.904 40.026 1.00 6.49 ATOM 1214 CA ILE 156 30.573 12.698 39.226 1.00 6.27 ATOM 1215 CB ILE 156 31.359 11.470 39.668 1.00 5.97 ATOM 1216 CG1 ILE 156 32.848 11.653 39.436 1.00 4.24 ATOM 1217 CD1 ILE 156 33.760 10.571 39.861 1.00 3.82 ATOM 1218 CG2 ILE 156 30.804 10.186 39.036 1.00 7.37 ATOM 1219 C ILE 156 29.066 12.513 39.298 1.00 5.98 ATOM 1220 O ILE 156 28.467 12.196 38.252 1.00 5.77 ATOM 1221 N ASP 157 28.408 12.644 40.429 1.00 5.23 ATOM 1222 CA ASP 157 26.978 12.553 40.507 1.00 5.85 ATOM 1223 CB ASP 157 26.371 12.978 41.821 1.00 7.42 ATOM 1224 CG ASP 157 26.314 11.911 42.878 1.00 10.11 ATOM 1225 OD1 ASP 157 26.594 10.731 42.577 1.00 9.03 ATOM 1226 OD2 ASP 157 25.822 12.253 43.982 1.00 10.69 ATOM 1227 C ASP 157 26.248 13.307 39.386 1.00 7.07 ATOM 1228 O ASP 157 25.287 12.755 38.834 1.00 8.10 ATOM 1229 N HIS 158 26.661 14.502 39.062 1.00 6.19 ATOM 1230 CA HIS 158 26.112 15.287 38.029 1.00 7.49 ATOM 1231 CB HIS 158 26.810 16.641 37.753 1.00 5.85 ATOM 1232 CG HIS 158 26.559 17.707 38.769 1.00 5.01 ATOM 1233 ND1 HIS 158 25.266 18.168 38.959 1.00 5.03 ATOM 1234 CE1 HIS 158 25.282 19.121 39.895 1.00 4.19 ATOM 1235 NE2 HIS 158 26.557 19.288 40.292 1.00 4.26 ATOM 1236 CD2 HIS 158 27.363 18.439 39.584 1.00 2.60 ATOM 1237 C HIS 158 26.090 14.599 36.656 1.00 8.47 ATOM 1238 O HIS 158 25.171 14.898 35.913 1.00 9.43 ATOM 1239 N LEU 159 27.078 13.780 36.392 1.00 8.63 ATOM 1240 CA LEU 159 27.220 13.074 35.122 1.00 9.33 ATOM 1241 CB LEU 159 28.636 12.532 34.967 1.00 7.47 ATOM 1242 CG LEU 159 29.853 13.426 35.128 1.00 7.64 ATOM 1243 CD1 LEU 159 31.101 12.606 34.923 1.00 6.21 ATOM 1244 CD2 LEU 159 29.832 14.677 34.295 1.00 6.97 ATOM 1245 C LEU 159 26.192 11.937 35.024 1.00 8.64 ATOM 1246 O LEU 159 25.885 11.426 33.947 1.00 7.94 ATOM 1247 N ASN 160 25.605 11.583 36.164 1.00 9.77 ATOM 1248 CA ASN 160 24.580 10.573 36.277 1.00 9.90 ATOM 1249 CB ASN 160 24.944 9.490 37.318 1.00 10.05 ATOM 1250 CG ASN 160 26.211 8.761 36.969 1.00 8.81 ATOM 1251 OD1 ASN 160 26.495 8.464 35.805 1.00 8.76 ATOM 1252 ND2 ASN 160 27.049 8.507 37.960 1.00 11.57 ATOM 1253 C ASN 160 23.207 11.100 36.542 1.00 10.13 ATOM 1254 O ASN 160 22.238 10.334 36.824 1.00 9.97 ATOM 1255 N GLY 161 22.996 12.404 36.413 1.00 10.67 ATOM 1256 CA GLY 161 21.695 13.015 36.647 1.00 9.90 ATOM 1257 C GLY 161 21.275 13.057 38.096 1.00 10.81 ATOM 1258 O GLY 161 20.049 13.064 38.394 1.00 11.80 ATOM 1259 N VAL 162 22.196 13.066 39.037 1.00 10.62 ATOM 1260 CA VAL 162 21.975 13.082 40.469 1.00 10.24 ATOM 1261 CB VAL 162 22.883 11.980 41.119 1.00 12.28 ATOM 1262 CG1 VAL 162 22.819 12.009 42.654 1.00 11.36 ATOM 1263 CG2 VAL 162 22.436 10.623 40.619 1.00 10.82 ATOM 1264 C VAL 162 22.378 14.419 41.070 1.00 9.72 ATOM 1265 O VAL 162 23.480 14.919 40.817 1.00 9.92 ATOM 1266 N MET 163 21.507 14.997 41.900 1.00 8.97 ATOM 1267 CA MET 163 21.754 16.260 42.575 1.00 9.40 ATOM 1268 CB MET 163 20.557 17.207 42.379 1.00 9.97 ATOM 1269 CG MET 163 20.282 17.521 40.923 1.00 11.50 ATOM 1270 SD MET 163 21.495 18.562 40.125 1.00 12.73 ATOM 1271 CE MET 163 21.165 20.109 40.910 1.00 11.88 ATOM 1272 C MET 163 22.009 15.970 44.058 1.00 10.17 ATOM 1273 O MET 163 21.477 14.989 44.595 1.00 10.49 ATOM 1274 N PHE 164 22.853 16.760 44.715 1.00 9.65 ATOM 1275 CA PHE 164 23.213 16.489 46.086 1.00 8.95 ATOM 1276 CB PHE 164 24.153 17.529 46.683 1.00 8.12 ATOM 1277 CG PHE 164 23.519 18.850 47.009 1.00 7.63 ATOM 1278 CD1 PHE 164 22.981 19.041 48.271 1.00 7.03 ATOM 1279 CD2 PHE 164 23.442 19.870 46.055 1.00 6.36 ATOM 1280 CE1 PHE 164 22.357 20.248 48.597 1.00 9.27 ATOM 1281 CE2 PHE 164 22.792 21.030 46.358 1.00 7.45 ATOM 1282 CZ PHE 164 22.288 21.248 47.613 1.00 7.70 ATOM 1283 C PHE 164 22.073 16.212 47.048 1.00 8.66 ATOM 1284 O PHE 164 22.221 15.427 47.999 1.00 8.17 ATOM 1285 N TYR 165 20.984 16.929 46.869 1.00 9.74 ATOM 1286 CA TYR 165 19.833 16.874 47.754 1.00 9.53 ATOM 1287 CB TYR 165 18.975 18.140 47.553 1.00 10.74 ATOM 1288 CG TYR 165 18.393 18.301 46.175 1.00 9.43 ATOM 1289 CD1 TYR 165 17.319 17.501 45.785 1.00 9.93 ATOM 1290 CE1 TYR 165 16.744 17.616 44.529 1.00 9.33 ATOM 1291 CZ TYR 165 17.210 18.604 43.679 1.00 8.93 ATOM 1292 OH TYR 165 16.640 18.714 42.431 1.00 11.39 ATOM 1293 CE2 TYR 165 18.278 19.393 44.033 1.00 7.81 ATOM 1294 CD2 TYR 165 18.833 19.277 45.291 1.00 8.68 ATOM 1295 C TYR 165 19.036 15.621 47.637 1.00 11.52 ATOM 1296 O TYR 165 18.088 15.381 48.431 1.00 12.08 ATOM 1297 N ASP 166 19.358 14.814 46.616 1.00 10.44 ATOM 1298 CA ASP 166 18.686 13.533 46.441 1.00 10.72 ATOM 1299 CB ASP 166 19.095 12.916 45.117 1.00 11.36 ATOM 1300 CG ASP 166 18.738 13.691 43.871 1.00 12.08 ATOM 1301 OD1 ASP 166 17.862 14.574 43.837 1.00 13.05 ATOM 1302 OD2 ASP 166 19.284 13.344 42.800 1.00 12.90 ATOM 1303 C ASP 166 19.152 12.599 47.567 1.00 10.61 ATOM 1304 O ASP 166 18.499 11.577 47.834 1.00 9.33 ATOM 1305 N HIS 167 20.291 12.921 48.205 1.00 10.36 ATOM 1306 CA HIS 167 20.793 12.039 49.255 1.00 11.38 ATOM 1307 CB HIS 167 22.358 12.033 49.264 1.00 10.95 ATOM 1308 CG HIS 167 22.964 11.631 47.957 1.00 13.93 ATOM 1309 ND1 HIS 167 22.923 10.334 47.453 1.00 13.92 ATOM 1310 CE1 HIS 167 23.546 10.300 46.291 1.00 13.33 ATOM 1311 NE2 HIS 167 24.004 11.501 46.018 1.00 12.92 ATOM 1312 CD2 HIS 167 23.645 12.366 47.027 1.00 13.06 ATOM 1313 C HIS 167 20.362 12.372 50.662 1.00 12.37 ATOM 1314 O HIS 167 20.858 11.734 51.630 1.00 13.63 ATOM 1315 N ILE 168 19.525 13.362 50.860 1.00 12.97 ATOM 1316 CA ILE 168 19.109 13.854 52.159 1.00 12.73 ATOM 1317 CB ILE 168 18.951 15.425 52.054 1.00 13.57 ATOM 1318 CG1 ILE 168 20.228 16.110 51.593 1.00 11.58 ATOM 1319 CD1 ILE 168 20.226 17.595 51.292 1.00 10.84 ATOM 1320 CG2 ILE 168 18.502 15.964 53.420 1.00 12.92 ATOM 1321 C ILE 168 17.838 13.216 52.672 1.00 14.26 ATOM 1322 O ILE 168 16.805 13.155 52.017 1.00 15.10 ATOM 1323 N ASP 169 17.823 12.772 53.913 1.00 15.41 ATOM 1324 CA ASP 169 16.631 12.138 54.507 1.00 16.46 ATOM 1325 CB ASP 169 17.078 11.500 55.840 1.00 16.03 ATOM 1326 CG ASP 169 15.931 10.619 56.316 1.00 17.04 ATOM 1327 OD1 ASP 169 14.943 11.119 56.861 1.00 18.29 ATOM 1328 OD2 ASP 169 16.030 9.434 55.962 1.00 17.14 ATOM 1329 C ASP 169 15.552 13.189 54.714 1.00 17.91 ATOM 1330 O ASP 169 15.803 14.268 55.270 1.00 16.68 ATOM 1331 N LYS 170 14.353 12.945 54.189 1.00 20.44 ATOM 1332 CA LYS 170 13.289 13.920 54.322 1.00 24.90 ATOM 1333 CB LYS 170 11.953 13.478 53.630 1.00 28.24 ATOM 1334 CG LYS 170 10.958 14.663 53.604 1.00 31.46 ATOM 1335 CD LYS 170 9.539 14.285 53.173 1.00 32.94 ATOM 1336 CE LYS 170 8.812 13.500 54.256 1.00 33.30 ATOM 1337 NZ LYS 170 7.402 13.165 53.899 1.00 34.02 ATOM 1338 C LYS 170 12.943 14.155 55.804 1.00 25.11 ATOM 1339 O LYS 170 12.858 15.277 56.264 1.00 26.53 ATOM 1340 N ASP 171 12.768 13.048 56.520 1.00 24.81 ATOM 1341 CA ASP 171 12.371 13.086 57.912 1.00 25.10 ATOM 1342 CB ASP 171 11.725 11.776 58.342 1.00 29.27 ATOM 1343 CG ASP 171 10.592 11.235 57.534 1.00 31.17 ATOM 1344 OD1 ASP 171 9.713 11.934 57.004 1.00 31.40 ATOM 1345 OD2 ASP 171 10.606 9.961 57.381 1.00 34.11 ATOM 1346 C ASP 171 13.414 13.491 58.919 1.00 23.57 ATOM 1347 O ASP 171 13.096 14.249 59.861 1.00 23.55 ATOM 1348 N HIS 172 14.650 13.038 58.756 1.00 21.67 ATOM 1349 CA HIS 172 15.718 13.379 59.697 1.00 19.37 ATOM 1350 CB HIS 172 16.113 12.098 60.464 1.00 21.26 ATOM 1351 CG HIS 172 14.941 11.559 61.215 1.00 23.69 ATOM 1352 ND1 HIS 172 14.618 12.008 62.472 1.00 24.87 ATOM 1353 CE1 HIS 172 13.515 11.392 62.882 1.00 26.42 ATOM 1354 NE2 HIS 172 13.139 10.532 61.925 1.00 26.64 ATOM 1355 CD2 HIS 172 14.026 10.625 60.873 1.00 25.35 ATOM 1356 C HIS 172 16.950 13.850 58.932 1.00 16.97 ATOM 1357 O HIS 172 17.981 13.177 58.955 1.00 16.83 ATOM 1358 N PRO 173 16.836 14.984 58.274 1.00 14.57 ATOM 1359 CA PRO 173 17.899 15.518 57.452 1.00 13.11 ATOM 1360 CB PRO 173 17.279 16.758 56.843 1.00 12.46 ATOM 1361 CG PRO 173 16.198 17.136 57.826 1.00 12.80 ATOM 1362 CD PRO 173 15.585 15.805 58.221 1.00 13.20 ATOM 1363 C PRO 173 19.199 15.766 58.159 1.00 13.01 ATOM 1364 O PRO 173 20.244 15.711 57.538 1.00 12.71 ATOM 1365 N LEU 174 19.213 16.071 59.457 1.00 13.35 ATOM 1366 CA LEU 174 20.415 16.341 60.183 1.00 13.25 ATOM 1367 CB LEU 174 20.352 17.642 60.973 1.00 14.23 ATOM 1368 CG LEU 174 20.025 18.898 60.156 1.00 13.91 ATOM 1369 CD1 LEU 174 20.038 20.108 61.077 1.00 16.72 ATOM 1370 CD2 LEU 174 20.967 19.113 58.996 1.00 15.55 ATOM 1371 C LEU 174 20.917 15.204 61.019 1.00 14.24 ATOM 1372 O LEU 174 21.890 15.390 61.748 1.00 14.10 ATOM 1373 N GLN 175 20.363 14.016 60.855 1.00 15.52 ATOM 1374 CA GLN 175 20.798 12.832 61.630 1.00 17.11 ATOM 1375 CB GLN 175 19.623 11.857 61.795 1.00 20.95 ATOM 1376 CG GLN 175 19.941 10.655 62.677 1.00 27.18 ATOM 1377 CD GLN 175 18.877 9.585 62.700 1.00 31.22 ATOM 1378 OE1 GLN 175 18.540 8.994 63.751 1.00 33.20 ATOM 1379 NE2 GLN 175 18.330 9.235 61.533 1.00 33.65 ATOM 1380 C GLN 175 21.922 12.122 60.898 1.00 16.99 ATOM 1381 O GLN 175 21.713 11.588 59.798 1.00 16.15 ATOM 1382 N PRO 176 23.104 12.137 61.448 1.00 17.92 ATOM 1383 CA PRO 176 24.264 11.514 60.860 1.00 19.07 ATOM 1384 CB PRO 176 25.425 11.958 61.729 1.00 18.77 ATOM 1385 CG PRO 176 24.866 13.138 62.518 1.00 18.47 ATOM 1386 CD PRO 176 23.452 12.771 62.748 1.00 17.86 ATOM 1387 C PRO 176 24.188 9.990 60.900 1.00 20.17 ATOM 1388 O PRO 176 23.732 9.400 61.895 1.00 20.92 ATOM 1389 N HIS 177 24.619 9.352 59.807 1.00 19.53 ATOM 1390 CA HIS 177 24.656 7.914 59.784 1.00 20.36 ATOM 1391 CB HIS 177 24.919 7.206 58.469 1.00 18.20 ATOM 1392 CG HIS 177 23.802 7.337 57.474 1.00 14.95 ATOM 1393 ND1 HIS 177 24.005 7.159 56.138 1.00 16.40 ATOM 1394 CE1 HIS 177 22.864 7.356 55.480 1.00 16.26 ATOM 1395 NE2 HIS 177 21.958 7.707 56.368 1.00 16.00 ATOM 1396 CD2 HIS 177 22.523 7.700 57.617 1.00 14.21 ATOM 1397 C HIS 177 25.658 7.423 60.841 1.00 21.02 ATOM 1398 O HIS 177 26.693 8.019 61.082 1.00 22.02 ATOM 1399 N THR 178 25.255 6.325 61.480 1.00 22.22 ATOM 1400 CA THR 178 26.106 5.744 62.510 1.00 23.81 ATOM 1401 CB THR 178 25.412 4.447 63.017 1.00 26.92 ATOM 1402 OG1 THR 178 24.070 4.779 63.455 1.00 28.11 ATOM 1403 CG2 THR 178 26.218 3.926 64.192 1.00 27.70 ATOM 1404 C THR 178 27.479 5.379 61.959 1.00 23.54 ATOM 1405 O THR 178 27.595 4.594 61.005 1.00 25.27 ATOM 1406 N ASP 179 28.540 5.880 62.536 1.00 22.85 ATOM 1407 CA ASP 179 29.901 5.593 62.172 1.00 22.95 ATOM 1408 CB ASP 179 30.170 4.097 62.080 1.00 28.84 ATOM 1409 CG ASP 179 29.950 3.241 63.312 1.00 33.14 ATOM 1410 OD1 ASP 179 29.420 2.094 63.173 1.00 34.35 ATOM 1411 OD2 ASP 179 30.323 3.605 64.467 1.00 34.72 ATOM 1412 C ASP 179 30.399 6.357 60.953 1.00 20.84 ATOM 1413 O ASP 179 31.509 6.146 60.505 1.00 19.20 ATOM 1414 N ALA 180 29.601 7.293 60.426 1.00 19.98 ATOM 1415 CA ALA 180 30.052 8.106 59.279 1.00 18.45 ATOM 1416 CB ALA 180 28.857 8.752 58.604 1.00 17.76 ATOM 1417 C ALA 180 31.020 9.145 59.822 1.00 18.09 ATOM 1418 O ALA 180 30.881 9.578 60.960 1.00 18.46 ATOM 1419 N VAL 181 32.063 9.501 59.124 1.00 17.49 ATOM 1420 CA VAL 181 33.062 10.462 59.459 1.00 17.25 ATOM 1421 CB VAL 181 34.320 10.313 58.578 1.00 17.21 ATOM 1422 CG1 VAL 181 35.301 11.466 58.792 1.00 17.56 ATOM 1423 CG2 VAL 181 35.050 9.012 58.805 1.00 17.06 ATOM 1424 C VAL 181 32.558 11.911 59.223 1.00 18.05 ATOM 1425 O VAL 181 32.154 12.253 58.113 1.00 16.95 ATOM 1426 N GLU 182 32.586 12.714 60.268 1.00 17.72 ATOM 1427 CA GLU 182 32.200 14.126 60.126 1.00 18.58 ATOM 1428 CB GLU 182 31.974 14.715 61.518 1.00 22.08 ATOM 1429 CG GLU 182 31.570 16.170 61.478 1.00 26.15 ATOM 1430 CD GLU 182 31.741 16.841 62.827 1.00 31.27 ATOM 1431 OE1 GLU 182 32.208 16.207 63.810 1.00 32.77 ATOM 1432 OE2 GLU 182 31.553 18.068 62.895 1.00 34.76 ATOM 1433 C GLU 182 33.434 14.816 59.533 1.00 18.49 ATOM 1434 O GLU 182 34.509 14.839 60.154 1.00 17.55 ATOM 1435 N VAL 183 33.323 15.377 58.351 1.00 19.14 ATOM 1436 CA VAL 183 34.454 16.036 57.698 1.00 20.41 ATOM 1437 CB VAL 183 34.382 15.826 56.174 1.00 18.55 ATOM 1438 CG1 VAL 183 35.474 16.547 55.414 1.00 17.81 ATOM 1439 CG2 VAL 183 34.544 14.317 55.887 1.00 16.84 ATOM 1440 C VAL 183 34.624 17.504 58.084 1.00 23.97 ATOM 1441 O VAL 183 33.925 18.419 57.618 1.00 23.28 ATOM 1442 N HIS 184 35.657 17.750 58.915 1.00 27.34 ATOM 1443 CA HIS 184 36.010 19.078 59.381 1.00 30.88 ATOM 1444 CB HIS 184 36.761 19.018 60.736 1.00 31.42 ATOM 1445 CG HIS 184 35.950 18.462 61.852 1.00 33.04 ATOM 1446 ND1 HIS 184 36.127 17.192 62.386 1.00 33.48 ATOM 1447 CE1 HIS 184 35.239 16.983 63.324 1.00 33.63 ATOM 1448 NE2 HIS 184 34.472 18.078 63.427 1.00 34.18 ATOM 1449 CD2 HIS 184 34.885 19.009 62.505 1.00 33.72 ATOM 1450 C HIS 184 36.944 19.774 58.398 1.00 33.03 ATOM 1451 OXT HIS 184 38.145 19.370 58.369 1.00 34.40 ATOM 1452 O HIS 184 36.482 20.674 57.663 1.00 34.98 ATOM 1453 O WAT 185 28.850 21.236 41.157 1.00 7.77 ATOM 1454 O WAT 186 31.430 6.491 39.145 1.00 5.36 ATOM 1455 O WAT 187 31.972 20.433 24.682 1.00 19.06 ATOM 1456 O WAT 188 43.418 17.395 32.297 1.00 7.22 ATOM 1457 O WAT 189 29.795 9.718 43.035 1.00 13.01 ATOM 1458 O WAT 190 25.169 14.868 44.564 1.00 7.63 ATOM 1459 O WAT 191 42.565 13.342 49.566 1.00 12.53 ATOM 1460 O WAT 192 23.545 16.936 36.967 1.00 11.47 ATOM 1461 O WAT 193 38.976 27.793 26.907 1.00 19.75 ATOM 1462 O WAT 194 35.953 1.677 55.506 1.00 8.03 ATOM 1463 O WAT 195 45.203 4.786 35.591 1.00 19.10 ATOM 1464 O WAT 196 40.702 22.372 37.469 1.00 5.65 ATOM 1465 O WAT 197 18.244 27.128 33.934 1.00 9.55 ATOM 1466 O WAT 198 43.230 2.407 45.385 1.00 14.44 ATOM 1467 O WAT 199 28.760 15.753 52.327 1.00 6.36 ATOM 1468 O WAT 200 39.314 16.273 54.340 1.00 10.38 ATOM 1469 O WAT 201 41.628 6.864 49.085 1.00 13.25 ATOM 1470 O WAT 202 32.628 8.643 33.259 1.00 14.96 ATOM 1471 O WAT 203 23.608 15.684 31.276 1.00 11.92 ATOM 1472 O WAT 204 41.619 27.241 32.862 1.00 12.62 ATOM 1473 O WAT 205 25.455 16.379 42.062 1.00 9.79 ATOM 1474 O WAT 206 23.458 25.587 46.689 1.00 9.28 ATOM 1475 O WAT 207 40.092 2.673 49.703 1.00 21.98 ATOM 1476 O WAT 208 35.495 30.435 31.702 1.00 9.21 ATOM 1477 O WAT 209 40.520 4.464 47.917 1.00 17.40 ATOM 1478 O WAT 210 28.201 9.930 46.793 1.00 14.09 ATOM 1479 O WAT 211 23.089 19.943 52.306 1.00 14.82 ATOM 1480 O WAT 212 44.399 21.289 35.915 1.00 13.38 ATOM 1481 O WAT 213 38.302 11.682 56.310 1.00 13.86 ATOM 1482 O WAT 214 29.194 31.320 26.877 1.00 14.92 ATOM 1483 O WAT 215 41.034 0.350 43.151 1.00 8.79 ATOM 1484 O WAT 216 37.315 5.552 55.980 1.00 15.69 ATOM 1485 O WAT 217 28.681 5.735 37.072 1.00 27.33 ATOM 1486 O WAT 218 27.519 26.142 27.532 1.00 20.83 ATOM 1487 O WAT 220 26.523 16.871 54.153 1.00 7.21 ATOM 1488 O WAT 221 26.631 8.829 40.556 1.00 13.85 ATOM 1489 O WAT 222 42.195 14.491 24.181 1.00 18.25 ATOM 1490 O WAT 223 39.484 2.299 47.684 1.00 17.37 ATOM 1491 O WAT 224 42.696 5.852 33.808 1.00 21.32 ATOM 1492 O WAT 225 21.738 21.298 24.368 1.00 34.50 ATOM 1493 O WAT 226 22.987 10.820 52.989 1.00 14.83 ATOM 1494 O WAT 227 46.793 19.037 41.919 1.00 17.41 ATOM 1495 O WAT 228 50.134 12.914 25.200 1.00 13.49 ATOM 1496 O WAT 229 34.941 32.358 33.918 1.00 10.04 ATOM 1497 O WAT 230 29.840 4.973 57.907 1.00 13.19 ATOM 1498 O WAT 231 41.476 32.535 41.932 1.00 16.82 ATOM 1499 O WAT 233 47.577 10.560 24.957 1.00 14.85 ATOM 1500 O WAT 234 31.423 7.923 35.851 1.00 18.25 ATOM 1501 O WAT 235 24.429 27.131 29.298 1.00 20.86 ATOM 1502 O WAT 236 45.316 2.958 43.842 1.00 16.57 ATOM 1503 O WAT 237 46.300 14.369 48.285 1.00 15.62 ATOM 1504 O WAT 238 22.551 21.212 56.437 1.00 20.75 ATOM 1505 O WAT 240 42.496 7.817 57.030 1.00 36.21 ATOM 1506 O WAT 241 29.753 7.840 45.086 1.00 20.48 ATOM 1507 O WAT 242 44.157 18.020 35.284 1.00 15.10 ATOM 1508 O WAT 243 32.571 28.209 41.063 1.00 26.82 ATOM 1509 O WAT 244 29.928 3.636 51.745 1.00 17.99 ATOM 1510 O WAT 245 17.606 26.422 41.913 1.00 14.25 ATOM 1511 O WAT 246 20.589 12.991 55.488 1.00 19.81 ATOM 1512 O WAT 247 39.341 29.548 29.158 1.00 18.35 ATOM 1513 O WAT 248 17.156 16.295 61.445 1.00 12.69 ATOM 1514 O WAT 249 24.354 14.243 33.242 1.00 12.22 ATOM 1515 O WAT 250 32.830 14.766 20.087 1.00 25.25 ATOM 1516 O WAT 251 16.815 19.536 36.675 1.00 15.62 ATOM 1517 O WAT 252 28.441 34.415 30.350 1.00 14.51 ATOM 1518 O WAT 253 26.031 8.747 44.300 1.00 20.25 ATOM 1519 O WAT 254 43.077 16.183 18.629 1.00 31.67 ATOM 1520 O WAT 256 33.197 19.064 19.853 1.00 24.22 ATOM 1521 O WAT 257 30.278 20.250 16.867 1.00 42.28 ATOM 1522 O WAT 258 20.798 17.479 26.186 1.00 29.53 ATOM 1523 O WAT 259 35.416 13.350 21.607 1.00 22.56 ATOM 1524 O WAT 260 35.637 44.109 41.691 1.00 21.90 ATOM 1525 O WAT 261 24.100 18.625 43.187 1.00 8.00 ATOM 1526 O WAT 263 22.843 12.530 27.491 1.00 22.94 ATOM 1527 O WAT 264 44.179 24.395 43.693 1.00 23.48 ATOM 1528 O WAT 265 18.860 10.472 42.233 1.00 22.82 ATOM 1529 O WAT 266 16.026 26.688 39.851 1.00 14.46 ATOM 1530 O WAT 267 26.345 14.750 24.426 1.00 23.54 ATOM 1531 O WAT 268 37.901 14.303 60.873 1.00 57.94 ATOM 1532 O WAT 269 23.911 8.885 51.213 1.00 19.17 ATOM 1533 O WAT 270 25.088 18.293 25.334 1.00 21.16 ATOM 1534 O WAT 271 32.345 12.423 22.061 1.00 26.85 ATOM 1535 O WAT 272 29.849 8.405 23.646 1.00 22.55 ATOM 1536 O WAT 273 38.933 19.380 16.508 1.00 29.99 ATOM 1537 O WAT 274 28.930 6.191 30.272 1.00 30.24 ATOM 1538 O WAT 277 51.699 18.896 51.858 1.00 26.44 ATOM 1539 O WAT 278 26.732 24.016 51.882 1.00 20.15 ATOM 1540 O WAT 280 35.901 30.991 27.045 1.00 31.15 ATOM 1541 O WAT 281 34.878 34.657 45.573 1.00 23.59 ATOM 1542 O WAT 282 22.582 24.196 49.931 1.00 17.52 ATOM 1543 O WAT 283 25.665 18.480 61.477 1.00 22.72 ATOM 1544 O WAT 285 16.617 23.741 53.679 1.00 22.92 ATOM 1545 O WAT 286 27.425 5.238 57.616 1.00 28.57 ATOM 1546 O WAT 287 24.194 17.156 62.543 1.00 22.92 ATOM 1547 O WAT 288 43.605 13.871 55.205 1.00 47.34 ATOM 1548 O WAT 289 14.252 10.820 52.850 1.00 28.43 ATOM 1549 O WAT 291 29.445 0.878 44.981 1.00 19.69 ATOM 1550 O WAT 292 33.986 13.974 64.333 1.00 37.04 ATOM 1551 O WAT 293 41.717 34.544 35.754 1.00 26.74 ATOM 1552 O WAT 294 44.822 15.305 22.321 1.00 16.03 ATOM 1553 O WAT 295 36.295 31.861 47.655 1.00 26.65 ATOM 1554 O WAT 296 42.599 28.766 43.606 1.00 26.10 ATOM 1555 O WAT 297 39.805 5.761 18.396 1.00 41.39 ATOM 1556 O WAT 298 13.973 17.827 35.310 1.00 54.73 ATOM 1557 O WAT 299 27.996 7.316 26.790 1.00 18.08 ATOM 1558 O WAT 300 42.886 21.511 50.516 1.00 18.76 ATOM 1559 O WAT 303 49.197 25.130 46.385 1.00 34.63 ATOM 1560 O WAT 304 30.514 20.096 22.934 1.00 26.25 ATOM 1561 O WAT 305 16.070 11.629 32.114 1.00 33.09 ATOM 1562 O WAT 307 45.009 9.505 49.911 1.00 38.13 ATOM 1563 O WAT 308 19.596 10.468 29.457 1.00 17.29 ATOM 1564 O WAT 309 15.205 14.450 44.995 1.00 14.06 ATOM 1565 O WAT 310 29.356 16.954 20.232 1.00 31.55 ATOM 1566 O WAT 311 24.108 38.264 35.844 1.00 39.11 ATOM 1567 O WAT 312 35.407 6.361 25.290 1.00 30.83 ATOM 1568 O WAT 313 39.712 31.481 26.164 1.00 59.55 ATOM 1569 O WAT 314 46.008 26.765 46.643 1.00 24.46 ATOM 1570 O WAT 315 31.206 32.756 27.472 1.00 25.26 ATOM 1571 O WAT 316 50.563 22.574 47.365 1.00 33.15 ATOM 1572 O WAT 317 44.191 6.963 54.611 1.00 37.60 ATOM 1573 O WAT 318 25.966 3.136 59.271 1.00 35.51 ATOM 1574 O WAT 319 37.521 28.687 19.179 1.00 42.82 ATOM 1575 O WAT 320 37.860 6.732 23.019 1.00 29.39 ATOM 1576 O WAT 321 16.404 30.148 38.616 1.00 44.90 ATOM 1577 O WAT 322 20.948 10.666 55.483 1.00 20.70 ATOM 1578 O WAT 323 42.010 40.095 40.065 1.00 30.74 ATOM 1579 O WAT 324 34.974 43.535 31.498 1.00 33.73 ATOM 1580 O WAT 325 36.339 21.393 17.438 1.00 22.90 ATOM 1581 O WAT 326 22.573 26.604 27.035 1.00 25.45 ATOM 1582 O WAT 327 43.925 1.275 33.700 1.00 31.52 ATOM 1583 O WAT 328 44.055 25.497 31.799 1.00 25.75 ATOM 1584 O WAT 329 21.385 6.303 61.996 1.00 33.54 ATOM 1585 O WAT 330 29.459 11.771 63.481 1.00 30.61 ATOM 1586 O WAT 331 44.458 29.701 35.168 1.00 21.73 ATOM 1587 O WAT 332 44.874 3.401 28.884 1.00 21.60 ATOM 1588 O WAT 333 35.791 46.126 38.798 1.00 31.81 ATOM 1589 O WAT 335 42.315 35.196 45.915 1.00 81.46 ATOM 1590 O WAT 336 31.457 36.447 45.501 1.00 48.90 ATOM 1591 O WAT 337 21.963 8.289 49.003 1.00 25.78 ATOM 1592 O WAT 338 46.389 28.795 37.209 1.00 25.28 ATOM 1593 O WAT 339 24.612 30.116 24.354 1.00 52.56 ATOM 1594 O WAT 340 32.083 2.650 30.885 1.00 67.46 ATOM 1595 O WAT 341 44.830 28.999 40.931 1.00 47.88 ATOM 1596 O WAT 342 30.337 12.782 23.955 1.00 18.21 ATOM 1597 O WAT 343 28.938 3.896 35.075 1.00 33.18 ATOM 1598 O WAT 344 14.617 18.243 39.459 1.00 29.61 ATOM 1599 O WAT 345 24.634 22.916 24.622 1.00 27.73 ATOM 1600 O WAT 346 39.434 34.582 32.483 1.00 20.28 ATOM 1601 O WAT 347 12.161 23.144 40.518 1.00 61.26 ATOM 1602 O WAT 348 27.481 2.007 50.279 1.00 79.56 ATOM 1603 O WAT 349 42.979 34.755 39.897 1.00 44.74 ATOM 1604 O WAT 350 28.778 41.078 42.112 1.00 28.20 ATOM 1605 O WAT 351 17.300 10.548 37.874 1.00 43.80 ATOM 1606 O WAT 352 19.099 8.296 59.238 1.00 40.38 ATOM 1607 O WAT 353 27.220 31.276 48.083 1.00 40.23 ATOM 1608 O WAT 354 25.981 34.775 41.644 1.00 40.74 ATOM 1609 O WAT 355 27.143 6.951 48.473 1.00 25.01 ATOM 1610 O WAT 356 38.151 11.528 18.954 1.00 25.07 ATOM 1611 O WAT 357 19.762 7.319 56.021 1.00 25.55 ATOM 1612 O WAT 358 28.144 1.582 55.375 1.00 89.67 ATOM 1613 O WAT 360 27.638 16.644 62.799 1.00 23.18 ATOM 1614 O WAT 361 14.684 31.678 44.174 1.00 71.66 ATOM 1615 O WAT 362 15.650 11.558 66.663 1.00 64.23 ATOM 1616 O WAT 363 15.237 18.359 54.178 1.00 39.41 ATOM 1617 O WAT 364 43.172 16.847 51.474 1.00 22.97 ATOM 1618 O WAT 365 18.986 26.729 27.844 1.00 48.99 ATOM 1619 O WAT 366 27.139 19.402 23.399 1.00 29.96 ATOM 1620 O WAT 367 45.600 0.114 38.791 1.00 74.35 ATOM 1621 O WAT 369 19.987 11.960 57.958 1.00 16.62 ATOM 1622 O WAT 372 27.335 27.231 54.352 1.00 40.25 ATOM 1623 O WAT 373 15.884 15.171 31.990 1.00 16.33 ATOM 1624 O WAT 374 15.330 24.772 50.039 1.00 32.03 ATOM 1625 O WAT 377 43.724 3.843 52.380 1.00 65.10 ATOM 1626 O WAT 378 38.825 38.327 52.464 1.00 49.54 ATOM 1627 O WAT 379 46.669 23.629 33.133 1.00 28.01 ATOM 1628 O WAT 380 25.700 12.197 66.584 1.00 89.69 ATOM 1629 O WAT 381 16.946 9.817 50.702 1.00 39.01 ATOM 1630 O WAT 382 28.300 9.517 63.491 1.00 33.60 ATOM 1631 O WAT 384 46.564 10.837 53.832 1.00 46.92 ATOM 1632 O WAT 385 19.884 8.624 51.494 1.00 27.80 ATOM 1633 O WAT 387 40.902 2.984 29.363 1.00 31.27 ATOM 1634 O WAT 391 34.316 2.463 62.378 1.00 58.47 ATOM 1635 O WAT 392 33.435 11.543 52.204 1.00 30.98 ATOM 1636 O WAT 393 31.770 25.813 26.248 1.00 27.06 ATOM 1637 O WAT 400 29.567 21.566 48.768 1.00 15.75 ATOM 1638 O WAT 402 48.664 8.376 47.162 1.00 18.07 ATOM 1639 O WAT 403 27.502 36.401 36.418 1.00 21.54 ATOM 1640 O WAT 404 38.545 3.037 55.400 1.00 13.22 ATOM 1641 O WAT 405 31.109 23.890 44.564 1.00 12.95 ATOM 1642 O WAT 406 37.990 6.814 28.956 1.00 20.51 ATOM 1643 O WAT 407 23.258 29.488 41.877 1.00 11.41 ATOM 1644 O WAT 409 38.433 6.626 31.944 1.00 19.15 ATOM 1645 O WAT 410 31.295 21.118 43.998 1.00 14.11 ATOM 1646 O WAT 411 29.526 7.658 41.193 1.00 14.42 ATOM 1647 O WAT 412 47.253 15.532 34.182 1.00 15.59 ATOM 1648 O WAT 413 32.025 22.355 49.225 1.00 22.54 ATOM 1649 O WAT 414 35.003 0.189 57.857 1.00 17.18 ATOM 1650 O WAT 415 38.803 38.578 33.800 1.00 50.11 ATOM 1651 O WAT 416 31.617 3.615 39.556 1.00 15.08 ATOM 1652 O WAT 417 41.233 19.520 51.473 1.00 26.94 ATOM 1653 O WAT 418 34.336 27.496 25.242 1.00 32.64 ATOM 1654 O WAT 419 31.486 2.145 58.952 1.00 26.96 ATOM 1655 O WAT 420 20.483 8.464 45.003 1.00 39.84 ATOM 1656 O WAT 421 38.402 6.719 60.710 1.00 53.78 ATOM 1657 O WAT 422 17.225 14.988 64.662 1.00 27.63 ATOM 1658 O WAT 423 29.858 4.786 43.647 1.00 25.15 ATOM 1659 O WAT 424 30.773 22.384 54.282 1.00 36.55 ATOM 1660 O WAT 425 38.526 14.414 56.721 1.00 20.85 ATOM 1661 O WAT 426 30.456 20.512 46.952 1.00 19.94 ATOM 1662 O WAT 427 22.093 34.199 38.603 1.00 30.42 ATOM 1663 O WAT 428 29.003 23.510 42.193 1.00 14.64 ATOM 1664 O WAT 430 24.931 30.471 52.337 1.00 30.16 ATOM 1665 O WAT 431 48.705 28.493 42.035 1.00 55.68 ATOM 1666 O WAT 432 39.117 4.219 32.847 1.00 25.71 ATOM 1667 O WAT 433 26.609 27.683 58.327 1.00 27.50 ATOM 1668 O WAT 434 39.186 −0.478 36.174 1.00 49.55 ATOM 1669 O WAT 435 41.271 4.828 21.864 1.00 39.72 ATOM 1670 O WAT 436 41.092 33.182 29.047 1.00 32.94 ATOM 1671 O WAT 437 15.296 21.832 45.786 1.00 40.79 ATOM 1672 O WAT 438 28.338 42.926 45.181 1.00 54.46 ATOM 1673 O WAT 439 18.910 32.039 47.096 1.00 34.92 ATOM 1674 O WAT 440 20.737 30.240 33.890 1.00 27.30 ATOM 1675 O WAT 441 39.566 2.311 52.603 1.00 9.84 ATOM 1676 O WAT 442 26.307 7.449 29.241 1.00 24.87 ATOM 1677 O WAT 443 33.345 6.388 32.193 1.00 25.75 ATOM 1678 O WAT 444 31.294 5.444 34.030 1.00 30.09 ATOM 1679 O WAT 445 28.477 5.556 33.091 1.00 33.90 ATOM 1680 O WAT 446 35.818 5.354 27.499 1.00 34.01 ATOM 1681 O WAT 447 38.643 6.449 25.935 1.00 36.56 ATOM 1682 O WAT 448 32.925 5.503 23.694 1.00 34.87 ATOM 1683 O WAT 449 36.725 28.997 25.274 1.00 30.86 ATOM 1684 O WAT 450 33.363 29.455 26.675 1.00 37.40 ATOM 1685 O WAT 451 41.451 27.420 25.703 1.00 33.62 ATOM 1686 O WAT 452 29.410 26.542 26.305 1.00 29.99 ATOM 1687 O WAT 453 36.755 35.395 27.932 1.00 31.87 ATOM 1688 O WAT 454 38.358 33.650 29.807 1.00 27.03 ATOM 1689 O WAT 455 37.465 31.045 29.786 1.00 24.00 ATOM 1690 O WAT 456 36.203 38.857 29.055 1.00 33.74 ATOM 1691 O WAT 457 43.139 26.818 23.216 1.00 42.86 ATOM 1692 O WAT 458 44.010 27.925 26.702 1.00 35.47 ATOM 1693 O WAT 459 42.654 24.489 23.829 1.00 36.86 ATOM 1694 O WAT 460 41.901 30.150 29.907 1.00 28.79 ATOM 1695 O WAT 461 26.772 28.402 27.845 1.00 24.54 ATOM 1696 O WAT 462 26.549 25.016 24.992 1.00 30.41 ATOM 1697 O WAT 463 24.198 25.675 25.291 1.00 29.34 ATOM 1698 O WAT 464 18.389 23.209 26.099 1.00 27.72 ATOM 1699 O WAT 465 15.792 17.751 27.506 1.00 35.38 ATOM 1700 O WAT 466 18.177 19.068 27.187 1.00 29.61 ATOM 1701 O WAT 467 20.277 34.110 40.402 1.00 39.33 ATOM 1702 O WAT 468 22.420 34.685 35.945 1.00 32.47 ATOM 1703 O WAT 469 25.586 36.936 38.120 1.00 30.14 ATOM 1704 O WAT 470 22.975 32.962 41.300 1.00 37.30 ATOM 1705 O WAT 471 22.668 19.271 25.898 1.00 29.84 ATOM 1706 O WAT 472 18.891 9.006 33.972 1.00 36.50 ATOM 1707 O WAT 473 24.180 8.334 27.833 1.00 29.82 ATOM 1708 O WAT 474 26.583 4.932 30.103 1.00 31.47 ATOM 1709 O WAT 475 35.276 12.918 19.062 1.00 29.07 ATOM 1710 O WAT 476 37.941 14.051 18.038 1.00 30.43 ATOM 1711 O WAT 477 38.446 16.323 16.217 1.00 33.99 ATOM 1712 O WAT 478 38.163 8.369 18.377 1.00 28.75 ATOM 1713 O WAT 479 42.854 7.090 21.196 1.00 35.78 ATOM 1714 O WAT 480 43.719 8.314 25.189 1.00 18.37 ATOM 1715 O WAT 481 44.810 8.599 19.951 1.00 33.64 ATOM 1716 O WAT 482 47.966 7.671 21.852 1.00 31.71 ATOM 1717 O WAT 483 45.820 13.136 19.737 1.00 32.03 ATOM 1718 O WAT 484 31.751 17.094 18.635 1.00 30.24 ATOM 1719 O WAT 485 27.993 14.973 20.979 1.00 33.51 ATOM 1720 O WAT 486 26.220 11.398 22.499 1.00 33.95 ATOM 1721 O WAT 487 28.510 14.814 17.996 1.00 35.70 ATOM 1722 O WAT 488 33.549 20.609 17.456 1.00 30.90 ATOM 1723 O WAT 489 27.960 13.392 23.087 1.00 26.06 ATOM 1724 O WAT 490 40.175 20.917 14.980 1.00 37.89 ATOM 1725 ZN Zn 500 26.949 20.605 41.894 1.00 12.48 END 

1-8. (canceled)
 9. A scalable three-dimensional configuration of points, at least a portion of said points derived from structure coordinates of at least a portion of an S. aureus peptide deformylase molecule or molecular complex listed in Table 1 and having a root mean square deviation of less than about 1.4 Å from said structure coordinates.
 10. A scalable three-dimensional configuration of points, all of said points derived from structure coordinates of an S. aureus peptide deformylase molecule or molecular complex listed in Table 1 and having a root mean square deviation of less than about 1.4 Å from said structure coordinates.
 11. The scalable three-dimensional configuration of points of claim 9 wherein at least a portion of the points derived from the S. aureus peptide deformylase structure coordinates are derived from structure coordinates representing the locations of at least the backbone atoms of a plurality of the amino acids defining at least one S. aureus peptide deformylase or S. aureus peptide deformylase-like active site, the active site comprising amino acids Gly58, Gly60, Leu61, Gln65, Glu109, Gly110, Cys111, Leu112, Ile150, His154, Glu155, and His158.
 12. The scalable three-dimensional configuration of points of claim 9 wherein at least a portion of the points derived from the S. aureus peptide deformylase structure coordinates are derived from structure coordinates representing the locations of at least the backbone atoms of a plurality of the amino acids defining at least one S. aureus peptide deformylase or S. aureus peptide deformylase-like active site, the active site comprising amino acids Arg56, Ser57, Gly58, Val59, Gly60, Leu61, Gln65, Leu105, Pro106, Thr107, Gly108, Glu109, Gly110, Cys111, Leu112, Asn117, Tyr147, Ile150, Val151, His154, Glu155, and His158.
 13. The scalable three-dimensional configuration of points of claim 9 displayed as a holographic image, a stereodiagram, a model or a computer-displayed image.
 14. A scalable three-dimensional configuration of points, at least a portion of the points derived from structure coordinates of at least a portion of a molecule or a molecular complex that is structurally homologous to an S. aureus peptide deformylase molecule or molecular complex, wherein the points derived from the structurally homologous molecule or molecular complex have a root mean square deviation of less than about 1.4 Å from the structure coordinates of said structurally homologous complex, and wherein the S. aureus peptide deformylase molecule or molecular complex is represented by S. aureus peptide deformylase structure coordinates listed in Table
 1. 15. The scalable three-dimensional configuration of points of claim 14 displayed as a holographic image, a stereodiagram, a model or a computer-displayed image
 16. A machine-readable data storage medium comprising a data storage material encoded with machine readable data which, when using a machine programmed with instructions for using said data, displays a graphical three-dimensional representation of at least one molecule or molecular complex selected from the group consisting of: (i) a molecule or molecular complex comprising at least a portion of an S. aureus peptide deformylase or an S. aureus peptide deformylase-like active site comprising amino acids Gly58, Gly60, Leu61, Gln65, Glu109, Gly110, Cys111, Leu112, Ile150, His154, Glu155, and His158, the active site being defined by a set of points having a root mean square deviation of less than about 0.35 Å from points representing the backbone atoms of said amino acids as represented by structure coordinates listed in Table 1; (ii) a molecule or molecular complex comprising at least a portion of an S. aureus peptide deformylase or an S. aureus peptide deformylase-like active site comprising amino acids Arg56, Ser57, Gly58, Val59, Gly60, Leu61, Gln65, Leu105, Pro106, Thr107, Gly108, Glu109, Gly110, Cys111, Leu112, Asn117, Tyr147, Ile150, Val151, His154, Glu155, and His158, the active site being defined by a set of points having a root mean square deviation of less than about 0.8 Å from points representing the backbone atoms of said amino acids as represented by structure coordinates listed in Table 1; and (iii) a molecule or molecular complex that is structurally homologous to an S. aureus peptide deformylase molecule or molecular complex, wherein the S. aureus peptide deformylase molecule or molecular complex is represented by structure coordinates listed in Table
 1. 17. A machine-readable data storage medium comprising a data storage material encoded with a first set of machine readable data which, when combined with a second set of machine readable data, using a machine programmed with instructions for using said first set of data and said second set of data, determines at least a portion of the structure coordinates corresponding to the second set of machine readable data, wherein said first set of data comprises a Fourier transform of at least a portion of the structural coordinates for S. aureus peptide deformylase listed in Table 1; and said second set of data comprises an x-ray diffraction pattern of a molecule or molecular complex of unknown structure.
 18. A computer-assisted method for obtaining structural information about a molecule or a molecular complex of unknown structure comprising: crystallizing the molecule or molecular complex; generating an x-ray diffraction pattern from the crystallized molecule or molecular complex; applying at least a portion of the structure coordinates set forth in Table 1 to the x-ray diffraction pattern to generate a three-dimensional electron density map of at least a portion of the molecule or molecular complex whose structure is unknown.
 19. A computer-assisted method for homology modeling an S. aureus peptide deformylase homolog comprising: aligning the amino acid sequence of an S. aureus peptide deformylase homolog with the amino acid sequence of S. aureus peptide deformylase SEQ ID NO:1 and incorporating the sequence of the S. aureus peptide deformylase homolog into a model of S. aureus peptide deformylase derived from structure coordinates set forth in Table 1 to yield a preliminary model of the S. aureus peptide deformylase homolog; subjecting the preliminary model to energy minimization to yield an energy minimized model; remodeling regions of the energy minimized model where stereochemistry restraints are violated to yield a final model of the S. aureus peptide deformylase homolog.
 20. A computer-assisted method for identifying a potential modifier of S. aureus peptide deformylase activity comprising: supplying a computer modeling application with a set of structure coordinates of a molecule or molecular complex, the molecule or molecular complex comprising at least a portion of at least one S. aureus peptide deformylase or S. aureus peptide deformylase-like active site, the active site comprising amino acids Gly58, Gly60, Leu61, Gln65, Glu109, Gly110, Cys111, Leu112, Ile150, His154, Glu155, and His158; supplying the computer modeling application with a set of structure coordinates of a chemical entity; and determining whether the chemical entity is expected to bind to the molecule or molecular complex, wherein binding to the molecule or molecular complex is indicative of potential modification of S. aureus peptide deformylase activity.
 21. The method of claim 20 further comprising assaying the potential modifier to determine whether it modifies S. aureus peptide deformylase activity.
 22. The method of claim 20 wherein the active site comprises amino acids Gly58, Gly60, Leu61, Gln65, Glu109, Gly110, Cys111, Leu112, Ile150, His154, Glu155, and His158, the active site being defined by a set of points having a root mean square deviation of less than about 0.35 Å from points representing the backbone atoms of said amino acids as represented by structure coordinates listed in Table
 1. 23. The method of claim 20 wherein determining whether the chemical entity is expected to bind to the molecule or molecular complex comprises performing a fitting operation between the chemical entity and at least one active site of the molecule or molecular complex, followed by computationally analyzing the results of the fitting operation to quantify the association between the chemical entity and the active site.
 24. The method of claim 20 further comprising screening a library of chemical entities.
 25. A computer-assisted method for identifying a potential modifier of S. aureus peptide deformylase activity comprising: supplying a computer modeling application with a set of structure coordinates of a molecule or molecular complex, the molecule or molecular complex comprising at least a portion of at least one S. aureus peptide deformylase or S. aureus peptide deformylase-like active site, the active site comprising amino acids Arg56, Ser57, Gly58, Val59, Gly60, Leu61, Gln65, Leu105, Pro106, Thr107, Gly108, Glu109, Gly110, Cys111, Leu112, Asn117, Tyr147, Ile150, Val151, His154, Glu155, and His158; supplying the computer modeling application with a set of structure coordinates of a chemical entity; and determining whether the chemical entity is expected to bind to the molecule or molecular complex, wherein binding to the molecule or molecular complex is indicative of potential modification of S. aureus peptide deformylase activity.
 26. The method of claim 25 further comprising assaying the potential modifier to determine whether it modifies S. aureus peptide deformylase activity.
 27. The method of claim 25 wherein the active site comprises amino acids Arg56, Ser57, Gly58, Val59, Gly60, Leu61, Gln65, Leu105, Pro106, Thr107, Gly108, Glu109, Gly110, Cys111, Leu112, Asn117, Tyr147, Ile150, Val151, His154, Glu155, and His158, the active site being defined by a set of points having a root mean square deviation of less than about 0.8 Å from points representing the backbone atoms of said amino acids as represented by structure coordinates listed in Table
 1. 28. The method of claim 25 wherein determining whether the chemical entity is expected to bind to the molecule or molecular complex comprises performing a fitting operation between the chemical entity and at least one active site of the molecule or molecular complex, followed by computationally analyzing the results of the fitting operation to quantify the association between the chemical entity and the active site.
 29. The method of claim 25 further comprising screening a library of chemical entities.
 30. A computer-assisted method for designing a potential modifier of S. aureus peptide deformylase activity comprising: supplying a computer modeling application with a set of structure coordinates of a molecule or molecular complex, the molecule or molecular complex comprising at least a portion of at least one S. aureus peptide deformylase or S. aureus peptide deformylase-like active site, the active site comprising amino acids Gly58, Gly60, Leu61, Gln65, Glu109, Gly110, Cys111, Leu112, Ile150, His154, Glu155, and His158; supplying the computer modeling application with a set of structure coordinates for a chemical entity; evaluating the potential binding interactions between the chemical entity and active site of the molecule or molecular complex; structurally modifying the chemical entity to yield a set of structure coordinates for a modified chemical entity; and determining whether the modified chemical entity is expected to bind to the molecule or molecular complex, wherein binding to the molecule or molecular complex is indicative of potential modification of S. aureus peptide deformylase activity.
 31. The method of claim 30 further comprising assaying the potential modifier to determine whether it modifies S. aureus peptide deformylase activity.
 32. The method of claim 30 wherein the active site comprises amino acids Gly58, Gly60, Leu61, Gln65, Glu109, Gly110, Cys111, Leu112, Ile150, His154, Glu155, and His158, the active site being defined by a set of points having a root mean square deviation of less than about 0.35 Å from points representing the backbone atoms of said amino acids as represented by structure coordinates listed in Table
 1. 33. The method of claim 30 wherein determining whether the modified chemical entity is expected to bind to the molecule or molecular complex comprises performing a fitting operation between the chemical entity and the active site of the molecule or molecular complex, followed by computationally analyzing the results of the fitting operation to quantify the association between the chemical entity and the active site.
 34. The method of claim 30 wherein the set of structure coordinates for the chemical entity is obtained from a chemical fragment library.
 35. A computer-assisted method for designing a potential modifier of S. aureus peptide deformylase activity comprising: supplying a computer modeling application with a set of structure coordinates of a molecule or molecular complex., the molecule or molecular complex comprising at least a portion of at least one S. aureus peptide deformylase or S. aureus peptide deformylase-like active site, the active site comprising amino acids Arg56, Ser57, Gly58, Val59, Gly60, Leu61, Gln65, Leu105, Pro106, Thr107, Gly108, Glu109, Gly110, Cys111, Leu112, Asn117, Tyr147, Ile150, Val151, His154, Glu155, and His158; supplying the computer modeling application with a set of structure coordinates for a chemical entity; evaluating the potential binding interactions between the chemical entity and active site of the molecule or molecular complex; structurally modifying the chemical entity to yield a set of structure coordinates for a modified chemical entity; and determining whether the modified chemical entity is expected to bind to the molecule or molecular complex, wherein binding to the molecule or molecular complex is indicative of potential modification of S. aureus peptide deformylase activity.
 36. The method of claim 35 further comprising assaying the potential modifer to determine whether it modifies S. aureus peptide deformylase activity.
 37. The method of claim 35 wherein the active site comprises amino acids Arg56, Ser57, Gly58, Val59, Gly60, Leu61, Gln65, Leu105, Pro106, Thr107, Gly108, Glu109, Gly110, Cys111, Leu112, Asn117, Tyr147, Ile150, Val150, Glu155, and His158, the active site being defined by a set of points having a root mean square deviation of less than about 0.8 Å from points representing the backbone atoms of said amino acids as represented by structure coordinates listed in Table
 1. 38. The method of claim 35 wherein determining whether the modified chemical entity is expected to bind to the molecule or molecular complex comprises performing a fitting operation between the chemical entity and the active site of the molecule or molecular complex, followed by computationally analyzing the results of the fitting operation to quantify the association between the chemical entity and the active site.
 39. The method of claim 35 wherein the set of structure coordinates for the chemical entity is obtained from a chemical fragment library.
 40. A computer-assisted method for designing a potential modifier of S. aureus peptide deformylase activity de novo comprising: supplying a computer modeling application with a set of structure coordinates of a molecule or molecular complex, the molecule or molecular complex comprising at least a portion of at least one S. aureus peptide deformylase or S. aureus peptide deformylase-like active site, wherein the active site comprises amino acids Gly58, Gly60, Leu61, Gln65, Glu109, Gly110, Cys111, Leu112, Ile150, His154, Glu155, and His158; forming a chemical entity represented by set of structure coordinates; and determining whether the chemical entity is expected to bind to the molecule or molecular complex, wherein binding to the molecule or molecular complex is indicative of potential modification of S. aureus peptide deformylase activity.
 41. The method of claim 40 further comprising assaying the potential modifier to determine whether it modifies S. aureus peptide deformylase activity.
 42. The method of claim 40 wherein the active site comprises amino acids Gly58, Gly60, Leu61, Gln65, Glu109, Gly110, Cys111, Leu112, Ile150, His154, Glu155, and His158, the active site being defined by a set of points having a root mean square deviation of less than about 0.35 Å from points representing the backbone atoms of said amino acids as represented by structure coordinates listed in Table
 1. 43. The method of claim 40 wherein determining whether the modified chemical entity is expected to bind to the molecule or molecular complex comprises performing a fitting operation between the chemical entity and the active site of the molecule or molecular complex, followed by computationally analyzing the results of the fitting operation to quantify the association between the chemical entity and the active site.
 44. A computer-assisted method for designing a potential modified of S. aureus peptide deformylase activity de novo comprising: supplying a computer modeling application with a set of structure coordinates of a molecule or molecular complex, the molecule or molecular complex comprising at least a portion of at least one S. aureus peptide deformylase or S. aureus peptide deformylase-like active site, wherein the active site comprises amino acids Arg56, Ser57, Gly58, Val59, Gly60, Leu61, Gln65, Leu105, Pro106, Thr107, Gly108, Glu109, Gly110, Cys111, Leu112, Asn117, Tyr147, Ile150, Val151, His154, Glu155, and His158; forming a chemical entity represented by set of structure coordinates; and determining whether the chemical entity is expected to bind to the molecule or molecular complex, wherein binding to the molecule or molecular complex is indicative of potential modification of S. aureus peptide deformylase activity.
 45. The method of claim 44 further comprising assaying the potential modifier to determine whether it modifies S. aureus peptide deformylase activity.
 46. The method of claim 44 wherein the active site comprises amino acids Arg56, Ser57, Gly58, Val59, Gly60, Leu61, Gln65, Leu105, Pro106, Thr107, Gly108, Glu109, Gly110, Cys111, Leu112, Asn117, Tyr147, Ile150, Val151, His154, Glu155, and His158, the active site being defined by a set of points having a root mean square deviation of less than about 0.8 Å from points representing the backbone atoms of said amino acids as represented by structure coordinates listed in Table
 1. 47. The method of claim 44 wherein determining whether the modified chemical entity is expected to bind to the molecule or molecular complex comprises performing a fitting operation between the chemical entity and the active site of the molecule or molecular complex, followed by computationally analyzing the results of the fitting operation to quantify the association between the chemical entity and the active site.
 48. The method of any of claims 20, 25, 30, 35, 40, or 44 further comprising supplying or synthesizing the potential modifier, then assaying the potential modifier to determine whether it modifies S. aureus peptide deformylase activity.
 49. A method for making a potential modifier of S. aureus peptide deformylase activity, the method comprising chemically or enzymatically synthesizing a chemical entity to yield a potential modifier of S. aureus peptide deformylase activity, the chemical entity having been identified during a computer-assisted process comprising supplying a computer modeling application with a set of structure coordinates of a molecule or molecular complex, the molecule or molecular complex comprising at least a portion of a S. aureus peptide deformylase or S. aureus peptide deformylase-like active site; supplying the computer modeling application with a set of structure coordinates of a chemical entity; and determining whether the chemical entity is expected to bind to the molecule or molecular complex at the active site, wherein binding to the molecule or molecular complex is indicative of potential modification of S. aureus peptide deformylase activity.
 50. A method for making a potential modifier of S. aureus peptide deformylase activity, the method comprising chemically or enzymatically synthesizing a chemical entity to yield a potential modifier of S. aureus peptide deformylase activity, the chemical entity having been designed during a computer-assisted process comprising supplying a computer modeling application with a set of structure coordinates of a molecule or molecular complex, the molecule or molecular complex comprising at least a portion of a S. aureus peptide deformylase or S. aureus peptide deformylase-like active site; supplying the computer modeling application with a set of structure coordinates for a chemical entity; evaluating the potential binding interactions between the chemical entity and the active site of the molecule or molecular complex; structurally modifying the chemical entity to yield a set of structure coordinates for a modified chemical entity; and determining whether the chemical entity is expected to bind to the molecule or molecular complex at the active site, wherein binding to the molecule or molecular complex is indicative of potential modification of S. aureus peptide deformylase activity.
 51. A method for making a potential modifier of S. aureus peptide deformylase activity, the method comprising chemically or enzymatically synthesizing a chemical entity to yield a potential modifier of S. aureus peptide deformylase activity, the chemical entity having been designed during a computer-assisted process comprising supplying a computer modeling application with a set of structure coordinates of a molecule or molecular complex, the molecule or molecular complex comprising at least a portion of a S. aureus peptide deformylase or S. aureus peptide deformylase-like active site; forming a chemical entity represented by set of structure coordinates; and determining whether the chemical entity is expected to bind to the molecule or molecular complex at the active site, wherein binding to the molecule or molecular complex is indicative of potential modification of S. aureus peptide deformylase activity.
 52. A potential modifier of S. aureus peptide deformylase activity identified or designed according to the method of claims 20, 25, 30, 35, 40, 44, 49, 50, or
 51. 53. A composition comprising a potential modifier of S. aureus peptide deformylase activity identified or designed according to the method of claims 20, 25, 30, 35, 40, 44, 49, 50, or
 51. 54. A pharmaceutical composition comprising a potential modifier of S. aureus peptide deformylase activity identified or designed according to the method of claims 20, 25, 30, 35, 40, 44, 49, 50, or 51, or a salt thereof, and pharmaceutically acceptable carrier. 55-69. (canceled) 